WO2023229032A1 - 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 - Google Patents
免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 Download PDFInfo
- Publication number
- WO2023229032A1 WO2023229032A1 PCT/JP2023/019755 JP2023019755W WO2023229032A1 WO 2023229032 A1 WO2023229032 A1 WO 2023229032A1 JP 2023019755 W JP2023019755 W JP 2023019755W WO 2023229032 A1 WO2023229032 A1 WO 2023229032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- therapeutic
- amino
- agent according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present disclosure relates to a CHK1 inhibitor, a liposome encapsulating a CHK1 inhibitor, or a combination thereof with an immune checkpoint inhibitor, as a therapeutic drug for cancer showing treatment resistance to immune checkpoint inhibitors. .
- CHK1 is a serine/threonine protein kinase downstream of ATR in the DNA damage checkpoint signaling pathway in the cell cycle.
- CHK1 is phosphorylated in an ATR-dependent manner in response to DNA damage caused by ionizing radiation, etc., or DNA replication stress caused by excessive cell proliferation and genome instability in cancer cells.
- Patent Documents 1 to 5 This phosphorylation that activates CHK1 causes CHK1 to phosphorylate CDC25A, inhibiting dephosphorylation of cyclin E/CDK2 by CDC25A, and arresting progression from S phase.
- CHK1 also phosphorylates CDC25C, inhibits dephosphorylation of cyclin B/CDK1 by CDC25C, and halts progression from the G2M phase. In either case, regulation of CDK activity induces cell cycle arrest and prevents cell division in the presence of DNA damage, thereby promoting repair of DNA damage. CHK1 inhibition suppresses the DNA damage checkpoint function in the cell cycle in cancer cells, causing DNA repair failure and uncontrolled DNA synthesis in the presence of DNA damage, resulting in DNA fragmentation and replication. induces catastrophe and cell death (Patent Documents 1 and 2).
- Patent Documents 1 to 3 Various inhibitors of CHK1 have been reported.
- the present disclosure provides a drug for treating cancer that is resistant to immune checkpoint inhibitors or for preventing recurrence of cancer that has gone into remission.
- CHK1 inhibitors or liposomes encapsulating CHK1 inhibitors enhance cell-killing effects and antigen presentation by continuously exposing cancer tissues to the drug.
- M2 macrophages decrease and the environment inside the tumor changes to an environment that attracts CD8-positive T cells (inflammatory microenvironment). It was found that the drug exhibited excellent antitumor effects.
- an immune checkpoint inhibitor is used in combination with the above-mentioned inhibitor or liposome, a more excellent antitumor effect is exhibited.
- [Section 1] A therapeutic and/or prophylactic agent for cancer patients exhibiting treatment resistance to immune checkpoint inhibitors, which contains a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor as an active ingredient.
- [Section 2] Item 2. The therapeutic and/or prophylactic agent according to item 1, characterized in that the CHK1 inhibitor and immune checkpoint inhibitor are used in combination.
- [Section 3] Item 3. The therapeutic and/or prophylactic agent according to Item 2, wherein the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously.
- [Section 4] Item 4. The therapeutic and/or prophylactic agent according to item 2 or 3, wherein the immune checkpoint inhibitor is administered after the CHK1 inhibitor is administered.
- [Section 5] The treatment according to any one of items 2 to 4, wherein the anti-PD-1 antibody is further administered after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously. agent and/or preventive agent.
- [Section 6] Any one of Items 2 to 4, wherein the anti-PD-1 antibody is administered 3 days or later after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously.
- [Section 7] The therapeutic and/or prophylactic agent according to any one of Items 2 to 6, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- FIG. 11 Any one of Items 1 to 10, wherein the number of CD8-positive cells in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- FIG. 12 Item 12.
- FIG. 13 Item 13.
- the expression of VEGFa in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Granzyme B in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Interferon ⁇ in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of H2ab1 in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of CD80 in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Mrc1 in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Arginase1 in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the DNA replication stress in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies. The therapeutic and/or prophylactic agents described.
- a therapeutic and/or prophylactic agent for preventing recurrence of remitted cancer which contains a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor as an active ingredient.
- [Section 27] 27.
- [Section 28] The therapeutic and/or prophylactic agent according to any one of Item 26 or 27, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- the immune checkpoint inhibitor is an anti-PD-1 antibody.
- the therapeutic and/or prophylactic agent according to any one of Item 26 or 27, wherein the anti-PD-1 antibody is pembrolizumab, nivolumab, spartalizumab, or cemiplimab.
- the cancer is squamous cell carcinoma, melanoma, acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, brain tumor, head and neck.
- cancer head and neck squamous cell carcinoma, esophageal cancer, thyroid cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic cancer, breast cancer, triple negative breast cancer, stomach cancer, gallbladder/bile duct cancer, Liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, MSI-high colon cancer, anal cancer, gastrointestinal stromal tumor, chorioepithelial carcinoma, endometrial cancer, cervix Cancer, ovarian cancer, platinum-resistant ovarian cancer, PARP inhibitor-resistant ovarian cancer, bladder cancer, urothelial cancer, renal cancer, renal cell cancer, prostate cancer, testicular tumor, At least one type of cancer selected from the group consisting of testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, chondrosarcoma,
- the therapeutic agent and/or prophylactic agent according to any one of Items 26 to 30.
- the cancer is melanoma, squamous cell carcinoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, non-muscle invasive bladder cancer, kidney cancer, hepatocyte cancer.
- the therapeutic agent and/or preventive agent according to item 1.
- the cancer is a group consisting of head and neck cancer, squamous cell carcinoma, non-small cell lung cancer, anal cancer, breast cancer, triple negative breast cancer, ovarian cancer, platinum-resistant ovarian cancer, or endometrial cancer.
- Item 31. The therapeutic and/or preventive agent according to any one of Items 26 to 30, which is at least one type of cancer selected from.
- TMB-High tumor mutation burden
- the phospholipid is one selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, soybean lecithin, egg yolk lecithin, hydrogenated egg yolk lecithin, and hydrogenated soybean lecithin. or a combination of two or more thereof, the therapeutic and/or prophylactic agent according to item 35.
- the therapeutic and/or preventive agent according to any one of Items 1 to 36, wherein the liposome further contains a sterol.
- the polymer portion of the polymer-modified lipid is polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, methoxypolyethylene glycol, methoxypolypropylene glycol, methoxypolyvinyl alcohol, methoxypolyvinylpyrrolidone, ethoxypolyethylene glycol, ethoxypolypropylene glycol, ethoxypolyvinyl alcohol, ethoxy Item 40.
- the therapeutic and/or prophylactic agent according to item 39 which is polyvinylpyrrolidone, propoxypolyethylene glycol, propoxypolypropylene glycol, propoxypolyvinyl alcohol, or propoxypolyvinylpyrrolidone.
- the liposome encapsulating the CHK1 inhibitor is (1) 40 to 70 mol% phospholipids, (2) 30-50 mol% cholesterol, and (3) 1 to 10 mol% polymer-modified lipid;
- the therapeutic agent and/or prophylactic agent according to item 1.
- [Section 1A] Use of a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor for producing a therapeutic and/or preventive agent for cancer patients showing treatment resistance to immune checkpoint inhibitors.
- [Section 2A] The use according to Item 1A, characterized in that the CHK1 inhibitor and an immune checkpoint inhibitor are used in combination.
- [Section 3A] The use according to item 2A, characterized in that the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously.
- [Section 4A] The use according to any one of paragraphs 2A or 3A, characterized in that the immune checkpoint inhibitor is administered after the administration of the CHK1 inhibitor.
- [Section 5A] The use according to any one of items 2A to 4A, wherein the anti-PD-1 antibody is further administered after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously.
- [Section 6A] Any one of Items 2A to 4A, wherein the anti-PD-1 antibody is administered 3 days or later after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously. Uses as described in.
- [Section 7A] The use according to any one of Items 2A to 6A, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- [Section 8A] The use according to any one of Items 2A to 6A, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
- [Section 9A] The use according to any one of items 2A to 6A, wherein the anti-PD-1 antibody is pembrolizumab, nivolumab, spartalizumab, cemiplimab.
- [Section 11A] Any one of Items 1A to 10A, wherein the number of CD8-positive cells in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies. Uses as described in.
- [Section 12A] The use according to any one of Items 1A to 11A, wherein the number of CD8-positive cells in the tumor tissue of the cancer patient is 0.135 or less.
- [Section 13A] The use according to any one of Items 1A to 12A, wherein the M1-M2 ratio of macrophages in tumor tissue of the cancer patient is 21 or less.
- [Section 14A] Any one of Items 1A to 13A, wherein the number of CD206-positive cells in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies. Uses as described in.
- [Section 18A] According to any one of Items 1A to 17A, the expression of VEGFa in the tumor tissue of the cancer patient is increased compared to the tumor tissue of an anti-PD-1 antibody-responsive patient. Use of.
- [Section 19A] Granzyme B expression in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of an anti-PD-1 antibody responsive patient, according to any one of clauses 1A to 17A. Use as described.
- [Section 20A] According to any one of Items 1A to 17A, wherein the expression of Interferon ⁇ in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of an anti-PD-1 antibody-responsive patient. Use as described.
- the expression of H2ab1 in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of CD80 in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Mrc1 in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- [Section 24A] According to any one of Items 1A to 17A, the expression of Arginase1 in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies. Use of.
- [Section 25A] According to any one of Items 1A to 17A, wherein the DNA replication stress in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies. Use as described.
- [Section 26A] Use of a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor for producing a therapeutic and/or preventive agent for preventing recurrence of cancer that has been in remission.
- [Section 27A] The use according to item 26A, characterized in that the CHK1 inhibitor and an immune checkpoint inhibitor are used in combination.
- [Section 28A] The use according to any one of Items 26A or 27A, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- [Section 29A] The use according to any one of Item 26A or 27A, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
- [Section 30A] The use according to any one of paragraphs 26A and 27A, characterized in that the anti-PD-1 antibody is pembrolizumab, nivolumab, spartalizumab, cemiplimab.
- the cancer is squamous cell carcinoma, melanoma, acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, brain tumor, head and neck.
- cancer head and neck squamous cell carcinoma, esophageal cancer, thyroid cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic cancer, breast cancer, triple negative breast cancer, stomach cancer, gallbladder/bile duct cancer, Liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, MSI-high colon cancer, anal cancer, gastrointestinal stromal tumor, chorioepithelial carcinoma, endometrial cancer, cervix Cancer, ovarian cancer, platinum-resistant ovarian cancer, PARP inhibitor-resistant ovarian cancer, bladder cancer, urothelial cancer, renal cancer, renal cell cancer, prostate cancer, testicular tumor, At least one type of cancer selected from the group consisting of testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, chondrosarcoma,
- the cancer is a group consisting of head and neck cancer, squamous cell carcinoma, non-small cell lung cancer, anal cancer, breast cancer, triple negative breast cancer, ovarian cancer, platinum-resistant ovarian cancer, or endometrial cancer.
- TMB-High tumor mutation burden
- the liposome further comprises a phospholipid.
- the phospholipid is one selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, soybean lecithin, egg yolk lecithin, hydrogenated egg yolk lecithin, and hydrogenated soybean lecithin. or a combination of two or more thereof.
- the liposome further contains a sterol.
- the sterol is cholesterol.
- the liposome further comprises a polymer-modified lipid.
- the polymer portion of the polymer-modified lipid is polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, methoxypolyethylene glycol, methoxypolypropylene glycol, methoxypolyvinyl alcohol, methoxypolyvinylpyrrolidone, ethoxypolyethylene glycol, ethoxypolypropylene glycol, ethoxypolyvinyl alcohol, ethoxy
- paragraph 39A which is polyvinylpyrrolidone, propoxypolyethylene glycol, propoxypolypropylene glycol, propoxypolyvinyl alcohol, or propoxypolyvinylpyrrolidone.
- [Section 41A] The use according to item 39A or 40A, wherein the lipid moiety of the polymer-modified lipid is phosphatidylethanolamine or diacylglycerol.
- the liposome encapsulating the CHK1 inhibitor is (1) 40 to 70 mol% phospholipids, (2) 30-50 mol% cholesterol, and (3) 1 to 10 mol% polymer-modified lipid; The use according to any one of paragraphs 1A to 41A, including.
- [Section 4B] The therapeutic and/or prophylactic agent according to any one of Items 2B and 3B, wherein the immune checkpoint inhibitor is administered after the CHK1 inhibitor is administered.
- [Section 5B] The treatment according to any one of items 2B to 4B, wherein the anti-PD-1 antibody is further administered after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously. agent and/or preventive agent.
- the immune checkpoint inhibitor is an anti-PD-1 antibody.
- the anti-PD-1 antibody is pembrolizumab, nivolumab, spartalizumab, or cemiplimab.
- [Section 18B] According to any one of Items 1B to 17B, the expression of VEGFa in the tumor tissue of the cancer patient is increased compared to the tumor tissue of an anti-PD-1 antibody-responsive patient.
- Granzyme B expression in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of an anti-PD-1 antibody responsive patient, according to any one of clauses 1B to 17B.
- [Section 20B] According to any one of Items 1B to 17B, wherein the expression of Interferon ⁇ in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of H2ab1 in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of CD80 in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Mrc1 in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- the expression of Arginase1 in the tumor tissue of the cancer patient is increased compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies.
- a therapeutic and/or prophylactic agent for. [Section 25B] According to any one of Items 1B to 17B, wherein the DNA replication stress in the tumor tissue of the cancer patient is reduced compared to the tumor tissue of a patient responsive to anti-PD-1 antibodies. The therapeutic and/or prophylactic agents described.
- [Section 26B] A therapeutic and/or prophylactic agent containing a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor as an active ingredient, for use in preventing recurrence of remitted cancer.
- [Section 27B] The therapeutic and/or prophylactic agent according to item 26B, characterized in that the CHK1 inhibitor and an immune checkpoint inhibitor are used in combination.
- [Section 28B] The therapeutic and/or prophylactic agent according to any one of Items 26B and 27B, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- the anti-PD-1 antibody is pembrolizumab, nivolumab, spartalizumab, or cemiplimab.
- the cancer is squamous cell carcinoma, melanoma, acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, brain tumor, head and neck.
- cancer head and neck squamous cell carcinoma, esophageal cancer, thyroid cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic cancer, breast cancer, triple negative breast cancer, stomach cancer, gallbladder/bile duct cancer, Liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, MSI-high colon cancer, anal cancer, gastrointestinal stromal tumor, chorioepithelial carcinoma, endometrial cancer, cervix Cancer, ovarian cancer, platinum-resistant ovarian cancer, PARP inhibitor-resistant ovarian cancer, bladder cancer, urothelial cancer, renal cancer, renal cell cancer, prostate cancer, testicular tumor, At least one cancer selected from the group consisting of testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, chondrosarcoma, soft tissue
- the therapeutic agent and/or prophylactic agent according to any one of Items 26B to 30B is melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, non-muscle invasive bladder cancer, kidney cancer, hepatocellular carcinoma, MSI- The therapeutic and/or prophylactic agent according to any one of Items 26B to 30B, which is for high colon cancer, esophageal cancer, colorectal cancer, breast cancer, and uterine body cancer.
- the cancer is a group consisting of head and neck cancer, squamous cell carcinoma, non-small cell lung cancer, anal cancer, breast cancer, triple negative breast cancer, ovarian cancer, platinum-resistant ovarian cancer, or endometrial cancer.
- the therapeutic and/or preventive agent according to any one of Items 26B to 30B which is at least one type of cancer selected from.
- TMB-High tumor mutation burden
- the phospholipid is one selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, soybean lecithin, egg yolk lecithin, hydrogenated egg yolk lecithin, and hydrogenated soybean lecithin. or a combination of two or more thereof, the therapeutic and/or prophylactic agent according to item 35B.
- the therapeutic and/or prophylactic agent according to item 35B or a combination of two or more thereof.
- the polymer portion of the polymer-modified lipid is polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, methoxypolyethylene glycol, methoxypolypropylene glycol, methoxypolyvinyl alcohol, methoxypolyvinylpyrrolidone, ethoxypolyethylene glycol, ethoxypolypropylene glycol, ethoxypolyvinyl alcohol, ethoxy
- the therapeutic and/or prophylactic agent according to item 39B which is polyvinylpyrrolidone, propoxypolyethylene glycol, propoxypolypropylene glycol, propoxypolyvinyl alcohol, or propoxypolyvinylpyrrolidone.
- the liposome encapsulating the CHK1 inhibitor is (1) 40 to 70 mol% phospholipids, (2) 30-50 mol% cholesterol, and (3) 1 to 10 mol% polymer-modified lipid;
- [Section 1C] A method for treating and/or preventing cancer patients exhibiting treatment resistance to immune checkpoint inhibitors, the method comprising administering a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor to the patient. A method that encompasses.
- [Section 2C] The method according to item 1C, characterized in that the CHK1 inhibitor and an immune checkpoint inhibitor are used in combination.
- [Section 4C] The method according to any one of Items 2C or 3C, wherein the immune checkpoint inhibitor is administered after the CHK1 inhibitor is administered.
- [Section 5C] The method according to any one of Items 2C to 4C, wherein the anti-PD-1 antibody is further administered after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously.
- [Section 6C] Any one of items 2C to 4C, wherein the anti-PD-1 antibody is administered 3 days later after the CHK1 inhibitor and the immune checkpoint inhibitor are administered simultaneously.
- [Section 7C] The method according to any one of Items 2C to 6C, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- [Section 8C] The method according to any one of Items 2C to 6C, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
- [Section 12C] The method according to any one of Items 1C to 11C, wherein the number of CD8-positive cells in the tumor tissue of the cancer patient is 0.135 or less.
- [Section 13C] The method according to any one of Items 1C to 12C, wherein the M1-M2 ratio of macrophages in tumor tissue of the cancer patient is 21 or less.
- [Section 27C] The method according to item 26C, characterized in that the CHK1 inhibitor and an immune checkpoint inhibitor are used in combination.
- [Section 28C] The method according to any one of Items 26C or 27C, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- [Section 29C] The method according to any one of Items 26A or 27C, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
- [Section 30C] The method according to any one of paragraphs 26C and 27C, wherein the anti-PD-1 antibody is pembrolizumab, nivolumab, spartalizumab, or cemiplimab.
- the cancer is squamous cell carcinoma, melanoma, acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, brain tumor, head and neck.
- cancer head and neck squamous cell carcinoma, esophageal cancer, thyroid cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic cancer, breast cancer, triple negative breast cancer, stomach cancer, gallbladder/bile duct cancer, Liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, MSI-high colon cancer, anal cancer, gastrointestinal stromal tumor, chorioepithelial carcinoma, endometrial cancer, cervix Cancer, ovarian cancer, platinum-resistant ovarian cancer, PARP inhibitor-resistant ovarian cancer, bladder cancer, urothelial cancer, renal cancer, renal cell cancer, prostate cancer, testicular tumor, At least one type of cancer selected from the group consisting of testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, chondrosarcoma,
- [Section 32C] The cancer is melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, non-muscle invasive bladder cancer, kidney cancer, hepatocellular carcinoma, MSI- The method according to any one of items 26C to 30C, wherein the cancer is high colon cancer, esophageal cancer, colorectal cancer, breast cancer, or endometrial cancer.
- the cancer is a group consisting of head and neck cancer, squamous cell carcinoma, non-small cell lung cancer, anal cancer, breast cancer, triple negative breast cancer, ovarian cancer, platinum-resistant ovarian cancer, or endometrial cancer.
- the method according to any one of Items 26C to 30C, wherein the cancer is at least one type of cancer selected from: [Section 34C] The method according to any one of Items 26C to 30C, wherein the cancer is a solid tumor with a high tumor mutation burden (TMB-High).
- TMB-High high tumor mutation burden
- the liposome further contains a phospholipid.
- the phospholipid is one selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, soybean lecithin, egg yolk lecithin, hydrogenated egg yolk lecithin, and hydrogenated soybean lecithin. or a combination of two or more thereof, the method according to item 35C.
- the polymer portion of the polymer-modified lipid is polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, methoxypolyethylene glycol, methoxypolypropylene glycol, methoxypolyvinyl alcohol, methoxypolyvinylpyrrolidone, ethoxypolyethylene glycol, ethoxypolypropylene glycol, ethoxypolyvinyl alcohol, ethoxy The method according to item 39C, wherein the polyvinylpyrrolidone, propoxypolyethylene glycol, propoxypolypropylene glycol, propoxypolyvinyl alcohol, or propoxypolyvinylpyrrolidone.
- [Section 41C] The method according to item 39C or 40C, wherein the lipid moiety of the polymer-modified lipid is phosphatidylethanolamine or diacylglycerol.
- the liposome encapsulating the CHK1 inhibitor is (1) 40 to 70 mol% phospholipids, (2) 30-50 mol% cholesterol, and (3) 1 to 10 mol% polymer-modified lipid;
- the CHK1 inhibitor has the formula (1): [In the formula, R 1 is a hydrogen atom, optionally substituted C 1-6 Alkyl, optionally substituted C 3-10 Cycloalkyl, optionally substituted 3- to 10-membered saturated heterocyclic group, optionally substituted C 6-10 represents aryl or optionally substituted 5- to 12-membered heteroaryl, R 2 is hydrogen atom, halogen atom, cyano, nitro, carboxyl, sulfonic acid, phosphoric acid, -OR 3 ,-SR 3 ,-COR 4 ,-CO 2 R 4 ,-CONR 5 R 6 ,-SO 2 R 4 ,-SO 2 N.R.
- R 6 optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-10 Cycloalkyl, optionally substituted 3- to 10-membered saturated heterocyclic group, optionally substituted C 6-10 represents aryl or optionally substituted 5- to 12-membered heteroaryl, R 3 is a hydrogen atom or C 1-6 represents alkyl, R 4 is C 1-6 represents alkyl, R 5 ,R 6 and R 7 are each independently a hydrogen atom or C 1-6 represents alkyl, where R bonded to the same nitrogen atom 5 and R 6 are both C 1-6 When alkyl, these may form a 3- to 8-membered nitrogen-containing saturated heterocycle together with the nitrogen atom to which they are bonded, X, Y and Z are each independently CR 8 or represents a nitrogen atom, where X, Y and Z are simultaneously CR 8 not, R 8 If there is more than one, each independently represents hydrogen
- R 12 optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-10 Cycloalkyl, optionally substituted 3- to 10-membered saturated heterocyclic group, optionally substituted C 6-10 represents aryl or optionally substituted 5- to 12-membered heteroaryl, R 9 is a hydrogen atom or C 1-6 represents alkyl, R 10 is C 1-6 represents alkyl, R 11 ,R 12 and R 13 are each independently a hydrogen atom or C 1-6 represents alkyl, where R bonded to the same nitrogen atom 11 and R 12 are both C 1-6 When alkyl, these may form a 3- to 8-membered nitrogen-containing saturated heterocycle together with the nitrogen atom to which they are bonded, L is a single bond or optionally substituted C 1-6 represents alkylene, V is a single bond, optionally substituted C 3-10 Represents cycloalkylene or an optionally substituted 3- to
- Nitro may be substituted with the same or different 1 to 5 substituents selected from the group consisting of;
- the group shown in cycloalkyl and (10) 3- to 10-membered saturated heterocyclic group is (a) halogen atom, (b) hydroxyl group, (c)C 6-10 aryl, (d) 5-12 membered heteroaryl, (e)C 1-6 alkyl, (f)C 2-6 alkenyl, (g)C 2-6 alkyny
- Nitro may be substituted with the same or different 1 to 5 substituents selected from the group consisting of; R 15 However, if there are multiple, each independently, C 1-6 is alkyl, R 16 and R 17 are each independently a hydrogen atom or C 1-6 is alkyl, R 16 or R 17 If there are multiple R 16 or R 17 may be the same or different, and here, R bonded to the same nitrogen atom 16 and R 17 are both C 1-6 When alkyl, these may form a 3- to 8-membered nitrogen-containing saturated heterocycle together with the nitrogen atom to which they are bonded, R 18 is a hydrogen atom or C 1-6 is an alkyl, The therapeutic agent and/or prophylactic agent according to item 44.
- R 1 is optionally substituted with a hydrogen atom or 1 to 3 fluorine atoms 1-6 is an alkyl, The therapeutic agent and/or prophylactic agent according to any one of Items 44 to 45.
- R 1 is a methyl group, The therapeutic agent and/or prophylactic agent according to any one of Items 44 to 46.
- R 2 is hydrogen atom, halogen atom, cyano, -OR 3 , C 1-6 alkyl, C 3-10 cycloalkyl, or a 3- to 10-membered saturated heterocyclic group, The therapeutic agent and/or prophylactic agent according to any one of Items 44 to 47.
- R 2 is cyano, The therapeutic agent and/or prophylactic agent according to any one of Items 44 to 46.
- R 8 If there is more than one, each independently hydrogen atom, halogen atom, cyano, -OR 9 ,-CO 2 R 10 ,-CONR 11 R 12 ,-NR 11 R 12 ,-NR 13 C.O.R.
- C 1-6 Alkyl (the alkyl is a fluorine atom, chlorine atom, bromine atom, hydroxyl group, phenyl, 5- to 6-membered heteroaryl, C 1-6 Alkoxy, C 3-7 cycloalkyl, 3- to 7-membered saturated heterocyclic group, -CONR 16 R 17 ,-NR 16 R 17 , and cyano), C 3-10 Cycloalkyl (cycloalkyl includes fluorine atom, chlorine atom, bromine atom, hydroxyl group, phenyl, 5- to 6-membered heteroaryl, C 1-6 alkyl, C 1-6 Alkoxy, C 3-7 cycloalkyl, 3- to 7-membered saturated heterocyclic group, -CONR 16 R 17 ,-NR 16 R 17 , and cyano), a 3- to 10-membered saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, a chlorine atom, atom, bromine atom, hydroxyl
- L is Single bond, or C. 1-6 Alkylene (the alkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17
- V is Single bond, C.
- Cycloalkylene (the cycloalkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), or 3- to 10-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a fluorine atom, a hydroxyl group, a C which may be substituted with 1 to 2 hydroxyl groups, or a fluorine atom) 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of The therapeutic agent and/or prophylactic agent according to any one of items 44 to 51.
- W is Single bond, or C. 1-6 Alkylene (the alkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of The therapeutic agent and/or prophylactic agent according to any one of items 44 to 52.
- R 14 but, Hydrogen atom, C. 1-6 Alkyl (the alkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), C.
- Cycloalkyl (the cycloalkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), or 3- to 10-membered saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of The therapeutic agent and/or prophylactic agent according to any one of items 44 to 53.
- Formula (1) becomes the following formula (2): [In the formula, X, Y and Z are each independently CR 8 or represents a nitrogen atom, where X, Y and Z are simultaneously CR 8 not, R 8 If there are multiple, each independently, Hydrogen atom, Fluorine atom, Chlorine atom, Bromine atom, C.
- Alkyl (the alkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), or 5- to 6-membered heteroaryl (the heteroaryl includes a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 2 substituents selected from the group consisting of L is Single bond, or C.
- Alkylene (the alkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of V is Single bond, C.
- Cycloalkylene (the cycloalkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), or 3- to 10-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a fluorine atom, a hydroxyl group, a C which may be substituted with 1 to 2 hydroxyl groups, or a fluorine atom) 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of W is Single bond, or C.
- 1-6 Alkylene (the alkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of Q is a hydrogen atom, or NHR 14 represents, R 14 teeth, Hydrogen atom, C.
- 1-6 Alkyl (the alkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), C.
- Cycloalkyl (the cycloalkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), or 3- to 10-membered saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, a hydroxyl group, a C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may be substituted with the same or different 1 to 3 substituents selected from the group consisting of R 16 and R 17 are each independently a hydrogen atom or C 1-6 Represents alkyl, R 16 or R 17 If there are multiple R 16 or R 17 may be the same or different, and here, R bonded to the same nitrogen atom 16 and R 17 are both C 1-6 When alkyl, these may be combined with the nitrogen atom to which they are bonded to form a 3- to 8-membered nitrogen-containing saturated heterocycle],
- [Section 56] The therapeutic and/or prophylactic agent according to any one of Items 44 to 55, wherein one or two of X, Y, and Z represent a nitrogen atom.
- X is a nitrogen atom
- Y and Z are CR 8 is, The therapeutic agent and/or prophylactic agent according to any one of items 44 to 56.
- Y is a nitrogen atom
- X and Z are CR 8 is, The therapeutic agent and/or prophylactic agent according to any one of items 44 to 56.
- [Section 59] Z is a nitrogen atom, X and Y are CR 8 is, The therapeutic agent and/or prophylactic agent according to any one of items 44 to 56.
- R 8 If there are multiple, each independently, Hydrogen atom, Fluorine atom, Chlorine atom, Bromine atom, or C. 1-6 Alkyl (the alkyl is a fluorine atom, a hydroxyl group, and a C 1-3 (optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of alkoxy), The therapeutic agent and/or prophylactic agent according to any one of items 44 to 59.
- L is a single bond, or C 1-6 alkylene (the alkylene may be substituted with the same or different 1 to 2 substituents selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano), The therapeutic agent and/or prophylactic agent according to any one of items 44 to 60.
- V is Single bond, C.
- Cycloalkylene (the cycloalkylene is a C which may be substituted with a fluorine atom, a hydroxyl group, or one or two hydroxyl groups) 1-3 alkyl, and cyano), or 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a C which may be substituted with a fluorine atom, a hydroxyl group, 1 to 2 hydroxyl groups, or a fluorine atom) 1-3 (optionally substituted with 1 to 2 same or different substituents selected from the group consisting of alkyl and cyano),
- the therapeutic agent and/or prophylactic agent according to any one of Items 44 to 61.
- W is Single bond, or C.
- Formula (1) becomes the following formula (3): [In the formula, R 8a and R 8b are each independently a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 represents alkyl, L is a single bond or C optionally substituted with one hydroxyl group 1-6 represents alkylene, V is Single bond, C.
- Cycloalkylene (the cycloalkylene has a hydroxyl group and a C 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), or 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, cyano, hydroxyl group, and C 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), W is Single bond, or C optionally substituted with one hydroxyl group 1-3 represents alkylene, Q is a hydrogen atom or NH 2 ]
- the therapeutic agent and/or prophylactic agent according to item 44.
- R 8a and R 8b are each independently a hydrogen atom, a fluorine atom or a chlorine atom, The therapeutic agent and/or prophylactic agent according to item 66.
- R 8a and R 8b are each independently a hydrogen atom or a chlorine atom, The therapeutic agent and/or prophylactic agent according to item 66.
- L is C 1-3 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of items 66 to 68.
- V is a single bond, The therapeutic agent and/or prophylactic agent according to any one of items 66 to 69.
- V is C 3-7 is cycloalkylene, The therapeutic agent and/or prophylactic agent according to any one of items 66 to 70.
- W is a single bond, The therapeutic agent and/or prophylactic agent according to any one of items 66 to 71.
- W is C 1-3 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of items 66 to 71.
- Q is NH 2 is, The therapeutic agent and/or prophylactic agent according to any one of items 66 to 73.
- Formula (1) becomes the following formula (4): [In the formula, R 8b and R 8c are each independently a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 represents alkyl, L is Single bond, or C. 1-6 represents alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano), V is Single bond, C.
- Cycloalkylene (the cycloalkylene has a hydroxyl group and a C 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), or 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a fluorine atom, cyano, a hydroxyl group, and a C which may be substituted with 1 to 3 hydroxyl groups and a fluorine atom) 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), W is Single bond, or C optionally substituted with one hydroxyl group 1-3 represents alkylene, Q is a hydrogen atom, NH 2 , or NHMe] The therapeutic agent and/or prophylactic agent according to item 44.
- R 8b and R 8c is a hydrogen atom, The therapeutic agent and/or prophylactic agent according to item 75.
- L is single bond, or C optionally substituted with one hydroxyl group or fluorine atom 1-6 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of item 75 or 76.
- V is single bond, C 3-7 cycloalkylene, or A 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, a hydroxyl group, and a C 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), The therapeutic agent and/or prophylactic agent according to any one of items 75 to 77.
- W is single bond, or C 1-3 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of items 75 to 78.
- Q is a hydrogen atom, The therapeutic agent and/or prophylactic agent according to any one of items 75 to 79.
- [Section 81] Q is NH 2 is, The therapeutic agent and/or prophylactic agent according to any one of items 75 to 79.
- [Section 82] Q is NHMe, The therapeutic agent and/or prophylactic agent according to any one of items 75 to 79.
- [Section 83] Formula (1) becomes the following formula (5): [In the formula, R 8a and R 8c are each independently a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 represents alkyl, L is a single bond or C optionally substituted with one hydroxyl group 1-6 represents alkylene, V is Single bond, C.
- Cycloalkylene (the cycloalkylene has a hydroxyl group and a C 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), or 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a C which may be substituted with a fluorine atom, cyano, a hydroxyl group, and one hydroxyl group) 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), W is Single bond, or C optionally substituted with one hydroxyl group 1-3 represents alkylene, Q is a hydrogen atom or NH 2 ]
- the therapeutic agent and/or prophylactic agent according to item 44.
- R 8a and R 8c is a hydrogen atom, The therapeutic agent and/or prophylactic agent according to item 83.
- L is optionally substituted with one hydroxyl group 1-6 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of item 83 or 84.
- V is Single bond, C 3-7 cycloalkylene or 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a hydroxyl group, and a C optionally substituted with one hydroxyl group) 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), The therapeutic agent and/or prophylactic agent according to any one of items 83 to 85.
- [Section 87] W is single bond, or C 1-3 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of items 83 to 86.
- [Section 88] Q is a hydrogen atom, The therapeutic agent and/or prophylactic agent according to any one of items 83 to 87.
- [Section 89] Q is NH 2 is, The therapeutic agent and/or prophylactic agent according to any one of items 83 to 87.
- Formula (1) becomes the following formula (6): [In the formula, R 8a is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 represents alkyl, L is Single bond, or C.
- 1-6 represents alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano), V is Single bond, C. 3-7 Cycloalkylene (the cycloalkylene has a hydroxyl group and a C 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), or 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a C which may be substituted with a fluorine atom, cyano, hydroxyl group, and 1 to 3 fluorine atoms) 1-3 optionally substituted with one substituent selected from the group consisting of alkyl), W is Single bond, or C optionally substituted with one hydroxyl group 1-3 represents alkylene, Q is a hydrogen atom, NH 2 , or NHMe] The therapeutic agent and/or prophylactic agent according to item 44.
- R 8a is a hydrogen atom, The therapeutic agent and/or prophylactic agent according to item 90.
- L is C 1-4 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of Item 90 or Item 91.
- V is single bond, or C 3-7 is cycloalkylene, The therapeutic agent and/or prophylactic agent according to any one of items 90 to 92.
- W is single bond, or C 1-3 is alkylene, The therapeutic agent and/or prophylactic agent according to any one of items 90 to 93.
- Q is NH 2 is, The therapeutic agent and/or prophylactic agent according to any one of items 90 to 94.
- the therapeutic and/or prophylactic agent according to item 44 which contains a compound selected from the following compounds or a pharmaceutically acceptable salt thereof: 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile, 5-( ⁇ 5-[2-(3-aminopropoxy)-6-chloro-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile, 5-( ⁇ 5-[3-(3-aminopropoxy)-5-methoxypyridin-4-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile, 5-( ⁇ 5-[4-(3-amino
- the therapeutic and/or prophylactic agent according to item 44 which contains a compound selected from the following compounds or a pharmaceutically acceptable salt thereof: 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile, 5-( ⁇ 5-[3-(3-aminopropoxy)-5-methoxypyridin-4-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile, 5-( ⁇ 5-[4-(3-aminopropoxy)-2-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile.
- the present disclosure provides a therapeutic and/or prophylactic agent for cancer patients exhibiting treatment resistance to immune checkpoint inhibitors, which contains a CHK1 inhibitor or a liposome encapsulating a CHK1 inhibitor as an active ingredient. be done. Furthermore, when an immune checkpoint inhibitor is used in combination with the above-mentioned inhibitor or liposome, it exhibits superior antitumor effects compared to a single agent. Furthermore, the inhibitor, the liposome, or the combination thereof with an immune checkpoint inhibitor also exhibits the effect of preventing recurrence of cancer that has been remitted.
- the present disclosure provides a CHK1 inhibitor comprising a 5-heteroaryl-1H-pyrazol-3-amine derivative or a pharmaceutically acceptable salt thereof.
- the compounds of the present disclosure have both excellent CHK1 inhibitory activity and high safety. By being encapsulated in liposomes and released from the liposome in a sustained manner, it acts on cancer continuously and exhibits strong antitumor effects.
- the compounds of the present disclosure are useful as therapeutic agents for diseases involving CHK1, and are specifically applicable to patients with pancreatic cancer, ovarian cancer, osteosarcoma, Ewing's sarcoma, chondrosarcoma, or soft tissue sarcoma. It is.
- the present disclosure has been shown to have a pharmacological effect in Phase 2 trials for ovarian cancer patients, and compared to Prexasertib, a 5-phenyl-1H-pyrazol-3-amine derivative, it has been inferred from non-clinical studies. It has been found that while maximal efficacy was not achieved with sustained exposure for 72 hours, the compounds of the present disclosure or salts thereof may further improve this. Furthermore, when administered in a single dose, the compounds or salts of the present disclosure did not cause such side effects compared to prexasertib, which causes side effects due to high peak blood concentrations.
- Non-patent Document 3 Non-Patent Document 6
- the present inventors have newly found that prexasertib has a risk of hepatotoxicity, and the compound of the present invention has a reduced risk of hepatotoxicity. From the above, the compound of the present disclosure has both excellent CHK1 inhibitory activity and high safety.
- the compound represented by formula (3) which has a pyridine ring with a nitrogen atom at a specific position, is characterized by both high antitumor activity and safety, as well as excellent pharmacokinetics.
- the compound of Example 1 which is included in formula (3), exhibits higher CHK1 inhibitory activity compared to prexasertib, has a strong cell proliferation inhibitory effect, and is characterized by high safety. Furthermore, the compound of Example 1 exhibits good pharmacokinetics and is characterized by being efficiently encapsulated in liposomes.
- the liposome preparation of the compound of Example 1 has excellent antitumor effects and high safety, and exhibits even more exceptional antitumor effects when used in combination with existing anticancer drugs.
- Figure 3 shows the powder X-ray diffraction pattern of Form I of the compound of Example 39.
- the horizontal axis shows the diffraction angle 2 ⁇ (°), and the vertical axis shows the count number (the same applies to FIGS. 2 to 6 below).
- Figure 4 shows the powder X-ray diffraction pattern of Form II of the compound of Example 40.
- Figure 4 shows the powder X-ray diffraction pattern of Form III of the compound of Example 41.
- Figure 4 shows the powder X-ray diffraction pattern of Form IV of the compound of Example 42.
- Figure 4 shows the powder X-ray diffraction pattern of Form V of the compound of Example 43.
- Figure 4 shows the powder X-ray diffraction pattern of Form VI of the compound of Example 44.
- FIG. 7 is a diagram showing the tumor PD response effect of Test A of Test Example 11, a solution formulation or a liposome formulation of prexasertib, using ES-2 tumor-bearing mice.
- PD response was evaluated by detecting the expression levels of ⁇ H2AX and Tubulin by Western blotting, quantifying the intensity of each band using ImageJ software, and calculating the relative value of the expression level of ⁇ H2AX based on the expression level of Tubulin.
- the vertical axis indicates the relative value of ⁇ H2AX.
- FIG. 8 is a diagram showing the tumor PD response effect of Test B of Test Example 11, the solution formulation of prexasertib, or the liposome formulation of Example 1 using ES-2 tumor-bearing mice.
- FIG. 9 is a diagram showing the tumor PD response effect of Test C of Test Example 11 and the liposome formulation of Example 1 using ES-2 tumor-bearing mice.
- FIG. 10 is a diagram showing an example of the administration regimen of the anti-PD-1 antibody and the liposome preparation of Example 1.
- the liposome formulation of Example 1 was administered simultaneously with anti-PD-1 antibody, and then 1 week/time (A1), 2 weeks/time (A2), 3 weeks/time (A3), and 4 weeks/time (A4). ) or 5 weeks/time (A5).
- Anti-PD-1 antibodies were administered at the same time as Example 1 and then administered 2 weeks/time (B1), 3 weeks/time (B2), 4 weeks/time (B3), or 6 weeks/time (B4) according to the individual regimen. ). That is, Example 1 and the anti-PD-1 antibody are administered according to an administration regimen selected from any combination thereof.
- FIG. 11 is a diagram showing the cell number and TCR repertoire clonotype for each clonal amount of CD8-positive T cells in the test of Test Example 28 and the liposome preparation of Example 1.
- FIG. 12 is a diagram showing the CD8 score of the test of Test Example 28 and the liposome formulation of Example 1.
- FIG. 13 is a diagram showing the test of Test Example 28 and the M1-M2 ratio of the liposome formulation of Example 1.
- FIG. 14 is a diagram showing the expression level of ssDNA according to the test of Test Example 34 and the treatment of Example 1.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. Preferably it is a fluorine atom or a chlorine atom.
- C 1-6 alkyl means an alkyl having 1 to 6 carbon atoms
- C 6 alkyl means an alkyl having 6 carbon atoms. The same applies to other numbers.
- C 1-6 alkyl means a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms.
- Preferred examples of C 1-6 alkyl include “C 1-4 alkyl", more preferably “C 1-3 alkyl”.
- Specific examples of “C 1-3 alkyl” include methyl, ethyl, propyl, 1-methylethyl, and the like.
- Specific examples of “C 1-4 alkyl” include butyl , 1,1-dimethylethyl, 1-methylpropyl, 2-methyl Examples include propyl.
- C 1-6 alkyl include pentyl , 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1 -Methylbutyl, 2-methylbutyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, hexyl and the like.
- C 2-6 alkenyl means a straight or branched unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing 1 to 3 double bonds.
- Preferred examples of “C 2-6 alkenyl” include “C 2-4 alkenyl.”
- Specific examples of “C 2-4 alkenyl” include vinyl, propenyl, methylpropenyl, butenyl, and the like.
- Specific examples of “C 2-6 alkenyl” include pentenyl, hexenyl, and the like, in addition to those listed above as specific examples of “C 2-4 alkenyl.”
- C 2-6 alkynyl means a straight or branched unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing one triple bond.
- C 2-6 alkynyl is preferably “C 2-4 alkynyl”.
- Specific examples of “C 2-4 alkynyl” include propynyl, methylpropynyl, butynyl, and the like.
- Specific examples of “C 2-6 alkynyl” include, in addition to those listed above as specific examples of "C 2-4 alkynyl", methylbutynyl, pentynyl, hexynyl, and the like.
- C 1-6 alkoxy means “C 1-6 alkyloxy", and the “C 1-6 alkyl” moiety has the same meaning as the above-mentioned “C 1-6 alkyl”.
- C 1-6 alkoxy preferably includes “C 1-4 alkoxy”, and more preferably “C 1-3 alkoxy”.
- Specific examples of “C 1-3 alkoxy” include methoxy, ethoxy, propoxy, 1-methylethoxy, and the like.
- Specific examples of “C 1-4 alkoxy” include, in addition to those listed above as specific examples of “C 1-3 alkoxy", butoxy, 1,1-dimethylethoxy, 1-methylpropoxy, 2-methyl Examples include propoxy.
- C 1-6 alkoxy examples include pentyloxy , 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1 -methylbutoxy, 2-methylbutoxy, 4-methylpentyloxy, 3-methylpentyloxy, 2-methylpentyloxy, 1-methylpentyloxy, hexyloxy and the like.
- C 1-6 alkyl portion of “C 1-6 alkylthio” has the same meaning as the above-mentioned "C 1-6 alkyl".
- C 1-6 alkylthio preferably includes “C 1-4 alkylthio", and more preferably “C 1-3 alkylthio".
- Specific examples of “C 1-3 alkylthio” include methylthio, ethylthio, propylthio, 1-methylethylthio, and the like.
- Specific examples of “C 1-4 alkylthio” include butylthio , 1,1-dimethylethylthio, 1-methylpropylthio, 2 -Methylpropylthio and the like.
- C 1-6 alkylthio include pentylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, in addition to those listed above as specific examples of "C 1-4 alkylthio". , 1-methylbutylthio, 2-methylbutylthio, 4-methylpentylthio, 3-methylpentylthio, 2-methylpentylthio, 1-methylpentylthio, hexylthio, and the like.
- C 1-6 alkylene means a straight or branched divalent saturated hydrocarbon group having 1 to 6 carbon atoms.
- C 1-6 alkylene preferably “C 1-4 alkylene” is mentioned, and more preferably “C 1-3 alkylene” is mentioned.
- Specific examples of “C 1-3 alkylene” include methylene, ethylene, propylene, trimethylene and the like.
- Specific examples of “C 1-4 alkylene” include butylene, 1,1-dimethylethylene, 1,2 -dimethylethylene, 1 -methyltrimethylene, 2-methyltrimethylene and the like.
- C 1-6 alkylene include pentylene, 1,1-dimethyltrimethylene, 1,2-dimethyltrimethylene, in addition to those listed as specific examples of “C 1-4 alkylene” above. , 1-methylbutylene, 2-methylbutylene, 1-methylpentylene, 2-methylpentylene, 3-methylpentylene, hexylene and the like.
- C 3-10 cycloalkyl means a cyclic saturated hydrocarbon group having 3 to 10 carbon atoms, and includes those having a partially unsaturated bond and those having a crosslinked structure.
- C 3-10 cycloalkyl preferably includes “C 3-7 cycloalkyl.” Specific examples of “C 3-7 cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
- C 3-10 cycloalkyl include, for example, cyclooctyl, cyclononyl, cyclodecyl, adamantyl, and the like, in addition to those listed above as specific examples of “C 3-7 cycloalkyl.”
- C 3-10 cycloalkyl includes a bicyclic ring in which the C 3-10 cycloalkyl and an aromatic hydrocarbon ring are condensed.
- Specific examples of the ring-fused compound include the structures shown below.
- C 3-10 cycloalkylene means a cyclic divalent saturated hydrocarbon group having 3 to 10 carbon atoms, and includes those having a partially unsaturated bond and those having a crosslinked structure.
- Preferred examples of “C 3-10 cycloalkylene” include “C 3-7 cycloalkylene”.
- Specific examples of “C 3-7 cycloalkylene” include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, and the like.
- C 3-10 cycloalkyl include, in addition to those listed above as specific examples of “C 3-7 cycloalkyl", cyclooctylene, cyclononylene, cyclodecylene, adamantylene, and the like.
- “3- to 10-membered saturated carbocycle” means a cyclic saturated hydrocarbon having 3 to 10 carbon atoms.
- the "3- to 10-membered saturated carbocycle” preferably includes "4- to 6-membered saturated carbocycle.”
- Specific examples of the "4- to 6-membered saturated carbocycle” include, for example, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, and the like.
- the "3- to 10-membered saturated carbocycle” include, in addition to the specific examples of the "4- to 6-membered saturated carbocycle", a cyclopropane ring, a cycloheptane ring, a cyclooctane ring, Examples include cyclononane and cyclodecane.
- a "3- to 10-membered saturated heterocyclic group” is composed of 1 to 2 atoms independently selected from the group consisting of nitrogen atoms, oxygen atoms, and sulfur atoms, and 2 to 9 carbon atoms. It means a monovalent saturated heterocyclic group, and also includes those having a partially unsaturated bond and those having a crosslinked structure.
- the atoms constituting the ring may include oxidized atoms such as -C(O)-, -S(O)-, and -SO 2 -.
- the "3- to 10-membered saturated heterocyclic group” preferably includes "4- to 7-membered monocyclic saturated heterocyclic group.”
- Specific examples of the "4- to 7-membered monocyclic saturated heterocyclic group” include oxetanyl, azetidinyl, tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, dioxothiomorpholinyl, hexamethyleneyl, Examples include minyl, oxazolidinyl, thiazolidinyl, oxoimidazolidinyl, dioxoimidazolidinyl, oxooxazolidinyl, dioxooxazolidinyl, dioxothiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, and the like.
- Examples of the "3- to 10-membered saturated heterocyclic group” include, in addition to those listed as specific examples of the "4- to 7-membered monocyclic saturated heterocyclic group", oxiranyl, aziridinyl, and the like.
- the "3- to 10-membered saturated heterocyclic group” includes a fused ring formed by the 3- to 10-membered saturated heterocyclic group and a 6-membered aromatic hydrocarbon ring or a 6-membered aromatic heterocyclic ring. Bicyclics are also included. Examples of the 6-membered aromatic hydrocarbon ring forming the condensed ring include a benzene ring.
- Examples of the 6-membered aromatic heterocycle forming the condensed ring include pyridine, pyrimidine, and pyridazine.
- Specific examples of the bicyclic "3- to 10-membered saturated heterocyclic group" forming a condensed ring include dihydroindolyl, dihydroisoindolyl, dihydropurinyl, dihydrothiazolopyrimidinyl, dihydrobenzodioxa Nyl, isoindolyl, indazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthyridinyl, and the like.
- “3- to 8-membered nitrogen-containing saturated heterocycle” means a saturated heterocycle composed of one nitrogen atom and 2 to 7 carbon atoms.
- the "3- to 8-membered nitrogen-containing saturated heterocycle” preferably includes "4- to 6-membered nitrogen-containing saturated heterocycle.”
- Specific examples of the "4- to 6-membered nitrogen-containing saturated heterocycle” include, for example, an azetidine ring, a pyrrolidine ring, a piperidine ring, and the like.
- the "3- to 8-membered nitrogen-containing saturated heterocycle” include, in addition to the specific examples of the "4- to 6-membered nitrogen-containing saturated heterocycle", an aziridine ring, an azepane ring, an azocane ring, etc. Examples include rings.
- "3- to 10-membered divalent saturated heterocyclic group” means 1 to 2 atoms independently selected from the group consisting of nitrogen atoms, oxygen atoms, and sulfur atoms, and 2 to 9 carbon atoms. It means a divalent saturated heterocyclic group consisting of, and also includes those having a partially unsaturated bond and those having a crosslinked structure.
- the atoms constituting the ring may include oxidized atoms such as -C(O)-, -S(O)-, and -SO 2 -.
- the "3- to 10-membered saturated heterocyclic group” preferably includes "4- to 7-membered monocyclic saturated heterocyclic group.”
- Specific examples of the "4- to 7-membered monocyclic saturated heterocyclic group” include oxetanylene, azetidinylene, tetrahydrofurylene, pyrrolidinylene, imidazolidinylene, piperidinylene, morpholinylene, thiomorpholinylene, dioxothiomol Holinylene, hexamethylene iminilene, oxazolidinylene, thiazolidinylene, oxoimidazolidinylene, dioxoimidazolidinylene, oxooxazolidinylene, dioxooxazolidinylene, dioxothiazolidinylene, tetrahydrofuranylene, Examples include tetrahydropyranylene.
- Examples of the "3- to 10-membered saturated heterocyclic group” include, in addition to those listed as specific examples of the "4- to 7-membered monocyclic saturated heterocyclic group", oxiranylene, aziridinylene, and the like.
- the "3- to 10-membered saturated heterocyclic group” includes a fused ring formed by the 3- to 10-membered saturated heterocyclic group and a 6-membered aromatic hydrocarbon ring or a 6-membered aromatic heterocyclic ring. Bicyclic types are also included. Examples of the 6-membered aromatic hydrocarbon ring forming the condensed ring include a benzene ring.
- Examples of the 6-membered aromatic heterocycle forming the condensed ring include pyridine, pyrimidine, and pyridazine.
- Specific examples of the bicyclic "3- to 10-membered saturated heterocyclic group" forming a condensed ring include dihydroindolylene, dihydroisoindolylene, dihydropurinylene, dihydrothiazolopyrimidinylene, dihydrobenzo Examples include dioxanylene, isoindolylene, indazolylene, tetrahydroquinolinylene, tetrahydroisoquinolinylene, and tetrahydronaphthyridinylene.
- C 6-10 aryl means an aromatic hydrocarbon ring group having 6 to 10 carbon atoms. Specific examples of “C 6-10 aryl” include phenyl, 1-naphthyl, 2-naphthyl, and the like. Preferred is phenyl. Further, “C 6-10 aryl” includes a bicyclic ring in which the C 6-10 aryl and a C 4-6 cycloalkyl or a 5- to 6-membered saturated heterocycle form a condensed ring. Specific examples of the bicyclic "C 6-10 aryl” forming a condensed ring include the groups shown below.
- Aromatic hydrocarbon ring means the ring portion of the above “C 6-10 aryl”.
- 5- to 12-membered heteroaryl means a monocyclic 5- to 7-membered aromatic group containing 1 to 4 atoms independently selected from the group consisting of nitrogen atoms, oxygen atoms, and sulfur atoms. It means a cyclic heterocyclic group or a bicyclic 8- to 12-membered aromatic heterocyclic group. Preferably, it is a "5- to 7-membered monocyclic heteroaryl.” More preferred are pyridyl, pyrimidinyl, quinolyl, or isoquinolyl. More preferred is pyridyl.
- 5- to 7-membered monocyclic heteroaryl include pyridyl, pyridazinyl, isothiazolyl, pyrrolyl, furyl, thienyl, thiazolyl, imidazolyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrazinyl, and triazinyl. , triazolyl, oxadiazolyl, triazolyl, tetrazolyl and the like.
- 5- to 12-membered heteroaryl include indolyl, indazolyl, chromenyl, quinolyl, isoquinolyl, benzofuranyl, in addition to those listed above as “5- to 7-membered monocyclic heteroaryl”. , benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzotriazolyl, benzimidazolyl, and the like.
- Aromatic heterocycle means the ring portion of the above “5- to 12-membered heteroaryl”.
- cancer and tumor are synonymous in this disclosure, both mean malignant tumor, and include cancer, sarcoma, and hematological malignancy.
- Specific examples of “cancer” or “tumor” include acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, polycythemia vera, malignant lymphoma, plasma cell tumor, and multiple myeloma.
- testicular tumor testicular germ cell tumor
- ovarian germ cell tumor Wilms tumor
- malignant melanoma neuroblastoma
- osteosarcoma Ewing's sarcoma
- chondrosarcoma soft tissue
- soft tissue examples include sarcoma or skin cancer.
- Prexasertib is a compound having the following structure.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8a , R 8b , R 8c , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , X, Y, Z, L , V, W, Q and Y are as follows, but the technical scope of the present disclosure is not limited to the range of the compounds listed below.
- a preferred embodiment of R 1 includes C 1-6 alkyl optionally substituted with 1 to 3 fluorine atoms. More preferred embodiments of R 1 include a methyl group or an ethyl group which may be substituted with 1 to 3 fluorine atoms. A more preferred embodiment of R 1 is a methyl group optionally substituted with 1 to 3 fluorine atoms. An even more preferred embodiment of R 1 is a methyl group.
- R 2 include hydrogen atom, halogen atom, cyano, -OR 3 , C 1-6 alkyl optionally substituted with 1 to 3 halogen atoms, C 3-10 cycloalkyl, or 3 to 3 halogen atoms. Examples include 10-membered saturated heterocyclic groups. More preferred embodiments of R 2 include hydrogen atom, halogen atom, cyano, or C 1-6 alkyl optionally substituted with 1 to 3 halogen atoms. More preferred embodiments of R 2 include C 1-6 alkyl optionally substituted with a halogen atom, cyano, or 1 to 3 halogen atoms. An even more preferred embodiment of R 2 is cyano.
- R 3 include a hydrogen atom or C 1-6 alkyl. A more preferred embodiment of R 3 is C 1-6 alkyl. A more preferred embodiment of R 3 is C 1-3 alkyl. An even more preferred embodiment of R 3 is a methyl group.
- R 4 is C 1-3 alkyl.
- a more preferred embodiment of R 4 is a methyl group.
- R 5 , R 6 and R 7 include a hydrogen atom or C 1-6 alkyl.
- a more preferred embodiment of R 5 , R 6 and R 7 is C 1-6 alkyl.
- a more preferred embodiment of R 5 , R 6 and R 7 is C 1-3 alkyl.
- An even more preferred embodiment of R 5 , R 6 and R 7 is a methyl group.
- R 8 include a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a C 1-6 alkyl (the alkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano). ), or a 5- to 6-membered heteroaryl (the heteroaryl is a fluorine atom, a hydroxyl group, a C 1-3 alkyl, (optionally substituted with 1 to 2 same or different substituents selected from the group consisting of C 1-3 alkoxy, -NR 16 R 17 , and cyano).
- R 8 More preferred embodiments of R 8 include a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a C 1-6 alkyl (the alkyl is a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and a cyano atom). (optionally substituted with one or two identical or different substituents selected from the group consisting of). More preferred embodiments of R 8 include hydrogen atom, fluorine atom, chlorine atom, bromine atom, or C 1-3 alkyl. An even more preferred embodiment of R 8 is a hydrogen atom or a chlorine atom.
- R 8a , R 8b and R 8c include a hydrogen atom, a fluorine atom, a chlorine atom, and a bromine atom. More preferable embodiments of R 8a , R 8b and R 8c include a hydrogen atom and a chlorine atom. A more preferred embodiment of R 8a , R 8b and R 8c is a hydrogen atom.
- R 9 include a hydrogen atom or C 1-6 alkyl. A more preferred embodiment of R 9 is C 1-3 alkyl. A more preferred embodiment of R 9 is a methyl group.
- R 10 is C 1-3 alkyl.
- a more preferred embodiment of R 10 is a methyl group.
- R 11 , R 12 and R 13 include a hydrogen atom or C 1-6 alkyl.
- a more preferred embodiment of R 11 , R 12 and R 13 is C 1-3 alkyl.
- a more preferred embodiment of R 11 , R 12 and R 13 is a methyl group.
- R 14 include a hydrogen atom, a C 1-6 alkyl (the alkyl is the same or different selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano).
- C 3-10 cycloalkyl (the cycloalkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkyl, a C 1-3 alkoxy, -NR 16 R 17 , and cyano), or a 3- to 10-membered saturated heterocyclic group (the saturated heterocyclic group is a fluorine atom, hydroxyl group, C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano, which may be substituted with the same or different 1 to 3 substituents). .
- R 14 is a hydrogen atom, C 1-6 alkyl (the alkyl is the same or the same selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano). (optionally substituted with 1 to 3 different substituents).
- a more preferred embodiment of R 14 is a hydrogen atom or C 1-3 alkyl (the alkyl may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano group). can be mentioned.
- An even more preferred embodiment of R 14 is a hydrogen atom or a methyl group.
- R 15 is C 1-6 alkyl. A more preferred embodiment of R 15 is C 1-3 alkyl. A more preferred embodiment of R 15 is a methyl group.
- R 16 and R 17 include a hydrogen atom or C 1-6 alkyl.
- a more preferred embodiment of R 16 and R 17 is C 1-6 alkyl.
- a more preferred embodiment of R 16 and R 17 is C 1-3 alkyl.
- An even more preferred embodiment of R 16 and R 17 is a methyl group.
- R 18 include a hydrogen atom or C 1-6 alkyl. A more preferred embodiment of R 18 is C 1-6 alkyl. A more preferred embodiment of R 18 is C 1-3 alkyl. An even more preferred embodiment of R 18 is a methyl group.
- Preferred embodiments of X, Y and Z include CR 8 or a nitrogen atom.
- X, Y and Z are not simultaneously CR8 .
- Another preferred embodiment of X, Y and Z is that one or two of X, Y and Z represent a nitrogen atom.
- Another preferred embodiment of X, Y and Z is that X is CR 8 and Y and Z are nitrogen atoms.
- Another preferred embodiment of X, Y and Z is that Y is CR 8 and X and Z are nitrogen atoms.
- Further different preferable embodiments of X, Y and Z include that Z is CR 8 and X and Y are nitrogen atoms.
- a preferred embodiment of L is a single bond, or C 1-6 alkylene (the alkylene is the same or different selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano). (optionally substituted with 1 to 3 substituents).
- a more preferred embodiment of L is a single bond or C 1-6 alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano group). Can be mentioned.
- L More preferred embodiments of L include a single bond or C 1-6 alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom and a hydroxyl group). Even more preferred embodiments of L include C 1-6 alkylene which may be substituted with a single bond or one hydroxyl group.
- V include a single bond, C 3-10 cycloalkylene (the cycloalkylene is a group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkyl, a C 1-3 alkoxy, -NR 16 R 17 , and cyano).
- the saturated heterocyclic group may be substituted with the same or different 1 to 3 substituents selected from 1 to 3 same or different substituents selected from the group consisting of C 1-3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano, which may be substituted with two hydroxyl groups or fluorine atoms; may be substituted with a group).
- More preferred embodiments of V include a single bond, C 3-7 cycloalkylene (the cycloalkylene is a fluorine atom, a hydroxyl group, a C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups, and cyano).
- the saturated heterocyclic group may be substituted with the same or different 1 to 2 substituents selected from the group consisting of a fluorine atom, a hydroxyl group, C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups or fluorine atoms, and cyano) may be substituted with the same or different 1 to 2 substituents selected from the group consisting of Can be mentioned.
- V include a single bond, a C 3-7 cycloalkylene (the cycloalkylene is a fluorine atom, a hydroxyl group, and a C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups or a fluorine atom). or a 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group may be substituted with the same or different 1 to 2 substituents selected from the group consisting of a fluorine atom, a hydroxyl group, (optionally substituted with 1 to 2 same or different substituents selected from the group consisting of C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups).
- V include a single bond, C 3-7 cycloalkylene (even if the cycloalkylene is substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl). or a 3- to 7-membered divalent saturated heterocyclic group (the 3- to 7-membered saturated heterocyclic group is one selected from the group consisting of fluorine atom, cyano, hydroxyl group, and C 1-3 alkyl) may be substituted with a substituent).
- a preferred embodiment of W is a single bond, or C 1-6 alkylene (the alkylene is the same or different selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano). (optionally substituted with 1 to 3 substituents).
- a more preferred embodiment of W is a single bond or a C 1-3 alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano group). Can be mentioned.
- W include a single bond or C 1-3 alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom and a hydroxyl group). Even more preferred embodiments of W include C 1-3 alkylene which may be substituted with a single bond or one hydroxyl group.
- a preferred embodiment of Q is a hydrogen atom or NHR 14 . More preferred embodiments of Q include a hydrogen atom, NH 2 , or NHMe. A more preferable embodiment of Q is a hydrogen atom or NH 2 . An even more preferred embodiment of Q is a hydrogen atom. Another even more preferred embodiment of Q includes NH2 .
- R 1 is a methyl group or an ethyl group optionally substituted with 1 to 3 fluorine atoms
- R 2 is hydrogen atom, halogen atom, cyano, -OR 3 , C 1-6 alkyl optionally substituted with 1 to 3 halogen atoms, C 3-10 cycloalkyl, or 3- to 10-membered saturated is a heterocyclic group
- R 3 is a hydrogen atom or C 1-6 alkyl
- X, Y and Z each independently represent CR 8 or a nitrogen atom, where X, Y and Z are not CR 8 at the same time
- R 8 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a C 1-6 alkyl (the alkyl is selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17
- W is a single bond, or C 1-6 alkylene (the alkylene is the same or different 1 to 3 atoms selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) (optionally substituted with a substituent),
- Q is a hydrogen atom or NHR 14
- R 14 is a hydrogen atom, C 1-6 alkyl (the alkyl is the same or different 1 to 3 selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) ( optionally substituted with a substituent of ), or a 3- to 10-membered saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, a hydroxyl group, a C 1 -3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may
- R 1 is a methyl group optionally substituted with 1 to 3 fluorine atoms
- R 2 is a halogen atom, cyano, or C 1-6 alkyl optionally substituted with 1 to 3 halogen atoms
- X, Y and Z each independently represent CR 8 or a nitrogen atom, where X, Y and Z are not CR 8 at the same time
- R 8 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 alkyl
- L is a single bond, or C 1-6 alkylene (the alkylene is the same or different 1 to 3 selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) (optionally substituted with a substituent)
- V is a single bond, C 3-10 cycloalkylene
- W is a single bond, or C 1-6 alkylene (the alkylene is the same or different 1 to 3 atoms selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) (optionally substituted with a substituent),
- Q is a hydrogen atom or NHR 14
- R 14 is a hydrogen atom, C 1-6 alkyl (the alkyl is the same or different 1 to 3 selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) ( optionally substituted with a substituent of ), or a 3- to 10-membered saturated heterocyclic group (the saturated heterocyclic group includes a fluorine atom, a hydroxyl group, a C 1 -3 alkyl, C 1-3 alkoxy, -NR 16 R 17 , and cyano), which may
- R 1 is a methyl group or a fluoromethyl group
- R 2 is a chlorine atom, cyano, or trifluoromethyl group
- X, Y and Z each independently represent CR 8 or a nitrogen atom, where X, Y and Z are not CR 8 at the same time
- R 8 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 alkyl
- L is a single bond, or C 1-6 alkylene (the alkylene is the same or different 1 to 3 selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) (optionally substituted with a substituent)
- V is a single bond
- C 3-10 cycloalkylene the cycloalkylene is selected from the group consisting of fluorine atom,
- W is a single bond, or C 1-6 alkylene (the alkylene is the same or different 1 to 3 atoms selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkoxy, -NR 16 R 17 , and cyano) (optionally substituted with a substituent),
- Q is a hydrogen atom or NHR 14
- R 14 is a hydrogen atom or C 1-3 alkyl (the alkyl may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and cyano)
- R 1 is a methyl group
- R 2 is cyano
- X, Y and Z each independently represent CR 8 or a nitrogen atom, where X, Y and Z are not CR 8 at the same time
- R 8 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or a C 1-3 alkyl
- L is a single bond or C 1-6 alkylene (the alkylene may be substituted with one substituent selected from the group consisting of a fluorine atom, a hydroxyl group, and a cyano)
- V is a single bond
- C 3-7 cycloalkylene the cycloalkylene is selected from the group consisting of a fluorine atom, a hydroxyl group, a C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups, and cyano
- One embodiment of the compound represented by formula (1) or (2) includes the following (E).
- (E) X, Y and Z each independently represent CR 8 or a nitrogen atom, where X, Y and Z are not CR 8 at the same time;
- R 8 is a hydrogen atom or a chlorine atom
- L is a single bond or C 1-6 alkylene optionally substituted with one hydroxyl group or fluorine atom
- V is a single bond
- C 3-7 cycloalkylene the cycloalkylene may be substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl), or 3 to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is from the group consisting of fluorine atom, cyano, hydroxyl group, and C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups or fluorine atoms) optionally substituted with one selected substituent),
- W is a single bond or C 1-3 al
- R 8a and R 8b are each independently a hydrogen atom or a chlorine atom
- L is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group
- V is a single bond
- C 3-7 cycloalkylene the cycloalkylene may be substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl
- 3 to 7-membered divalent saturated heterocyclic group the saturated heterocyclic group may be substituted with one substituent selected from the group consisting of fluorine atom, cyano, hydroxyl group, and C 1-3 alkyl
- W is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group
- Q is a hydrogen atom or NH2
- a compound or a pharmaceutically acceptable salt thereof A compound or a pharmaceutically acceptable salt thereof.
- R 8a and R 8b are each independently a hydrogen atom or a chlorine atom, L is C 1-3 alkylene optionally substituted with one hydroxyl group, V is a single bond, W is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group, Q is NH2 , A compound or a pharmaceutically acceptable salt thereof.
- R 8a and R 8b are each independently a hydrogen atom
- L is C 1-3 alkylene optionally substituted with one hydroxyl group
- V is C 3-7 cycloalkylene
- W is C 1-3 alkylene optionally substituted with one hydroxyl group
- Q is NH2
- R 8b and R 8c are hydrogen atoms
- L is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group or fluorine atom
- V is a single bond
- C 3-7 cycloalkylene the cycloalkylene may be substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl
- 3 to 7-membered divalent saturated heterocyclic group the saturated heterocyclic group is from the group consisting of fluorine atom, cyano, hydroxyl group, and C 1-3 alkyl optionally substituted with 1 to 3 hydroxyl groups or fluorine atoms
- W is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group
- Q is a hydrogen atom, NH 2 or NHMe
- R 8b and R 8c are each independently a hydrogen atom
- L is C 1-3 alkylene optionally substituted with one hydroxyl group or fluorine atom
- V is a 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is a fluorine atom, cyano, a hydroxyl group, and C 1-3 which may be substituted with 1 to 3 hydroxyl groups and a fluorine atom) (optionally substituted with one substituent selected from the group consisting of alkyl)
- W is a single bond
- Q is a hydrogen atom
- One embodiment of the compound represented by formula (4) includes the following (K).
- R 8b and R 8c are each independently a hydrogen atom
- L is C 1-3 alkylene optionally substituted with one hydroxyl group or fluorine atom
- V is C 3-7 cycloalkylene (the cycloalkylene may be substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl)
- W is C 1-3 alkylene optionally substituted with one hydroxyl group
- Q is NH2
- a compound or a pharmaceutically acceptable salt thereof is
- One embodiment of the compound represented by formula (4) includes the following (L).
- (L) R 8b and R 8c are each independently a hydrogen atom, L is a single bond, V is C 3-7 cycloalkylene (the cycloalkylene may be substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl), W is a single bond, Q is NH 2 or NHMe; A compound or a pharmaceutically acceptable salt thereof.
- One embodiment of the compound represented by formula (4) includes the following (M).
- (M) R 8b and R 8c are each independently a hydrogen atom, L is C 1-3 alkylene optionally substituted with one hydroxyl group or fluorine atom, V is a single bond, W is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group, Q is NH 2 or NHMe; A compound or a pharmaceutically acceptable salt thereof.
- R 8a and R 8c are each independently a hydrogen atom
- L is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group
- V is a single bond
- C 3-7 cycloalkylene the cycloalkylene may be substituted with one substituent selected from the group consisting of hydroxyl group and C 1-3 alkyl
- 3 to 7-membered divalent saturated heterocyclic group the saturated heterocyclic group is selected from the group consisting of fluorine atom, cyano, hydroxyl group, and C 1-3 alkyl optionally substituted with 1 to 2 hydroxyl groups
- W is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group
- Q is a hydrogen atom or NH2
- R 8a and R 8c are each independently a hydrogen atom
- L is C 1-3 alkylene optionally substituted with one hydroxyl group
- V is a 3- to 7-membered divalent saturated heterocyclic group (the saturated heterocyclic group is one selected from the group consisting of a hydroxyl group and a C 1-3 alkyl optionally substituted with one hydroxyl group) (optionally substituted with a substituent)
- W is a single bond
- Q is a hydrogen atom
- One embodiment of the compound represented by formula (5) includes the following (P).
- R 8a and R 8c are each independently a hydrogen atom, L is C 1-3 alkylene optionally substituted with one hydroxyl group, V is a single bond, W is a single bond or C 1-3 alkylene optionally substituted with one hydroxyl group, Q is NH2 , A compound or a pharmaceutically acceptable salt thereof.
- One embodiment of the compound represented by formula (5) includes the following (Q).
- (Q) R 8a is each independently a hydrogen atom
- L is C 1-3 alkylene optionally substituted with one hydroxyl group
- V is C 3-7 cycloalkylene
- W is C 1-3 alkylene optionally substituted with one hydroxyl group
- Q is NH2
- One embodiment of the compound represented by formula (6) includes the following (R).
- (R) R 8a is a hydrogen atom
- L is C 1-3 alkylene
- V is a single bond or C 3-7 cycloalkylene
- W is a single bond or C 1-3 alkylene
- Q is NH2
- a further aspect of the invention is a crystalline form of Form I of 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino) Pyrazine-2-carbonitrile hydrochloride, expressed in 2 ⁇ , 7.2° ⁇ 0.2°, 8.8° ⁇ 0.2°, 9.8° ⁇ 0.2°, 10.2 ° ⁇ 0.2°, 10.7° ⁇ 0.2°, 16.7° ⁇ 0.2°, 18.5° ⁇ 0.2°, 26.2° ⁇ 0.2°, and 27.
- Those having a powder X-ray diffraction pattern with characteristic peaks at 0° ⁇ 0.2° and 26.4° ⁇ 0.2° are mentioned.
- the crystal is identified by having four or five peaks selected from these ten peaks.
- 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile Mention is made of a crystalline form (Form II) of a phosphate salt having a powder X-ray diffraction pattern having a characteristic peak at at least 6.8° ⁇ 0.2°, expressed in 2 ⁇ .
- 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino)pyrazine-2-carbonitrile Mention is made of a crystalline form (Form II) of a phosphate salt having a powder X-ray diffraction pattern having a characteristic peak at at least 13.0° ⁇ 0.2°, expressed in 2 ⁇ .
- a further aspect of the invention is the crystalline form of 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino) Pyrazine-2-carbonitrile phosphate, expressed in 2 ⁇ , 6.8° ⁇ 0.2°, 7.5° ⁇ 0.2°, 11.7° ⁇ 0.2°, 11. 9° ⁇ 0.2°, 13.0° ⁇ 0.2°, 16.4° ⁇ 0.2°, 19.3° ⁇ 0.2°, 20.4° ⁇ 0.2°, 22.
- Examples include those having a powder X-ray diffraction pattern with characteristic peaks at 7° ⁇ 0.2° and 24.3° ⁇ 0.2°. The crystal is identified by having four or five peaks selected from these ten peaks.
- a further aspect of the invention is a crystalline form of 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino) of Form III.
- Pyrazine-2-carbonitrile tosylate expressed in 2 ⁇ , 6.0° ⁇ 0.2°, 9.0° ⁇ 0.2°, 12.1° ⁇ 0.2°, 14. Characterized by 4° ⁇ 0.2°, 16.2° ⁇ 0.2°, 17.0° ⁇ 0.2°, 22.8° ⁇ 0.2°, and 26.3° ⁇ 0.2° Examples include those having a powder X-ray diffraction pattern with a typical peak. The crystal is identified by having four or five peaks selected from these ten peaks.
- a further aspect of the invention is a crystalline form of 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino) of Form IV.
- Pyrazine-2-carbonitrile expressed in 2 ⁇ , 9.3° ⁇ 0.2°, 10.2° ⁇ 0.2°, 10.7° ⁇ 0.2°, 13.6° ⁇ 0.2°, 16.7° ⁇ 0.2°, 17.1° ⁇ 0.2°, 17.8° ⁇ 0.2°, 18.6° ⁇ 0.2°, 26.1° ⁇
- Examples include those having a powder X-ray diffraction pattern with characteristic peaks at 0.2° and 26.4° ⁇ 0.2°. The crystal is identified by having four or five peaks selected from these ten peaks.
- a further aspect of the invention is a crystalline form of Form V of 5-( ⁇ 5-[2-(3-aminopropoxy)-4-methoxypyridin-3-yl]-1H-pyrazol-3-yl ⁇ amino) Pyrazine-2-carbonitrile, expressed in 2 ⁇ , 7.9° ⁇ 0.2°, 8.7° ⁇ 0.2°, 12.2° ⁇ 0.2°, 13.1° ⁇ 0.2°, 15.9° ⁇ 0.2°, 17.6° ⁇ 0.2°, 19.9° ⁇ 0.2°, 21.9° ⁇ 0.2°, 22.8° ⁇
- Examples include those having a powder X-ray diffraction pattern having characteristic peaks at 0.2° and 26.6° ⁇ 0.2°. The crystal is identified by having four or five peaks selected from these ten peaks.
- Examples include those having a powder X-ray diffraction pattern having characteristic peaks at 0.2° and 14.1° ⁇ 0.2°. The crystal is identified by having four or five peaks selected from these ten peaks.
- the amount used varies depending on the symptoms, age, administration method, etc., but for example, in the case of intravenous injection, the lower limit is 0.01 mg per day for adults ( Effects are expected by administering 1000 mg (preferably 100 mg) once or in several doses depending on the symptoms.
- the administration schedule include single administration, once a day for three consecutive days, or twice a day for one week.
- each of the administration methods described above can be repeated at intervals of about 1 day to about 60 days.
- the compounds of the present disclosure may be administered parenterally or orally, but are preferably administered parenterally, more preferably by intravenous injection.
- the compounds of the present disclosure are also preferably formulated and administered in a pharmaceutically acceptable carrier, such as a liposome.
- the liposome encapsulating the compound of the present disclosure contains at least one type of phospholipid.
- phospholipids include phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and sphingomyelin.
- the fatty acid residue in the phospholipid is not particularly limited, but includes, for example, saturated or unsaturated fatty acid residues having 14 to 18 carbon atoms, and specifically, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, etc.
- Examples include acyl groups derived from fatty acids such as acids.
- phospholipids derived from natural products such as egg yolk lecithin and soybean lecithin, and hydrogenated egg yolk lecithin in which the unsaturated fatty acid residues thereof are hydrogenated, hydrogenated soybean lecithin (also called hydrogenated soybean phospholipid or hydrogenated soybean phosphatidylcholine). ) etc. can also be used.
- the amount (mole fraction) of phospholipids to be blended with respect to the entire liposome membrane component is not particularly limited, but is preferably 30 to 80%, more preferably 40 to 70%.
- Liposomes encapsulating the compounds of the present disclosure can include sterols.
- sterols include cholesterol, ⁇ -sitosterol, stigmasterol, campesterol, brassicasterol, ergosterol, and fucosterol.
- Preferable examples of sterols include cholesterol.
- the amount (mole fraction) of sterols to be added to the entire liposome membrane component is not particularly limited, but is preferably 0 to 60%, more preferably 10 to 50%, and still more preferably 30 to 50%. Can be mentioned.
- Liposomes encapsulating compounds of the present disclosure can include polymer-modified lipids to improve retention in vivo.
- the amount (mole fraction) of the polymer-modified lipid to be blended with respect to the entire liposome membrane component is not particularly limited, but is preferably 0 to 20%, more preferably 1 to 10%.
- the polymer portion of the polymer-modified lipid preferably includes a hydrophilic polymer, and more preferably includes a hydrophilic polymer in which the terminal of the polymer that is not bonded to a lipid is alkoxylated.
- the polymer moiety of the polymer-modified lipid is not particularly limited, but includes, for example, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, methoxypolyethylene glycol, methoxypolypropylene glycol, methoxypolyvinyl alcohol, methoxypolyvinylpyrrolidone, and ethoxy.
- examples include polyethylene glycol, ethoxypolypropylene glycol, ethoxypolyvinyl alcohol, ethoxypolyvinylpyrrolidone, propoxypolyethylene glycol, propoxypolypropylene glycol, propoxypolyvinyl alcohol, and propoxypolyvinylpyrrolidone.
- the polymer portion of the polymer-modified lipid preferably includes polyethylene glycol, methoxypolyethylene glycol, methoxypolypropylene glycol, ethoxypolyethylene glycol, ethoxypolypropylene glycol, propoxypolyethylene glycol, and propoxypolypropylene glycol. More preferred examples of the polymer moiety of the polymer-modified lipid include polyethylene glycol, methoxypolyethylene glycol, ethoxypolyethylene glycol, ethoxypolypropylene glycol, and propoxypolyethylene glycol. Even more preferred polymer moieties of polymer-modified lipids include polyethylene glycol and methoxypolyethylene glycol.
- the polymer moiety of the polymer-modified lipid most preferably includes methoxypolyethylene glycol.
- the molecular weight of the polymer moiety of the polymer-modified lipid is not particularly limited, but examples include 100 to 10,000 Daltons, preferably 1,000 to 7,000 Daltons, more preferably 1,500 to 5,000 Daltons, and most preferably 1,500 to 7,000 Daltons. An example is 3000 Daltons.
- the lipid moiety of the polymer-modified lipid is not specifically limited, but examples thereof include phosphatidylethanolamine and diacylglycerol.
- the lipid moiety of the polymer-modified lipid is preferably phosphatidylethanolamine having a saturated or unsaturated fatty acid residue having 14 to 18 carbon atoms, and diacylglycerol having a saturated or unsaturated fatty acid residue having 14 to 18 carbon atoms. and more preferably phosphatidylethanolamine having a saturated fatty acid residue having 14 to 18 carbon atoms, and diacylglycerol having a saturated fatty acid residue having 14 to 18 carbon atoms, and more preferably a palmitoyl group or a stearoyl group. and diacylglycerols having a palmitoyl group or a stearoyl group.
- the most preferred lipid moiety of the polymer-modified lipid is distearoyl phosphatidylethanolamine.
- Liposomes encapsulating the compounds of the present disclosure can include pharmaceutically acceptable additives.
- additives include inorganic acids, inorganic acid salts, organic acids, organic acid salts, sugars, buffers, antioxidants, and polymers.
- inorganic acids examples include phosphoric acid, hydrochloric acid, and sulfuric acid.
- inorganic acid salts include sodium hydrogen phosphate, sodium chloride, ammonium sulfate, and magnesium sulfate.
- organic acids examples include citric acid, acetic acid, succinic acid, and tartaric acid.
- organic acid salts examples include sodium citrate, sodium acetate, disodium succinate, and sodium tartrate.
- sugars examples include glucose, sucrose, mannitol, sorbitol, and trehalose.
- buffer examples include L-arginine, L-histidine, trometamol (trishydroxymethylaminomethane, Tris), and salts thereof.
- antioxidants examples include sodium sulfite, L-cysteine, sodium thioglycolate, sodium thiosulfate, ascorbic acid, and tocopherol.
- polymers examples include polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, and sodium carboxymethylcellulose.
- the compounds of the present disclosure can be produced using known compounds as starting materials, for example, by the following production methods A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, It can be produced by appropriately combining the methods of Q and R, methods analogous thereto, or synthetic methods well known to those skilled in the art.
- Compounds of the present disclosure other than formula (a2) can also be produced by methods similar to these or by appropriately combining synthesis methods well known to those skilled in the art.
- the compound of the present disclosure represented by formula (a2) can be produced, for example, by the following method.
- R 1 , R 2 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 1 means an amino protecting group. Examples of P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Step 1 Compound (a2) can be produced by removing the protecting group P 1 of compound (a1) obtained by the following production method. This step can be performed, for example, according to the method described in Protective Groups in Organic Synthesis (written by Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (b3) is available as a commercial product.
- Step 1 Compound (b2) can be produced by removing the protecting group P 2 of compound (b1) obtained by the following production method. This step can be performed, for example, according to the method described in Protective Groups in Organic Synthesis (written by Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (a1) can be produced by a Mitsunobu reaction between compound (b2) and compound (b3) in a suitable solvent in the presence of a Mitsunobu reagent.
- Mitsunobu reagent examples include diethyl azodicarboxylate (DEAD), isopropyl azodicarboxylate (DIAD), N,N,N',N'-tetraisopropylazodicarboxamide (TIPA), and 1,1'-(azodicarboxylate).
- DEAD diethyl azodicarboxylate
- DIAD isopropyl azodicarboxylate
- TIPA N,N,N',N'-tetraisopropylazodicarboxamide
- 1,1'-(azodicarboxylate) carbonyl)dipiperidine
- TMAD N,N,N',N'-tetramethylazodicarboxamide
- CMMP cyanomethylenetrimethylphosphorane
- CMBP cyano Methylenebutylphosphorane
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane.
- ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane.
- Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, Examples include aprotic solvents such as 1,3-dimethyl-2-imidazolidinone and dimethyl sulfoxide; or mixed solvents thereof.
- Preferred solvents include toluene, benzene, THF, 1,4-dioxane, and mixed solvents thereof.
- the reaction time is usually 5 minutes to 72 hours, preferably 12 hours to 24 hours.
- the reaction temperature is usually 0°C to 100°C, preferably 0°C to 50°C.
- the compound of the present disclosure represented by formula (b1) can be produced, for example, by the following method.
- R 1 , R 2 , X, Y and Z have the same meanings as described in Item 1, and P 2 means a phenol protecting group.
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (c2) can be produced by reacting compound (c1) with hydrazine monohydrate in a suitable solvent in the presence or absence of a suitable acid.
- acids examples include acetic acid, propionic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, hydrochloric acid, sulfuric acid, camphorsulfonic acid, and the like.
- Preferred acids include acetic acid, p-toluenesulfonic acid, and the like.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide; alcoholic solvents such as methanol, ethanol, isopropyl alcohol, butanol; or mixtures thereof.
- the solvent include 1,4-dioxane, toluene, and ethanol.
- the reaction time is usually 5 minutes to 72 hours, preferably 12 hours to 24 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 50°C to 100°C.
- Compound (b1) can be produced by reacting compound (c2) with a 5-chloropyrazine derivative in a suitable solvent in the presence of a suitable base.
- Compound (b1) can also be produced by reacting compound (c2) with a 5-chloropyrazine derivative in a suitable solvent in the presence of a suitable palladium catalyst, a ligand and a base.
- Examples of the base include triethylamine, diisopropylethylamine, tributylamine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7 -ene (DBU), pyridine, dimethylaminopyridine, picoline, N-methylmorpholine (NMM), organic bases such as N-ethylmorpholine, or sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, Examples include inorganic bases such as sodium hydroxide and potassium hydroxide.
- Preferred examples of the base include triethylamine, diisopropylethylamine, N-ethylmorpholine, potassium carbonate, and cesium carbonate.
- the palladium catalyst examples include salts such as palladium chloride and palladium acetate, and zero-valent palladium complexes such as tris(dibenzylideneacetone) dipalladium (0) chloroform adduct.
- Examples of the ligand include 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xanthos), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) , 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), and other phosphine ligands.
- Preferred examples of the ligand include 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantophos).
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide, and other aprotic solvents; or mixtures thereof.
- Preferred solvents include tetrahydrofuran, 1,4-dioxane, toluene, dimethyl sulfoxide and the like.
- the reaction time is usually 5 minutes to 48 hours, preferably 1 hour to 6 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 50°C to 100°C.
- Manufacturing method D The compound of the present disclosure represented by formula (c1) can be produced, for example, by the following method.
- R 1 , X, Y and Z have the same meanings as described in Item 1, and P 2 means a phenol protecting group.
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999). ]
- Compound (c1) can be produced by reacting compound (d1) with acetonitrile in an appropriate solvent in the presence of an appropriate base.
- an inorganic base can be used as the base.
- Inorganic bases include hydrides such as sodium hydride, alkali halides such as potassium fluoride, alkali hydroxides such as sodium hydroxide and potassium hydroxide, carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium hydrogen carbonate.
- Examples include alkali, alkali alkoxides such as sodium ethoxide, sodium tert-butoxide and potassium tert-butoxide, and alkali metals such as n-butyllithium, methyllithium and isopropylmagnesium bromide.
- Preferred bases include sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, n-butyllithium, and the like.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide; alcoholic solvents such as methanol, ethanol, isopropyl alcohol, butanol; or mixtures thereof.
- Preferred solvents include tetrahydrofuran, toluene, and the like.
- the reaction time is usually 5 minutes to 72 hours, preferably 12 hours to 24 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 50°C to 100°C.
- the compound of the present disclosure represented by formula (b1) can be produced, for example, by the following method.
- R 1 , R 2 , X, Y and Z have the same meanings as described in Item 1, and P 2 means a phenol protecting group.
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (e2) can be produced by reacting compound (e1) with carbon disulfide and iodomethane in a suitable solvent in the presence of a suitable base.
- an inorganic base can be used as the base.
- Inorganic bases include hydrides such as sodium hydride, alkali halides such as potassium fluoride, alkali hydroxides such as sodium hydroxide and potassium hydroxide, carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium hydrogen carbonate.
- Examples include alkali, alkali alkoxides such as sodium ethoxide, sodium tert-butoxide and potassium tert-butoxide, and alkali metals such as n-butyllithium, methyllithium and isopropylmagnesium bromide.
- Preferred bases include sodium hydride, potassium tert-butoxide, and the like.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide; alcoholic solvents such as methanol, ethanol, isopropyl alcohol, butanol; or mixtures thereof.
- Preferred solvents include tetrahydrofuran, toluene, N,N-dimethylformamide, and the like.
- the reaction time is usually 5 minutes to 72 hours, preferably 30 minutes to 2 hours.
- the reaction temperature is usually -78°C to 200°C, preferably 0°C to 25°C.
- Compound (e3) can be produced by reacting compound (e2) with a 5-aminopyrazine derivative in an appropriate solvent in the presence of an appropriate base.
- Examples of the base include triethylamine, diisopropylethylamine, tributylamine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7 -Ene (DBU), pyridine, dimethylaminopyridine, picoline, N-methylmorpholine (NMM), organic bases such as N-ethylmorpholine, or sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide and inorganic bases such as potassium hydroxide.
- Preferred bases include triethylamine, diisopropylethylamine, and the like.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide, and other aprotic solvents; or mixtures thereof.
- Preferred solvents include tetrahydrofuran, toluene, dimethyl sulfoxide, and the like.
- the reaction time is usually 5 minutes to 48 hours, preferably 2 hours to 8 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 50°C to 100°C.
- Compound (b1) can be produced by reacting compound (e3) with hydrazine monohydrate in a suitable solvent in the presence or absence of a suitable acid.
- acids examples include acetic acid, propionic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, hydrochloric acid, sulfuric acid, camphorsulfonic acid, and the like.
- the acid is acetic acid.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide; alcoholic solvents such as methanol, ethanol, isopropyl alcohol, butanol; or mixtures thereof.
- the solvent include 1,4-dioxane and ethanol.
- the reaction time is usually 5 minutes to 72 hours, preferably 12 hours to 24 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 50°C to 100°C.
- the compound of the present disclosure represented by formula (c1) can be produced, for example, by the following method.
- R 1 , X, Y and Z have the same meanings as described in Item 1, and P 2 means a phenol protecting group.
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (f1) can be produced by reacting compound (e1) with dimethylformamide dimethyl acetal in a suitable solvent.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide, and other aprotic solvents; or mixtures thereof.
- Preferred solvents include N,N-dimethylformamide and the like.
- the reaction time is usually 5 minutes to 48 hours, preferably 24 hours to 48 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 60°C to 120°C.
- Compound (f2) can be produced by reacting compound (f1) with hydroxyamine hydrochloride in a suitable solvent.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide; alcoholic solvents such as methanol, ethanol, isopropyl alcohol, butanol; or mixtures thereof.
- the solvent include ethanol, isopropyl alcohol, and the like.
- the reaction time is usually 5 minutes to 48 hours, preferably 6 hours to 12 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 40°C to 80°C.
- Compound (c1) can be produced by reacting compound (f2) with a base in an appropriate solvent.
- Examples of the base include inorganic bases such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, and potassium hydroxide.
- Preferred examples of the base include sodium hydroxide and potassium hydroxide.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, anisole, and 1,4-dioxane; Aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, and xylene; Ester solvents such as ethyl acetate and methyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1 , 3-dimethyl-2-imidazolidinone, dimethyl sulfoxide; protic solvents such as water, methanol, ethanol, isopropyl alcohol, butanol; or mixtures thereof.
- the solvent includes a mixed solvent of water and ethanol.
- the reaction time is usually 5 minutes to 48 hours, preferably 1 hour to 6 hours.
- the reaction temperature is usually 0°C to 200°C, preferably 20°C to 50°C.
- the compound of the present disclosure represented by formula (a1) can be produced, for example, by the following method.
- R 1 , R 2 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (g2) can be produced from compound (g1) obtained by the following production method by the method described in Step 1 of Production Method C or a method similar thereto.
- Compound (a1) can be produced from compound (g2) by the method described in Step 2 of Production Method C or a method analogous thereto.
- Manufacturing method H The compound represented by formula (a1) can be produced, for example, by the following method.
- R 1 , R 2 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 1 means an amino protecting group. Examples of P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (h2) can be produced from compound (h1) obtained by the following production method by the method described in Step 1 of Production Method E or a method analogous thereto.
- Compound (h3) can be produced from compound (h2) by the method described in Step 2 of Production Method E or a method analogous thereto.
- Compound (a1) can be produced from compound (h3) by the method described in Step 3 of Production Method E or a method analogous thereto.
- the compound represented by formula (g1) can be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 1 means an amino protecting group. Examples of P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Step 1 Compound (i1) can be produced from compound (h1) obtained by the following production method by the method described in Step 1 of Production Method F or a method analogous thereto.
- Compound (i2) can be produced from compound (i1) by the method described in Step 2 of Production Method F or a method analogous thereto.
- Step 3 Compound (g1) can be produced from compound (i2) by the method described in Step 3 of Production Method F or a method analogous thereto.
- the compound represented by formula (g1) can also be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 1 means an amino protecting group. Examples of P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (g1) can be produced from compound (j1) obtained by the following production method by the method described in Step 1 of Production Method D or a method analogous thereto.
- the compound of the present disclosure represented by formula (d1) can be produced, for example, by the following method.
- R 1 , X, Y and Z have the same meanings as described in Item 1, and P 2 means a phenol protecting group.
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (k1) is available as a commercial product.
- Compound (d1) can be produced from compound (k1), for example, by the method described in Protective Groups in Organic Synthesis (written by Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999). can do.
- the compound of the present disclosure represented by formula (e1) can be produced, for example, by the following method.
- R 1 , X, Y and Z have the same meanings as described in Item 1, and P 2 means a phenol protecting group.
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 2 include the phenol protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (l1) is available as a commercial product.
- Step 1 Compound (e1) can be produced from compound (l1) by the method described in Step 1 of Production Method K or a method analogous thereto.
- the compound of the present disclosure represented by formula (j1) can be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 1 means an amino protecting group. Examples of P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (j1) can be produced from compound (k1) and compound (b3) by the method described in Step 2 of Production Method B or a method analogous thereto.
- the compound of the present disclosure represented by formula (j1) can be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, P 1 means an amino protecting group, and LG means a leaving group do.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- LG include halogen, methanesulfonyloxy, p-toluenesulfonic acid, and trifluoromethanesulfonic acid.
- Compound (j1) can be produced by reacting compound (k1) and compound (n1) in an appropriate solvent in the presence or absence of an appropriate base.
- Examples of the base include triethylamine, diisopropylethylamine, tributylamine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7 -Ene (DBU), pyridine, 4-dimethylaminopyridine, picoline, organic bases such as N-methylmorpholine (NMM), or sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide, hydroxide Examples include inorganic bases such as potassium. Preferable examples of the base include triethylamine, diisopropylethylamine, potassium carbonate, and sodium hydroxide.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include alcoholic solvents such as methanol, ethanol, 2-propanol (isopropyl alcohol), and tert-butanol; diethyl ether, diisopropyl Ether solvents such as ether, tetrahydrofuran, methylcyclopentyl ether, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, anisole, and xylene; ester solvents such as ethyl acetate and methyl acetate; acetonitrile, Aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide; or mixtures thereof.
- Preferred solvents include 2-propanol, te
- the reaction temperature is usually -80°C to heating under reflux, preferably 25°C to 90°C.
- the reaction time is usually 30 minutes to 48 hours, preferably 6 to 12 hours.
- the compound of the present disclosure represented by formula (h1) can be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, and P 1 means an amino protecting group.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- P 1 means an amino protecting group. Examples of P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Compound (h1) can be produced from compound (l1) and compound (b3) by the method described in Step 2 of production method B or a method analogous thereto.
- the compound of the present disclosure represented by formula (h1) can be produced, for example, by the following method.
- P 1 means an amino protecting group
- LG means a leaving group do.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- LG include halogen, methanesulfonyloxy, p-toluenesulfonic acid, and trifluoromethanesulfonic acid.
- Compound (h1) can be produced from compound (l1) and compound (n1) by the method described in Step 2 of production method B or a method analogous thereto.
- the compound of the present disclosure represented by formula (h1) can be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, P 1 means an amino protecting group, and LG means a leaving group do.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- LG include halogen, methanesulfonyloxy, p-toluenesulfonic acid, and trifluoromethanesulfonic acid.
- Compound (q3) can be produced from compound (q1) and compound (q2) by the method described in Step 1 of Production Method N or a method analogous thereto.
- Compound (q4) can be produced by reacting compound (q3) and acetaldehyde in an appropriate solvent in the presence of an appropriate base.
- Examples of the base include n-butyllithium, sec-butyllithium, tert-butyllithium, lithium diisopropylamide, lithium tetramethylpiperidide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide.
- Examples include silazide, isopropylmagnesium chloride-lithium chloride complex, and the like.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methylcyclopentyl ether, and 1,4-dioxane; benzene, Aromatic hydrocarbon solvents such as toluene, chlorobenzene, anisole, xylene; halogen solvents such as methylene chloride, chloroform, 1,2-dichloroethane; acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N- Examples include aprotic solvents such as methyl-2-pyrrolidinone, 1,3-dimethyl-2-imidazolidinone, and dimethyl sulfoxide; or mixtures thereof. Preferred solvents include tetrahydrofuran.
- ether solvents such as diethyl ether, diisopropyl ether,
- the reaction temperature is usually -80°C to heating under reflux, preferably -80°C to 25°C.
- the reaction time is usually 30 minutes to 48 hours, preferably 6 to 12 hours.
- Compound (q5) can be produced by reacting compound (q4) with an appropriate oxidizing agent in an appropriate solvent in the presence or absence of an appropriate base.
- oxidizing agent examples include manganese dioxide, Dess-Martin reagent, dimethyl sulfoxide-oxalyl chloride, dimethyl sulfoxide-trifluoroacetic anhydride, sulfur trioxide-pyridine complex, 2,2,6,6-tetramethylpiperidine-1 -Oxyradical-sodium hypochlorite and the like.
- Examples of the base include triethylamine, diisopropylethylamine, tributylamine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7 -Ene (DBU), pyridine, 4-dimethylaminopyridine, picoline, organic bases such as N-methylmorpholine (NMM), or sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide, hydroxide Examples include inorganic bases such as potassium.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include halogenated solvents such as methylene chloride, chloroform, and 1,2-dichloroethane; diethyl ether, diisopropyl ether, tetrahydrofuran, and methyl.
- Ether solvents such as cyclopentyl ether and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, anisole, and xylene; ester solvents such as ethyl acetate and methyl acetate; acetonitrile, N,N-dimethyl
- aprotic solvents such as formamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1,3-dimethyl-2-imidazolidinone, and dimethylsulfoxide; or mixtures thereof.
- Preferred solvents include methylene chloride, tetrahydrofuran, toluene, acetonitrile, N,N-dimethylformamide and the like.
- the reaction temperature is usually -80°C to heating under reflux, preferably -80°C to 25°C.
- the reaction time is usually 30 minutes to 48 hours, preferably 6 to 12 hours.
- Compound (h1) can be produced from compound (q5) and compound (b3) by the method described in Step 2 of Production Method B or a method analogous thereto.
- the compound of the present disclosure represented by formula (i2) can be produced, for example, by the following method.
- R 1 , R 14 , X, Y, Z, L, V and W have the same meanings as described in Item 1, P 1 means an amino protecting group, and LG means a leaving group do.
- P 1 include the amino protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- LG include halogen, methanesulfonyloxy, p-toluenesulfonic acid, and trifluoromethanesulfonic acid.
- Step 1 Compound (r1) can be produced from compound (l1) by the method described in Step 1 of Production Method F or a method analogous thereto.
- Compound (r2) can be produced from compound (r1) by the method described in Step 2 of Production Method F or a method analogous thereto.
- Compound (r3) can be produced by reacting compound (r2) with a suitable halogenating agent or sulfonylating agent in the presence or absence of a suitable base, in a suitable solvent or without a solvent. .
- halogenating agent or sulfonylating agent examples include thionyl chloride, phosphorus oxychloride, oxalyl chloride, phosphorus tribromide, methanesulfonyl chloride, N-phenylbis(trifluoromethanesulfonimide), trifluoromethanesulfonic anhydride, etc. Can be mentioned.
- Examples of the base include triethylamine, diisopropylethylamine, tributylamine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7 -Ene (DBU), pyridine, 4-dimethylaminopyridine, picoline, organic bases such as N-methylmorpholine (NMM), or sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide, hydroxide Examples include inorganic bases such as potassium.
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include halogenated solvents such as methylene chloride, chloroform, and 1,2-dichloroethane; diethyl ether, diisopropyl ether, tetrahydrofuran, and methyl.
- Ether solvents such as cyclopentyl ether and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, anisole, and xylene; ester solvents such as ethyl acetate and methyl acetate; acetonitrile, N,N-dimethyl
- aprotic solvents such as formamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1,3-dimethyl-2-imidazolidinone, and dimethylsulfoxide; or mixtures thereof.
- Preferred solvents include methylene chloride, tetrahydrofuran, toluene, acetonitrile, N,N-dimethylformamide and the like.
- the reaction temperature is usually -80°C to heating reflux, preferably 0°C to heating refluxing.
- the reaction time is usually 30 minutes to 48 hours, preferably 30 minutes to 12 hours.
- Compound (i2) can be produced by a reaction of compound (r3) and compound (b3) in an appropriate solvent in the presence of an appropriate base, catalyzed by an appropriate palladium source and a ligand.
- the base examples include organic bases such as triethylamine, diisopropylethylamine, tributylamine, pyridine, 4-dimethylaminopyridine, picoline, and N-methylmorpholine (NMM), or sodium carbonate, potassium carbonate, cesium carbonate, and sodium hydroxide. and inorganic bases such as potassium hydroxide.
- organic bases such as triethylamine, diisopropylethylamine, tributylamine, pyridine, 4-dimethylaminopyridine, picoline, and N-methylmorpholine (NMM), or sodium carbonate, potassium carbonate, cesium carbonate, and sodium hydroxide.
- inorganic bases such as potassium hydroxide.
- Preferred bases include diisopropylethylamine, cesium carbonate, and the like.
- the palladium source examples include salts such as palladium chloride and palladium acetate, and zero-valent palladium complexes such as tris(dibenzylideneacetone) dipalladium (0) chloroform adduct.
- a ligand 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantophos), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 2- Examples include phosphine ligands such as dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos). Preferred examples of the ligand include 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantophos).
- the solvent is not particularly limited as long as it does not react under the reaction conditions of this step, but examples include halogenated solvents such as methylene chloride, chloroform, and 1,2-dichloroethane; diethyl ether, diisopropyl ether, tetrahydrofuran, and methyl.
- Ether solvents such as cyclopentyl ether and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene, toluene, chlorobenzene, anisole, and xylene; ester solvents such as ethyl acetate and methyl acetate; acetonitrile, N,N-dimethyl
- aprotic solvents such as formamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone, 1,3-dimethyl-2-imidazolidinone, and dimethylsulfoxide; or mixtures thereof.
- Preferred solvents include tetrahydrofuran, 1,4-dioxane, toluene, acetonitrile, N,N-dimethylformamide and the like.
- the reaction temperature is usually 0°C to reflux, preferably 50°C to reflux.
- the reaction time is usually 5 minutes to 72 hours, preferably 2 to 12 hours.
- a protecting group can be used as necessary, even if the use of a protecting group is not specifically specified. For example, if any functional group other than the reactive site changes under the described reaction conditions or is inappropriate in the absence of a protecting group to carry out the described method, other functional groups other than the reactive site may be protected as necessary. Then, the target compound can be obtained by deprotecting the compound after the completion of the reaction or after performing a series of reactions.
- protecting group for example, the protecting groups described in Protective Groups in Organic Synthesis (written by Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999) can be used. I can do it.
- Specific examples of amino protecting groups include benzyloxycarbonyl, tert-butoxycarbonyl, acetyl, benzyl and the like.
- Specific examples of the hydroxyl protecting group include trialkylsilyl such as trimethylsilyl and tert-butyldimethylsilyl, acetyl, and benzyl.
- the introduction and removal of a protecting group can be carried out by a method commonly used in organic synthetic chemistry (for example, see the above-mentioned Protective Groups in Organic Synthesis) or a method analogous thereto.
- the intermediates or target compounds in the production method explained above should be modified as appropriate by converting their functional groups (e.g., protecting and deprotecting the functional groups as necessary, and using amino, hydroxyl, carbonyl, halogen, etc. as a foothold).
- Various transformations can also lead to other compounds included in this disclosure. Transformation of the functional group can be performed by a commonly used method (for example, see Comprehensive Organic Transformations, RC Larock, John Wiley & Sons Inc. (1999), etc.).
- the intermediates and target compounds in the production method explained above are isolated by purification methods commonly used in organic synthetic chemistry (e.g., neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography, etc.). Can be purified. Furthermore, the intermediate can be used in the next reaction without being particularly purified.
- acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, phosphate, or citrate, oxalate, phthalate, etc. Fumarate, maleate, succinate, malate, acetate, formate, propionate, benzoate, trifluoroacetate, methanesulfonate, benzenesulfonate, para-toluenesulfonic acid Examples include organic acid salts such as salts and camphorsulfonates.
- base addition salts include inorganic base salts such as sodium salts, potassium salts, calcium salts, magnesium salts, barium salts, and aluminum salts, or trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, and diethanolamine. , triethanolamine, tromethamine [tris(hydroxymethyl)methylamine], tert-butylamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylamine, and other organic base salts.
- examples of “pharmaceutically acceptable salts” include amino acid salts with basic or acidic amino acids such as arginine, lysine, ornithine, aspartic acid, or glutamic acid.
- Suitable salts of the starting materials and intermediates and salts acceptable as pharmaceutical raw materials are customary non-toxic salts. These include, for example, organic acid salts (e.g. acetate, trifluoroacetate, maleate, fumarate, citrate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate). salts, etc.) and acid addition salts such as inorganic acid salts (e.g. hydrochlorides, hydrobromides, hydroiodides, sulfates, nitrates, phosphates, etc.), amino acids (e.g.
- metal salts such as alkali metal salts (e.g. sodium salts, potassium salts, etc.), alkaline earth metal salts (e.g. calcium salts, magnesium salts, etc.), ammonium salts, organic base salts (e.g. trimethylamine salts, triethylamine salts) , pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), and can be appropriately selected by those skilled in the art.
- alkali metal salts e.g. sodium salts, potassium salts, etc.
- alkaline earth metal salts e.g. calcium salts, magnesium salts, etc.
- ammonium salts e.g. trimethylamine salts, triethylamine salts
- organic base salts e.g. trimethylamine salts, triethylamine salts
- pyridine salt e.g. trimethylamine salts, triethylamine
- deuterium converters obtained by converting any one or more of 1 H of compounds represented by formulas (1) to (5) to 2 H (D) also include deuterium converted products of formulas (1) to (5). It is included in the compounds represented by 5).
- the present disclosure includes compounds represented by formulas (1) to (5) or pharmaceutically acceptable salts thereof. Furthermore, since the compounds of the present disclosure may exist in the form of hydrates and/or solvates with various solvents (ethanolates, etc.), these hydrates and/or solvates are also included in the present disclosure. Included in the disclosed compounds.
- the compounds of the present disclosure include optical isomers based on optically active centers, atropisomers based on axial or planar chirality caused by intramolecular rotation constraints, other stereoisomers, tautomers, It includes all possible isomers such as geometric isomers and all forms of crystalline forms, as well as mixtures thereof.
- optical isomers and atropisomers can be obtained as racemates or as optically active forms when optically active starting materials or intermediates are used.
- the corresponding raw material, intermediate, or racemic form of the final product may be separated by a known separation method such as a method using an optically active column or a fractional crystallization method. They can be physically or chemically separated into their optical antipodes.
- separation methods include, for example, reacting a racemate with an optically active resolving agent to synthesize two diastereomers, and then taking advantage of their different physical properties to resolve the diastereomers by methods such as fractional crystallization. Examples include the stereomer method.
- a pharmaceutically acceptable salt of the compound of the present disclosure when it is desired to obtain a pharmaceutically acceptable salt of the compound of the present disclosure, when the compounds represented by formulas (1) to (5) are obtained in the form of a pharmaceutically acceptable salt, It may be purified as it is, or if it is obtained in a free form, it may be dissolved or suspended in an appropriate organic solvent, and an acid or base may be added to form a salt by a conventional method.
- a liposome encapsulating the compound of the present disclosure can be produced, for example, by the method below.
- Step 1 Membrane components such as phospholipids and cholesterol are dissolved in an organic solvent such as chloroform, and the organic solvent is distilled off within the flask to form a thin film of the lipid mixture on the inner wall of the flask.
- the lipid mixture may be obtained as a freeze-dried product by dissolving it in t-butyl alcohol or the like and then freeze-drying it.
- a lipid mixture can be obtained by using an instant vacuum dryer CRUX (manufactured by Hosokawa Micron Corporation) to obtain a powdered lipid mixture, which is known as Presome (registered trademark). It can be obtained from Nippon Fine Chemical Co., Ltd.
- Step 2 A crude liposome dispersion is obtained by adding an internal aqueous phase solution such as an aqueous ammonium sulfate solution to the lipid mixture obtained in Step 1 and dispersing it.
- an internal aqueous phase solution such as an aqueous ammonium sulfate solution
- Step 3 Using an extruder, the crude liposome dispersion obtained in step 2 is passed through a filter to obtain a desired particle size. Alternatively, the crude liposome dispersion obtained in step 2 is discharged from a nozzle at high pressure using a high-pressure homogenizer to obtain a desired particle size.
- the particle size of the liposome is not particularly limited, but is, for example, 10 nm to 200 nm, preferably 30 nm to 150 nm, more preferably 40 nm to 140 nm, even more preferably 50 to 120 nm, and most preferably 60 to 100 nm.
- the particle size of the liposome is an average value measured by a dynamic light scattering method, and can be measured using, for example, Zetasizer Nano ZS (Malvern Instruments).
- Step 4 The external aqueous phase of the liposome solution obtained in step 3 is replaced by gel filtration, dialysis, tangential flow filtration, ultracentrifugation, or the like.
- Step 5 The compound is encapsulated in the liposome by incubating the liposome solution obtained in step 4, in which the external aqueous phase has been replaced, with the compound to be encapsulated.
- Step 6 The resulting compound-encapsulated liposome is subjected to gel filtration, dialysis, tangential flow filtration, ultracentrifugation, or the like to remove unencapsulated compounds. Note that if the desired encapsulation rate is obtained in step 5, step 6 can be omitted.
- the compounds of the present disclosure can be used in combination with other drugs for the purpose of enhancing their effects.
- the compounds of the present disclosure can be used in combination with drugs such as hormonal therapeutic agents, chemotherapeutic agents, immunotherapeutic agents, or agents that inhibit the action of cell growth factors and their receptors.
- drugs such as hormonal therapeutic agents, chemotherapeutic agents, immunotherapeutic agents, or agents that inhibit the action of cell growth factors and their receptors.
- a drug that can be used in combination with the compound of the present disclosure will be abbreviated as a concomitant drug.
- the compound of the present disclosure exhibits excellent anticancer activity even when used as a single agent, but when used in combination with one or more of the above-mentioned concomitant drugs (multidrug combination), the compound can further enhance its effect or improve the patient's health. QOL can be improved.
- hormone therapy agents include fosfestrol, diethylstilbestrol, chlorotrianisene, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, cyproterone acetate, danazol, dienogest, asoprisnil, allylestrenol, Rinone, Nomegestol, Tadenane, Mepartricin, Raloxifene, Ormeloxifene, Levormeloxifene, Antiestrogens (e.g.
- chemotherapeutic agents include alkylating agents, antimetabolites, anticancer antibiotics, plant-derived anticancer agents, molecular target therapeutic agents, immunomodulators, and other chemotherapeutic agents. Typical examples are listed below.
- alkylating agent examples include nitrogen mustard, nitrogen mustard hydrochloride-N-oxide, chlorambutyl, cyclophosphamide, ifosfamide, thiotepa, carbocone, improsulfan tosylate, busulfan, nimustine hydrochloride, mitobronitol, mer Faran, dacarbazine, ranimustine, estramustine sodium phosphate, triethylenemelamine, carmustine, lomustine, streptozodin, pipobroman, etogluside, carboplatin, cisplatin, miboplatin, nedaplatin, oxaliplatin, altretamine, ambamustine, dibrospidium hydrochloride, fotemustine , prednimustine, pumitepa, ribomustine, temozolomide, treosulfan, trophosfamide, dinostatin stimaramer, ado
- antimetabolites include mercaptopurine, 6-mercaptopurine riboside, thioinosine, methotrexate, pemetrexed, eocitabine, cytarabine, cytarabine oxphosphate, ancitabine hydrochloride, 5-FU drugs (e.g., fluorouracil, tegafur, UFT, doxifluridine, carmofur, gallocitabine, emitefur, capecitabine, etc.), aminopterin, nerzarabine, leucoporin calcium, tabloid, butocin, folinate calcium, levofolinate calcium, cladribine, emitefur, fludarabine, gemcitabine, hydroxycarpamide, pentostatin , pyritrexime, idoxyuridine, mitoguazone, tiazofurin, ambamustine, bendamustine, and DDS formulations thereof.
- 5-FU drugs e.g., fluorour
- anticancer antibiotics include actinomycin D, actinomycin C, mitomycin C, chromomycin A3, bleomycin hydrochloride, bleomycin sulfate, pepromycin sulfate, daunorubicin hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, pirarubicin hydrochloride, and epirubicin hydrochloride.
- neocarzinostatin mithramycin, sarcomycin, carcinophylline, mitotane, zorubicin hydrochloride, mitoxantrone hydrochloride, idarubicin hydrochloride, eribulin, and DDS preparations thereof.
- plant-derived anticancer drugs include etoposide, etoposide phosphate, vinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, paclitaxel, docetaxel, DJ-927, vinorelbine, irinotecan, topotecan, and DDS preparations thereof.
- molecular target therapeutic agents include imatinib, gefitinib, erlotinib, sorafenib, dasatinib, sunitinib, nilotinib, lapatinib, pazopanib, ruxolitinib, crizotinib, vemurafenib, vandetanib, ponatinib, cabozantinib, tofacitinib, regorafenib, bosutinib, Axitinib, dabrafenib , trametinib, nintedanib, idelalisib, ceritinib, lenvatinib, palbociclib, alectinib, afatinib, osimertinib, ribociclib, abemaciclib, brigatinib, neratinib, copanlisib,
- immunomodulators examples include lenalidomide and pomalidomide.
- immunotherapeutic agents include picibanil, krestin, schizophyllan, lentinan, ubenimex, interferon, interleukin, macrophage colony stimulating factor, granulocyte colony stimulating factor, erythropoietin, lymphotoxin, BCG vaccine, corynebacterium Umparvum, levamisole, polysaccharide K, procodazole, anti-CTLA4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, Toll-like Receptors agonist (e.g., TLR7 agonist, TLR8 agonist, TLR9 agonist, etc.) can be mentioned.
- TLR7 agonist e.g., TLR7 agonist, TLR8 agonist, TLR9 agonist, etc.
- the cell growth factor in a drug that inhibits the action of cell growth factors and their receptors may be any substance as long as it promotes cell growth, and is usually a peptide with a molecular weight of 20,000 or less. There are factors that exert their effects at low concentrations due to their binding with the body.
- EGF epidermal growth factor
- a substance having substantially the same activity as EGF e.g., TGFalpha, etc.
- insulin or a substance having substantially the same activity as EGF e.g., insulin, IGF (insulin- like growth factor)-1, IGF-2, etc.
- FGF fibroblast growth factor
- a substance that has an assay substantially the same as it for example, acidic FGF, basic FGF, KGK (keratinocyte growth factor) factor), FGF-10
- other cell growth factors e.g.
- CSF colony stimulating factor
- EPO erythropoietin
- IL-2 interleukin-2
- NGF nerve growth factor
- PDGF platelet-derived growth factor
- TGF-beta transforming growth factor beta
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- the administration period of the compound of the present disclosure and the concomitant drug is not limited, and they may be administered to the subject at the same time or at different times. It may also be a combination of the compound of the present disclosure and a concomitant drug.
- the dosage of the concomitant drug can be appropriately selected based on the clinically used dosage.
- the compounding ratio of the compound of the present disclosure and the concomitant drug can be appropriately selected depending on the subject of administration, administration route, target disease, symptoms, combination, etc. For example, when the subject to be administered is a human, 0.01 to 100 parts by weight of the concomitant drug may be used per 1 part by weight of the compound of the present disclosure.
- drugs concomitant drugs
- it can be used in combination with drugs (concomitant drugs) such as antiemetics, sleep-inducing drugs, and anticonvulsants.
- “Showing treatment resistance to immune checkpoint inhibitors” refers to a state in which tumor growth cannot be suppressed in solid cancers even if immune checkpoint inhibitors are administered.
- Showing resistance to anti-PD-1 antibodies means a state in which tumor growth cannot be suppressed even when the above-mentioned anti-PD-1 antibodies are administered.
- Showing resistance to anti-PD-L1 antibody means a state in which tumor growth cannot be suppressed even when the above-mentioned anti-PD-L1 antibody is administered.
- blood cancer this refers to a state in which the increase in the number of cancer cells in the blood cannot be suppressed even if immune checkpoint inhibitors are administered.
- Showing resistance to anti-PD-1 antibodies means a state in which an increase in the number of cancer cells in the blood cannot be suppressed even if the anti-PD-1 antibody described above is administered.
- Showing resistance to anti-PD-L1 antibodies means a state in which an increase in the number of cancer cells in the blood cannot be suppressed even if the anti-PD-L1 antibody described above is administered.
- Anti-PD-1 antibody is a protein that recognizes PD-1 molecules, has a Y-shaped four-chain structure (two polypeptide chains each of light chain and heavy chain), and has a Fab site. This is a molecule that selectively recognizes one molecule.
- Anti-PD-1 antibodies are produced by fusing antibody-producing B cells with myeloma to produce hybridomas, and then purifying the antibodies secreted into the culture supernatant.
- the M1-M2 ratio of macrophages refers to the cell group defined by M1 macrophage markers (e.g., CD86, STAT1, IL-1beta, iNOS, CXCL9, CXCL10, etc.) and the M2 macrophage markers (e.g., Mrc1, Arg1, CD163, etc.). etc.) refers to the ratio of cell groups defined by The higher this value is, the more inflammatory the environment within the tumor becomes, meaning that the anti-PD-1/PD-L1 antibody is more likely to exert its effect.
- M1 macrophage markers e.g., CD86, STAT1, IL-1beta, iNOS, CXCL9, CXCL10, etc.
- Mrc1, Arg1, CD163, etc. M2 macrophage markers
- TMB-High Tumor Mutation Burden-High
- TMB-High refers to a cancer whose TMB score measured in the Foundation One CDx cancer genome profile is 10 mut/Mb or more.
- a patient who is anti-PD-1 antibody responsive refers to a state in which tumor growth can be suppressed by administering an anti-PD-1 antibody.
- a state in which tumor growth is suppressed refers to a state of stable disease (SD), partial response (PR), or complete response (CR) according to the RECIST criteria.
- SD stable disease
- PR partial response
- CR complete response
- DCB Durable Clinical Benefit
- anti-PD-1 antibodies are detected 3 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks later. may be administered.
- the M1-M2 ratio of macrophages in cancer patients showing treatment resistance to immune checkpoint inhibitors is preferably 21 or less, 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 Below, 13 or less, 12 or less, 11 or less, 10 or less, 9.9 or less, 9.8 or less, 9.7 or less, 9.6 or less, 9.5 or less, 9.4 or less, 9.3 or less, 9 .2 or less, 9.1 or less, 9.0 or less, 8.9 or less, 8.8 or less, 8.7 or less, 8.6 or less, 8.5 or less, 8.4 or less, 8.3 or less, 8 .2 or less, 8.1 or less, 8.0 or less, 7.9 or less, 7.8 or less, 7.7 or less, 7.6 or less, 7.5 or less, 7.4 or less, 7.3 or less, 7 .2 or less, 7.1 or less, 7.0 or less, 6.9 or less, 6.8 or less, 6.7 or less, 6.6 or less, 6.5 or less
- the number of CD8-positive cells in tumor tissues of cancer patients exhibiting treatment resistance to immune checkpoint inhibitors is preferably 0.135 or less, 0.130 or less, 0.125 or less, 0.120 or less, 0.115 or less, 0.110 or less, 0.095 or less, 0.090 or less, 0.085 or less, 0.080 or less, 0.075 or less, 0.070 or less, 0.065 or less, 0.060 or less, 0.055 or less, 0.050 or less, 0.045 or less, 0.040 or less, 0.035 or less, 0.030 or less, 0.025 or less, 0.020 or less, 0.015 or less, 0.010 or less be.
- Ts p-Toluenesulfonyl
- THF Tetrahydrofuran
- TFA Trifluoroacetic acid
- DMF N,N-dimethylformamide
- DMSO Dimethyl sulfoxide
- MeCN Acetonitrile
- Dess-Martin reagent Dess-Martin periodinane ( 1,1,1-triacetoxy-1,1-dihydro-1,2-benzoiodoxol-3-(1H)-one)
- NMR (Nuclear Magnetic Resonance) data used for compound identification was obtained using a JNM-ECS400 nuclear magnetic resonance apparatus (400 MHz) manufactured by JEOL Ltd. Symbols used in NMR include s for singlet, d for doublet, dd for doublet, t for triplet, td for triplet doublet, q for quartet, m stands for multiplet, br for broad, brs for broad singlet, brm for broad multiplet and J for coupling constant.
- the LC/MS (Liquid Chromatography-Mass Spectrometry) analysis conditions used for compound identification are as follows. Among the observed mass spectrometry values [MS (m/z)], the value corresponding to the monoisotopic mass (accurate mass consisting only of the main isotope) is expressed as [M+H] + , [MH] - or [M+2H] 2+ etc., and the retention time is indicated as Rt (minutes).
- a Detection device ACQUITY (registered trademark) SQ detector (Waters)
- HPLC ACQUITY UPLC (registered trademark) system
- Column Waters ACQUITY UPLC (registered trademark) BEH C18 (1.7 ⁇ m, 2.1 mm x 30 mm)
- Solvent A solution: 0.06% formic acid/H 2 O, B solution: 0.06% formic acid/MeCN Gradient condition: 0.0-1.3min Linear gradient from B 2% to 96% Flow rate: 0.8mL/min UV: 220nm and 254nm Column temperature: 40°C
- Measurement condition B Detection equipment: APCI 6120 Quadrupole LC/MS (Agilent Technologies) HPLC: Agilent Technologies 1260 Infinity® system Column: Agilent Technologies (registered trademark) ZORBAX SB-C18 (1.8 ⁇ m, 2.1 mm x 50 mm) Solvent: A solution: 0.1% formic acid/H 2 O, B solution: MeCN Gradient condition: 0.0-5.0min Linear gradient from B 5% to 90% Flow rate: 0.6mL/min UV: 210nm, 254nm, and 280nm Column temperature: 40°C
- tert-butyl (3- ⁇ [3-(cyanoacetyl)-4-methoxypyridin-2-yl]oxy ⁇ propyl)carbamate tert-butyl (3- ⁇ [4-methoxy-3-(1, Potassium hydroxide (0.29 g) was added to a mixed solution of 2-oxazol-5-yl)pyridin-2-yl]oxy ⁇ propyl) carbamate (1.63 g) in ethanol (20.0 mL) and water (5.00 mL). ) and stirred at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was added to saturated brine for quenching.
- reaction mixture was quenched by adding saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. After drying the organic layer over anhydrous sodium sulfate, it was filtered off, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain the title compound (4.25 g).
- Reference examples 8 to 41 Compounds of Reference Examples 8 to 41 shown in the table below were obtained by the same method as described in Reference Examples 1 to 7 using the corresponding raw material compounds.
- Reference examples 43 to 78 Compounds of Reference Examples 43 to 78 shown in the table below were obtained by a method similar to that described in Reference Example 42 using the corresponding raw material compounds.
- Examples 2-38 Compounds of Examples 2 to 38 shown in the table below were obtained in the same manner as in Example 1 using the corresponding starting compounds.
- Examples 39 to 44 Powder X-ray diffraction measurements of Examples 39 to 44 were performed under the conditions shown below. The obtained diffraction patterns (XRD spectra) are shown in FIGS. 1 to 6. Examples 39 to 41 are crystals of various salts of the compound of Example 1, and Examples 42 to 44 are crystal polymorphs of the compound of Example 1.
- the crystal form may be determined based on the characteristic diffraction peaks of each crystal shown in the diffraction diagrams of FIGS. 1 to 6.
- the main diffraction peaks and characteristic diffraction peaks identified from the diffraction patterns shown in FIGS. 1 to 6 are listed below. It should be noted that the diffraction peak values at the diffraction angle 2 ⁇ (°) described in the following examples may have some measurement error depending on the measuring equipment or measurement conditions. Specifically, the measurement error may be within the range of ⁇ 0.2, preferably ⁇ 0.1.
- Powder X-ray diffraction measurement method Detection equipment: Spectris Power X-ray diffraction system Empyrian X-ray tube: CuK ⁇ (wavelength: 1.54 angstroms) Tube voltage: 45kV Tube current: 40mA Measurement range: 4 to 40 degrees (2 ⁇ ) Step width: 0.013 degrees Accumulated time: 100 seconds/step
- Test example Test Example 1 CHK1 inhibitory activity test IMAP TR-FRET Screening Express Kit (R8160) was obtained from Molecular Devices. CHK1 kinase (02-117, CarnaBio Inc.), FAM-labeled CHK1tide (R7185, Molecular Devices Inc.), and ATP were diluted with assay buffer to final concentrations of 4 ⁇ g/mL, 2 ⁇ M, and 20 ⁇ M, respectively. FAM-PKAtide (R7255, Molecular Devices) and FAM-Phospho-PKAtide (R7304, Molecular Devices) were diluted and mixed, followed by a standard series of calibrations with phosphorylation levels from 0 to 100%. Created.
- Binding Reagent 80% Buffer A, 20% Buffer B, 60 ⁇ L of 1:600 Binding Reagent, 1:400 Tb-Donor was added, and binding reaction was performed at room temperature for 2 hours. Fluorescence intensities at 520 nm and 490 nm upon excitation at 340 nm were obtained using SpectraMax Paradigm (Molecular Devices).
- the phosphorylation level of CHK1tide was calculated using standard, the phosphorylation level was set as 100% in the DMSO-treated group, and the kinase activity was determined using the formula shown below, and the concentration corresponds to the concentration of the evaluation compound showing 50% kinase activity. IC50 values were calculated.
- Test Example 1 The test shown in Test Example 1 was conducted on the compounds obtained in the examples and prexasertib purchased from MedChemExpress (the source is the same in the following test examples).
- IC 50 values (nM) of test results for each test substance are shown in the table below.
- Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 17, 18, 19, 20, 21, 22, 24 , 26, 28, 30 and 37 showed a stronger inhibitory effect on CHK1 activity than prexasertib.
- the compounds of Examples 1 and 8 have an exceptional effect of particularly strongly suppressing CHK1 activity.
- ES-2 cells were obtained from the American Type Culture Collection (ATCC). The cells were cultured in McCoy's 5a medium containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37° C. in the presence of 5% CO 2 . 500 cells per well were seeded in a 384-well plate, the evaluation compound was added so that the final concentration of DMSO was 0.1%, and the cells were cultured for 2 days. After completion of the culture, cell viability was calculated using CellTiter-Glo (registered trademark) 3D Reagent (Promega, G968B). From the survival rate curve, an IC 50 value corresponding to the concentration of the evaluation compound at which the inhibition rate of cell proliferation was 50% was calculated. Note that ES-2 cells are known to exhibit resistance to cisplatin.
- Test Example 2 The test shown in Test Example 2 was conducted on the compounds obtained in Examples and prexasertib.
- the table below shows the concentration (IC 50 value; nM) of each test substance that inhibits cell proliferation by 50%.
- results of cell growth inhibition tests of representative compounds of the present disclosure are listed based on the ratings of I, II, III, IV, and V (1000 nM ⁇ I, 1000 nM>II> 300nM, 300nM>III>100nM, 100nM>IV>30nM, 30nM>V).
- Examples 1, 3, 4, 5, 6, 11, 15, 17, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32 , 33, 35, 36, 37, and 38 showed good cell proliferation inhibitory effects comparable to prexasertib.
- Test Example 3 hERG current inhibition test A test substance was added to cultured CHO cell line cells stably expressing hERG (human ether-a-go-go related gene) gene at a concentration of 0.27 to 100 ⁇ M. The hERG current under voltage stimulation was measured using Qube384 (Sophion Bioscience), and the concentration (IC 50 value; ⁇ M) at which each test substance inhibited the hERG current by 50% was calculated.
- Test Example 3 The test shown in Test Example 3 was conducted on the compounds obtained in Examples and prexasertib. Furthermore, for the compounds of each Example, the value obtained by dividing the hERG IC 50 obtained in Test Example 3 by the CHK1 inhibition IC 50 obtained in Test Example 1 was calculated as hERG/CHK1. The results are shown in the table below.
- the compounds of Examples 1, 3, 4, 7 to 10, 14, 24, 32, and 34 have a deviation width of 50,000 times or more between the IC 50 of CHK1 inhibition and the IC 50 of hERG. It was shown that Among them, the compounds of Examples 1, 3, 7, 8, 14, and 24 were shown to have a deviation width of 100,000 times or more between the IC 50 of CHK1 inhibition and the IC 50 of hERG. These 6 compounds showed disparity more than 18 times that of prexasertib, and had heterogeneous effects with high safety.
- CYP3A4 MBI and Enzyme Inactivation Clearance Evaluation Cytochrome P450 (hereinafter referred to as CYP) is the most important enzyme group involved in drug metabolism, and many pharmacokinetic interactions are based on inhibition of these CYP activities. There are multiple molecular species of CYP, and in particular, CYP3A4 is most involved in the metabolism of pharmaceuticals in the oxidation reaction by CYP, and also accounts for the majority of the CYPs present in the liver.
- CYP inhibition There are two main types of CYP inhibition: “reversible inhibition” and “mechanism-based inhibition (MBI).”
- MBI mechanism-based inhibition
- CYP inhibition based on MBI can cause not only drug interactions but also serious side effects (hepatic side effects). Toxicity, etc.) (Curr Open Drug Discov Dev. 2010 January, 13(1), 66-77, Therapeutics and Clinical Risk Management, 2005, 1(1), 3-13).
- MBI and enzyme inactivation clearance of CYP3A4 were evaluated using the compound of this example and prexasertib.
- the inhibitory effect and inhibition mode of the test compound on CYP3A4 was evaluated. After metabolic reaction at 37°C for 30 minutes, the substrate-derived metabolic products of the test compound addition group (4 concentrations) and the substrate-derived metabolic products of the non-addition group were measured by LC-MS/MS, and the inhibition rate was calculated from the ratio. was calculated. In addition, IC 50 values were calculated from the concentration plots.
- kinact maximal enzyme inactivation rate constant
- K I concentration of inhibitor resulting in a rate of 50% of the maximum enzyme inactivation rate
- the table below shows the fold change in IC 50 value and enzyme inactivation clearance due to preincubation, which are indicators of the MBI action of each example compound and prexasertib on CYP3A4.
- prexasertib inhibits MBI-based CYP3A4, which poses a risk of causing serious side effects such as hepatotoxicity.
- Test example 5 Human bone marrow cell colony formation test (blood toxicity evaluation test) Human bone marrow CD34-positive hematopoietic stem cells were obtained from Lonza Corporation. The frozen cells were thawed in a 9:1 mixture of Methocult Express medium, RPMI1640 medium containing 10% fetal bovine serum, and 1% penicillin/streptomycin, and 5000 cells were seeded per well in a 6-well plate. The cells were then cultured overnight at 37°C in the presence of 5% CO2 . The evaluation compound was added at a final DMSO concentration of 0.1%, 100 nM, and cultured for 48 hours. Cells were collected and washed with PBS.
- Test Example 5 The test shown in Test Example 5 was conducted on the representative compounds obtained in Examples and plexasertib. The results are shown in the table below.
- Example 1 does not show a suppressive effect on human bone marrow cell colony formation. became clear. The results show that the compound of Example 1 has a different effect with high safety on hematologic toxicity.
- Liposomal encapsulation test A liposome encapsulation test was conducted for representative example compounds and prexasertib.
- Hydrogenated soybean phosphatidylcholine (COATSOME NC-21E, manufactured by NOF Corporation) 6.48 g, cholesterol (manufactured by Sigma) 2.32 g and distearoyl phosphatidylethanolamine-methoxypolyethylene glycol 2000 (SUNBRIGHT DSPE-020CN, NOF Corporation) 2.06 g of t-butyl alcohol was dissolved in 560 mL of t-butyl alcohol heated to 65°C. After freezing this solution in a dry ice/acetone bath, t-butyl alcohol was removed by distillation under reduced pressure to obtain a lipid mixture.
- COATSOME NC-21E manufactured by NOF Corporation
- cholesterol manufactured by Sigma
- SUNBRIGHT DSPE-020CN distearoyl phosphatidylethanolamine-methoxypolyethylene glycol 2000
- the liposome external aqueous phase was diluted with 10 mM L-histidine buffer/10% sucrose solution (pH 6). By replacing .5) with An empty liposome solution was obtained. Filter with a 0.22 ⁇ m membrane filter, add 10mM L-histidine buffer/10% sucrose solution (pH 6.5), and adjust the total lipid concentration to 75mM (75 ⁇ mol/mL) or 50mM (50 ⁇ mol/mL). did. Note that the amount prepared was increased or decreased as appropriate.
- test compound Weigh out 2 to 3 mg of the test compound, add 1 mL of empty liposome solution with a total lipid concentration of 50 mM, adjust the pH to 5.5 to 7 by adding 1 mol/L hydrochloric acid or 1 mol/L aqueous sodium hydroxide solution, and place in a water bath at 65°C. After heating for 10 to 30 minutes, the mixture was cooled on ice. If there were any insoluble materials, they were removed by centrifugation at 15,000 xg for 5 minutes.
- the liposome encapsulation rate was calculated as follows. 100 ⁇ L of the liposome solution was placed on an ultrafiltration filter (Amicon Ultra, 100K, 0.5 mL, manufactured by Merck & Co.), and centrifuged at 4° C. and 15,000 ⁇ g for 10 minutes. The compound concentration in the filtrate after ultrafiltration was measured by HPLC, and was defined as the unencapsulated compound concentration. The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and left at 5° C. for 10 minutes or more.
- Encapsulation rate (%) (Compound concentration in liposome solution - Unencapsulated compound concentration) x 100 / Compound concentration in liposome solution
- Encapsulation efficiency (%) (Compound concentration in liposome solution - Unencapsulated compound concentration ) ⁇ 100/concentration at the time of compound introduction
- HPLC measurement conditions are as follows. HPLC conditions Column: Acquity UPLC BEH C18, 1.7 ⁇ m, 50x2.1mm Column temperature: 40°C Mobile phase: A: Water containing 0.1% trifluoroacetic acid B: Acetonitrile A/B (min): 95/5 (0) ⁇ 0/100 (3.5) ⁇ 0/100 (4) ⁇ 95/5 (4.01) ⁇ 95/5 (5) Flow rate: 0.8mL/min Detection: UV-visible detector Measurement wavelength 254nm Injection volume: 3 ⁇ L or 5 ⁇ L
- Test example 6A Liposome Encapsulation Test of Example 1 The compound of Example 1 was subjected to a liposome encapsulation test.
- Presome ACD-1 (a pre-prepared mixture consisting of hydrogenated soybean phosphatidylcholine, cholesterol and distearoyl phosphatidylethanolamine-methoxypolyethylene glycol 2000 in a mass ratio of 3:1:1, manufactured by Nippon Fine Chemical Co., Ltd.) 11.08 g It was weighed out, 200 mL of 250 mM ammonium sulfate solution was added, heated to 65° C., and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion.
- ULTRA-TURRAX ULTRA-TURRAX, manufactured by IKA
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 80 nm.
- a dialysis cassette (Slide-A-Lyzer G2 Dialysis Cassettes 20K MWCO, manufactured by Thermo Scientific)
- the liposome external aqueous phase was diluted with 10 mM L-histidine buffer/10% sucrose solution (pH 6). .5) and 0.5).
- an empty liposome solution with a total lipid concentration of 75 mM (75 ⁇ mol/mL) was obtained.
- Example 2 Weigh out the compound of Example 1, add about 0.4 mL of 10 mM L-histidine buffer/10% sucrose solution (pH 6.5), about 0.1 mL of 0.1 mol/L hydrochloric acid, and 1 mL of the above empty liposome solution. , 1 mol/L hydrochloric acid was added to adjust the pH to 6 to 6.5, heated in a 65° C. water bath for 30 minutes, and then cooled on ice. Thereafter, it was filtered using a 0.22 ⁇ m membrane filter.
- the liposome encapsulation rate was calculated as follows. Unencapsulated compound concentration: The compound concentration was measured by HPLC for a solution obtained by adding 100 ⁇ L of a 4% phosphoric acid aqueous solution to 100 ⁇ L of the liposome solution. The HPLC measurement conditions are as follows.
- the liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and left at 5° C. for 10 minutes or more. Insoluble matter was removed by centrifugation at 15,000 ⁇ g for 5 minutes, and the compound concentration of the supernatant was measured by HPLC.
- the HPLC measurement conditions are as follows.
- Encapsulation rate (%) (Compound concentration in liposome solution - Unencapsulated compound concentration) x 100 / Compound concentration in liposome solution
- Encapsulation efficiency (%) (Compound concentration in liposome solution - Unencapsulated compound concentration ) ⁇ 100/concentration at the time of compound introduction
- Example 1 could achieve a high liposome encapsulation efficiency of 90% or more.
- Test example 6B Liposome Encapsulation Test of Example 1 The compound of Example 1 was subjected to a liposome encapsulation test.
- Presome ACD-1 (a pre-prepared mixture consisting of hydrogenated soybean phosphatidylcholine, cholesterol and distearoyl phosphatidylethanolamine-methoxypolyethylene glycol 2000 in a mass ratio of 3:1:1, manufactured by Nippon Fine Chemical Co., Ltd.) 11.08 g It was weighed out, 200 mL of 250 mM ammonium sulfate solution was added, heated to 65° C., and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion.
- ULTRA-TURRAX ULTRA-TURRAX, manufactured by IKA
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a dialysis cassette (Slide-A-Lyzer G2 Dialysis Cassettes 20K MWCO, manufactured by Thermo Scientific)
- the liposome external aqueous phase was diluted with 10 mM L-histidine buffer/9.4% sucrose solution (pH 6.5), By filtering through a 0.22 ⁇ m membrane filter, an empty liposome solution with a total lipid concentration of 53.1 mg/mL was obtained.
- Example 1 120 mg of the compound of Example 1 was weighed out, and 18.3 mL of 10 mM L-histidine buffer/9.4% sucrose solution (pH 6.5), 0.3 mL of 1 mol/L hydrochloric acid, and 41.7 mL of the above empty liposome solution were added. In addition, the pH was adjusted to 6.5 with 1 mol/L hydrochloric acid or 1 mol/L sodium hydroxide. This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter. The compound concentration in the liposome solution of Example 1 was 2.00 mg/mL, the encapsulation rate was 98.0%, and the average particle size (Z-average) was 84 nm.
- the liposome encapsulation rate was calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did. Compound concentration in liposome solution: The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and left at 5° C. for 10 minutes or more. Insoluble matter was removed by centrifugation at 15,000 ⁇ g for 5 minutes, and the compound concentration of the supernatant was measured by HPLC.
- HPLC measurement conditions are as follows. HPLC conditions Column: Acquity UPLC BEH C18, 1.7 ⁇ m, 50x2.1mm Column temperature: 40°C Mobile phase: A: Water containing 0.1% trifluoroacetic acid B: Acetonitrile A/B (min): 95/5 (0) ⁇ 0/100 (3.5) ⁇ 0/100 (4) ⁇ 95/5 (4.01) ⁇ 95/5 (5) Flow rate: 0.8mL/min Detection: UV-visible detector Measurement wavelength 254nm Injection volume: 5 ⁇ L
- Encapsulation rate (%) (Compound concentration in liposome solution - Unencapsulated compound concentration) x 100/Compound concentration in liposome solution
- the liposomes encapsulating the compound of Example 1 were stored at 5°C, and changes in compound concentration, encapsulation rate, and average particle diameter were confirmed. As shown in Table 11, the liposomes encapsulating Example 1 showed no major changes in compound concentration, encapsulation rate, or average particle diameter, and were found to have excellent storage stability.
- Test example 7 Pharmacokinetic study The solution formulations of prexasertib, Examples 1, 3, and 6, and the liposome formulations of prexasertib were administered intravenously to mice, and the concentration of the test substance in the blood was measured.
- liposomes encapsulating the test compound were prepared in the same manner as in Test Example 6, and the aqueous phase outside the liposome was mixed with 10 mM L-histidine buffer using a gel filtration column PD-10 (manufactured by GE Healthcare). / after replacing with 10% sucrose solution (pH 6.5), filtered with a 0.22 ⁇ m membrane filter, and adjusting the concentration by adding 10mM L-histidine buffer / 10% sucrose solution (pH 6.5). did.
- ⁇ Administration test> The solution formulation or liposome formulation was instantaneously administered intravenously to 7-week-old female BALB/c mice, and blood was collected over time from the jugular vein up to 72 hours after administration without anesthesia. Immediately after blood collection, 4 times the amount of methanol was added to the blood, which was then centrifuged, and the concentration of the test compound in the resulting supernatant was determined by LC-MS/MS.
- LC-MS/MS The measurement conditions for LC-MS/MS are as follows.
- HPLC Prominence system (Shimadzu Corporation) MS/MS:4000 QTRAP(SCIEX) Column: Cadenza CD-C18, 3 ⁇ m, 50 x 2 mm (Intact Co., Ltd.) Column temperature: 40°C Mobile phase: A: Water containing 0.1% formic acid B: Acetonitrile containing 0.1% formic acid A/B (min): 90/10 (0) ⁇ 10/90 (2.5) ⁇ 10/90 (3. 5) ⁇ 90/10 (3.6) ⁇ 90/10 (5.0) Flow rate: 0.4mL/min Detection: ESI (positive mode) Injection volume: 0.1-5 ⁇ L
- test results are shown in the table below.
- “mean” means the average
- “S.D.” means the standard deviation.
- Tables 12, 13, 14, 15 and 16 show the test compound concentrations in plasma from 0 hours after administration to 72 hours after administration.
- the AUC was calculated using the trapezoidal method from 0 hours after administration to the time (t) when the plasma test compound concentration could be quantified, and is shown in Table 17. show.
- Example 1 and Example 3 have excellent pharmacokinetic profiles and are extremely useful as anticancer agents. It was shown that it is important that the nitrogen atom on the pyridine ring is present at a specific position, which is a characteristic of the compound represented by formula (3).
- Test example 8 Drug efficacy evaluation test using tumor-bearing mice transplanted with ES-2 cells Antitumor effects were evaluated using prexasertib, a liposome preparation containing prexasertib, and a liposome preparation containing Example 1.
- prexasertib was dissolved in a 10 mM glycine/5% mannitol solution (pH 2) containing 20% sulfobutylether- ⁇ -cyclodextrin, and then filtered through a 0.22 ⁇ m membrane filter.
- a liposome formulation was prepared in the same manner as in Test Example 6.
- the test compound was weighed out, an empty liposome solution with a total lipid concentration of 50 mM was added so that the compound concentration was 2 mg/mL, and the pH was adjusted to 6 to 7 by adding 1 mol/L hydrochloric acid.
- This solution was heated in a 65°C water bath for 10 to 30 minutes and then cooled on ice. After standing in a refrigerator at 5° C. for at least one night, it was filtered with a 0.22 ⁇ m membrane filter.
- the liposome encapsulation rate calculated by the method described in Test Example 6 was 99% or more.
- ES-2 cells (ATCC) were added to 4-7 week old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) at 1 ⁇ 10 6 cells/mouse. It was implanted intradermally around the ventral region. After confirming the engraftment of ES-2 cells 5 to 14 days after transplantation, intravenous injection was performed once a week at a dose of 30 mg/kg for the solution formulation or 3 mg/kg, 7.5 mg/kg, or 20 mg/kg for the liposome formulation. or subcutaneously administered twice a day for 3 consecutive days (total of 6 doses per week). The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated.
- rate of complete tumor regression (CR) at the end of administration of the solution formulation or liposome formulation was recorded.
- an empty liposome solution prepared in the same manner as in Test Example 6 was used.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 18 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with ES-2 cells at each dose and administration period of the test compound.
- Example 1 In a drug efficacy evaluation test using tumor-bearing mice, it was revealed that Example 1 formulated into liposomes exhibited excellent antitumor effects similar to prexasertib formulated into liposomes at any dose. Ta. These liposomal formulations have achieved tumor regression in evaluation studies using a dose of 20 mg/kg that cannot be achieved with prexasertib in solution formulation. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 9 Measurement of neutrophil counts using tumor-bearing mice transplanted with ES-2 cells 4-7 week old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) ES-2 cells (ATCC) were intradermally transplanted around the ventral region at 1 ⁇ 10 6 cells/mouse. After confirming the engraftment of ES-2 cells 5 to 14 days after transplantation, a single dose of each dose of the liposome preparation containing prexasertib and the liposome preparation containing Example 1 was administered intravenously. Blood was collected 72 hours after administration, and the number of neutrophils was measured. For comparison in this test, an empty liposome solution prepared by the same method as Test Example 6 was used.
- a control group administered with empty liposome solution was compared with a group administered with liposome-formulated Example 1 and liposome-formulated prexasertib, and the residual rate of neutrophils was calculated using the following formula, The safety of each formulation was evaluated.
- Neutrophil residual rate (%) (Number of neutrophils 72 hours after administration in the administration group) / (Number of neutrophils 72 hours after administration in the control group) x 100
- Table 19 shows the survival rate of neutrophils in tumor-bearing mice transplanted with ES-2 cells.
- the liposome-formulated Example 1 shows the same antitumor effect as the liposome-formulated prexasertib at the same dose. At the minimum effective dose of 3 mg/kg, liposome-formulated prexasertib has a neutrophil survival rate of 15%, and antitumor effects and hematologic toxicity have been observed simultaneously. On the other hand, in Example 1, which was formulated into a liposome formulation, at the minimum effective dose of 3 mg/kg, the residual rate of neutrophils was 61%, and the side effects of blood toxicity were reduced.
- Example 1 is an excellent compound that has both higher safety and efficacy than prexasertib, and has exceptional effects.
- the liposome preparation of Example 1 is an excellent compound having both high safety and efficacy, and has exceptional effects.
- Test example 10 Human bone marrow cell Myeloid differentiation induction test (blood toxicity evaluation test) Human bone marrow CD34-positive hematopoietic stem cells were obtained from Lonza Corporation. The frozen cells were thawed in IMDM medium containing 1% fetal bovine serum, suspended in Complete hemaTox (registered trademark) Myeloid Medium, and 1000 cells per well were seeded in a 96-well plate. The evaluation compound was added so that the final concentration of DMSO was 0.1%, 3 nM, and the cells were cultured for 7 days at 37° C. in the presence of 5% CO 2 .
- Cell survival ratio (%) (Measured luminescence value of the evaluation compound after 7 days) / (Measured luminescence value after 7 days of the control group) ⁇ 100
- Test Example 10 The test shown in Test Example 10 was conducted on the representative compounds obtained in Examples and plexasertib. The results are shown in the table below.
- Example 1 suppresses Myeloid cells induced to differentiate from human bone marrow cells. It was revealed that the drug had no suppressive effect on cells. From these results, compared to prexasertib, Example 1 is a compound with high safety in terms of blood toxicity, and has exceptional and different effects.
- Test example 11 Tumor PD test using tumor-bearing mice transplanted with ES-2 cells Using prexasertib, a liposome preparation encapsulating prexasertib, and a liposome preparation encapsulating Example 1, pharmacodynamics (PD) in tumors was investigated. ) The response effect was evaluated.
- prexasertib was dissolved in a 10 mM glycine/5% mannitol solution (pH 2) containing 20% sulfobutylether- ⁇ -cyclodextrin, and then filtered through a 0.22 ⁇ m membrane filter.
- a liposome formulation was prepared in the same manner as in Test Example 6.
- the test compound was weighed out, an empty liposome solution with a total lipid concentration of 50 mM was added so that the compound concentration was 2 mg/mL, and the pH was adjusted to 6 to 7 by adding 1 mol/L hydrochloric acid.
- This solution was heated in a 65°C water bath for 10 to 30 minutes and then cooled on ice. After standing in a refrigerator at 5° C. for at least one night, it was filtered with a 0.22 ⁇ m membrane filter.
- the liposome encapsulation rate calculated by the method described in Test Example 6 was 99% or more.
- Ovarian cancer ES-2 cells (ATCC) were injected into 4- to 7-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) at 1 ⁇ 10 6 cells/mouse. It was implanted intradermally around the ventral region. After confirming the engraftment of ES-2 cells 5 to 14 days after transplantation, each test was administered under the following conditions: Test A: A single intravenous dose of 30 mg/kg for the solution formulation or 7.5 mg/kg, 3 mg/kg, 1 mg/kg, 0.3 mg/kg for the liposome formulation was administered intravenously.
- Test B A single intravenous dose of 30 mg/kg for the solution formulation or 7.5 mg/kg, 3 mg/kg, 1 mg/kg, 0.3 mg/kg for the liposome formulation was administered intravenously.
- Study C Liposomal formulations were administered intravenously in a single dose at 20 mg/kg, 7.5 mg/kg, 3 mg/kg, 1 mg/kg, 0.3 mg/kg. Tumors were collected 1, 3, or 6 days after administration, and the PD response of the tumors to compound administration was evaluated.
- the PD response effect in the tumor was evaluated by Western blotting.
- the intensity of each band detected by anti-anti- ⁇ H2AX antibody (05-636, Merck) and anti-Tubulin antibody (3873, Cell Signaling Technology) was calculated using ImageJ software.
- a control administration group in which only the solvent was administered and a compound administration group of the present disclosure were compared, and the relative value of each band intensity was calculated using the following formula to evaluate the PD response effect on the tumor.
- For the control administration group an empty liposome solution prepared in the same manner as in Test Example 6 was used.
- Intensity of ⁇ H2AX ⁇ (band intensity of ⁇ H2AX in the tumor of the compound administration group of the present disclosure)/(band intensity of Tubulin in the tumor of the compound administration group of the present disclosure) ⁇ / ⁇ (band intensity of ⁇ H2AX in the tumor of the control administration group) /Tubulin band intensity in tumor of control administration group) ⁇ 100
- Figures 7-9 show the intensity of ⁇ H2AX in tumor-bearing mice transplanted with ES-2 cells at each dose and administration period of the test compound.
- Test Example 11 Test A when liposome-formulated prexasertib was administered, a strong PD response effect was confirmed at a dose of 7.5 mg/kg 3 days after administration, and a solution-formulated prexasertib was confirmed. It achieved a PD response effect that cannot be achieved with prexasertib.
- Test Example 11 As shown in Test B, when the liposome formulation of Example 1 was administered, a strong PD response effect was confirmed at a dose of 7.5 mg/kg one day after administration, and the solution formulation of prexasertib showed a strong PD response effect. A previously unattainable PD response effect was achieved.
- Test Example 11 As shown in Test C, when the liposome-formulated Example 1 was administered, a strong PD response effect was confirmed at doses of 7.5 mg/kg and 20 mg/kg 3 days and 6 days after administration. Ta. These liposome formulations, as shown in Test Example 7, demonstrated the achievement of sustained exposure for 72 hours, which is important for maximizing the efficacy reported in non-clinical studies of prexasertib. Therefore, Example 1 has an excellent pharmacokinetic and pharmacodynamic profile and is extremely useful as an anticancer agent.
- Test example 12 Drug efficacy evaluation test using peritoneally disseminated tumor-bearing mice transplanted with ES-2 cells Antitumor effects were evaluated using prexasertib, a liposome preparation containing prexasertib, and a liposome preparation containing Example 1.
- prexasertib was dissolved in a 10 mM glycine/5% mannitol solution (pH 2) containing 20% sulfobutylether- ⁇ -cyclodextrin, and then filtered through a 0.22 ⁇ m membrane filter.
- a liposome formulation encapsulating prexasertib was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 80 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter.
- the concentration of prexasertib in the liposome solution was 1.97 mg/mL, and the encapsulation rate was 98%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- a liposome formulation containing Example 1 was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- the compound concentration in the liposome solution of Example 1 was 1.99 mg/mL, and the encapsulation rate was 97%.
- the liposome encapsulation rate was calculated as follows. Unencapsulated compound concentration: The compound concentration was measured by HPLC for a solution obtained by adding 100 ⁇ L of a 4% phosphoric acid aqueous solution to 100 ⁇ L of the liposome solution. The HPLC measurement conditions are as follows.
- mice Five-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) were injected with 1 ⁇ ovarian cancer ES-2 cells (ATCC), a cell line in which Luciferase was expressed. The cells were transplanted intraperitoneally at 10 6 cells/mouse. After confirming the engraftment of ES-2 cells using the IVIS Imaging System (PerkinElmer) 5 to 14 days after transplantation, the solution formulation was administered at a dose of 30 mg/kg or the liposome formulation at a dose of 4.5 mg/kg or 20 mg/kg for one week. One dose was administered intravenously.
- ATC ovarian cancer ES-2 cells
- the luminescence caused by Luciferase is measured over time from the start of administration to evaluate the tumor shrinkage effect caused by compound administration. Mice were observed based on tumor size, systemic symptoms, and body weight changes estimated from luminescence caused by Luciferase, and the survival period of mice that showed a healthy condition without any serious findings was measured.
- the median survival time of the control administration group in which only the vehicle was administered and the compound administration group of the present disclosure was calculated, and the antitumor effect was evaluated. Empty liposome solution was used for the control administration group.
- Table 21 shows the median survival time for peritoneally disseminated tumor-bearing mice transplanted with ES-2 cells at each dose and administration period of the test compound.
- Example 1 In a drug efficacy evaluation test using peritoneal disseminated tumor-bearing mice, liposome-formulated Example 1 was found to exhibit the same excellent antitumor effect as liposome-formulated prexasertib at a dose of 20 mg/kg. It became clear. These liposome formulations have achieved survival extensions that cannot be achieved with solution-formulated prexasertib in evaluation studies using a dose of 20 mg/kg. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 13 Drug efficacy evaluation test using ovarian orthotopic tumor-bearing mice transplanted with ES-2 cells Antitumor effects were evaluated using prexasertib, a liposome preparation containing prexasertib, and a liposome preparation containing Example 1.
- prexasertib was dissolved in a 10 mM glycine/5% mannitol solution (pH 2) containing 20% sulfobutylether- ⁇ -cyclodextrin, and then filtered through a 0.22 ⁇ m membrane filter.
- a liposome formulation encapsulating prexasertib was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 80 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter.
- the concentration of prexasertib in the liposome solution was 1.97 mg/mL, and the encapsulation rate was 98%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- a liposome formulation containing Example 1 was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- the compound concentration in the liposome solution of Example 1 was 1.99 mg/mL, and the encapsulation rate was 97%.
- the liposome encapsulation rate was calculated as follows. Unencapsulated compound concentration: The compound concentration was measured by HPLC for a solution obtained by adding 100 ⁇ L of a 4% phosphoric acid aqueous solution to 100 ⁇ L of the liposome solution. The HPLC measurement conditions are as follows.
- mice Five-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) were injected with 1 ⁇ ovarian cancer ES-2 cells (ATCC), a cell line in which Luciferase was expressed. The cells were transplanted into the right ovary at 10 6 cells/mouse. After confirming the engraftment of ES-2 cells using the IVIS Imaging System (PerkinElmer) 5 to 14 days after transplantation, the solution formulation was administered at a dose of 30 mg/kg or the liposome formulation at a dose of 4.5 mg/kg or 20 mg/kg for one week. One dose was administered intravenously.
- ATC ovarian cancer ES-2 cells
- the luminescence caused by Luciferase is measured over time from the start of administration, and the tumor shrinkage effect due to compound administration is evaluated. Mice were observed based on tumor size, systemic symptoms, and weight changes estimated from luminescence caused by Luciferase, and the survival period of mice that showed a healthy condition without any serious findings was measured.
- the median survival time of the control administration group in which only the vehicle was administered and the compound administration group of the present disclosure was calculated, and the antitumor effect was evaluated. Empty liposome solution was used for the control administration group.
- Table 22 shows the median survival time of ovarian orthotopic tumor-bearing mice transplanted with ES-2 cells at each dose and administration period of the test compound.
- Example 1 In a drug efficacy evaluation test using ovarian orthotopic tumor-bearing mice, liposome-formulated Example 1 exhibited excellent antitumor effects similar to liposome-formulated prexasertib at a dose of 20 mg/kg. became clear. These liposome formulations have achieved survival extensions that cannot be achieved with solution-formulated prexasertib in evaluation studies using a dose of 20 mg/kg. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 14 Drug efficacy evaluation test using cancer-bearing mice transplanted with various cancer cells The antitumor effect was evaluated using a liposome preparation containing Example 1.
- the liposome preparation encapsulating Example 1 was the one used in Test Example 12 or the one prepared by the following method. Weighed 138.4 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 2437 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a high-pressure homogenizer Mocrofluidizer M-110 EH-30, manufactured by Microfluidics
- Z-average average particle size
- the aqueous phase outside the liposomes was mixed with 10mM L-histidine buffer/9.4% sucrose solution (pH 6.5). ) and filtered with a 0.2 ⁇ m membrane filter. This liquid was dispensed into glass vials in an amount of 50 mL each, which was capped and sealed.
- the compound concentration in the liposome solution of Example 1 was 1.98 mg/mL, and the encapsulation rate was 97%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows.
- Unencapsulated compound concentration Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Encapsulation rate (%) (Compound concentration in liposome solution - Unencapsulated compound concentration) x 100/Compound concentration in liposome solution or Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) 11.08 g and 250 mM ammonium sulfate solution 200 mL were mixed and dispersed using a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a dialysis cassette (Slide-A-Lyzer G2 Dialysis Cassettes 20K MWCO, manufactured by Thermo Scientific)
- the aqueous phase outside the liposomes was replaced with 10 mM L-histidine buffer/9.4% sucrose solution (pH 6.5), By filtering through a 0.22 ⁇ m membrane filter, an empty liposome solution with a total lipid concentration of 53.1 mg/mL was obtained.
- Example 1 60 mg of the compound of Example 1, 9.16 mL of 10 mM L-histidine buffer/9.4% sucrose solution (pH 6.5), and 20.8 mL of the above empty liposome solution were added, and the pH was adjusted to 6.5. This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter. The compound concentration in the liposome solution of Example 1 was 2.08 mg/mL, and the encapsulation rate was 98%. The compound concentration and encapsulation rate in the liposome solution were calculated as follows.
- Unencapsulated compound concentration Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- mice 4-7 week old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) or NODSCID mice (NOD.CB17-Prkdc scid /J, female, Charles River, Japan)
- Ovarian cancer SKOV-3 cells ATCC or sarcoma SJCRH30 cells (ATCC) or sarcoma HT-1080 cells (ATCC) or pancreatic cancer AsPC-1 cells (ATCC) or pancreatic cancer BxPC-3 cells (ATCC) or Lung cancer Calu-6 cells (ATCC) or ovarian cancer OV5304 cells (Crown Bioscience) at 5 ⁇ 10 5 cells/mouse or 1 ⁇ 10 6 cells/mouse or 3 ⁇ 10 6 cells/mouse or 5 ⁇ 10 6 cells/mouse Alternatively, it was implanted intradermally around the ventral region so that the tumor mass was 8 mm 3 to 27 mm 3 per mouse.
- the liposome preparation was administered intravenously once a week at a dose of 4.5 mg/kg, 10 mg/kg, or 20 mg/kg.
- the tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated.
- the tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo). It is known that BxPC-3 cells exhibit resistance to gemcitabine, and OV5304 exhibits resistance to PARP inhibitors.
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 23 shows the T/C (%) for tumor-bearing mice transplanted with various cancer cells at each dose and administration period of the test compound.
- Example 1 In a combination drug efficacy evaluation test using tumor-bearing mice, it was revealed that Example 1 formulated into liposomes exhibited excellent antitumor effects against various cancer cell lines. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test Example 14A Drug efficacy evaluation test using cancer-bearing mice transplanted with various cancer cells The antitumor effect was evaluated using a liposome preparation containing Example 1.
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- A2780 cells (ECACC) or HCC1806 cells (ATCC) or An3CA cells (ATCC) or Detroit562 cells were injected into 4-7 week old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan).
- the cells were intradermally transplanted around the ventral region at 3 ⁇ 10 6 cells/mouse.
- the liposome preparation was intravenously administered at a dose of 20 mg/kg once a week.
- the tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated.
- the tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo). It is known that BxPC-3 cells exhibit resistance to gemcitabine, and OV5304 exhibits resistance to PARP inhibitors.
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 23A shows the T/C (%) for tumor-bearing mice transplanted with various cancer cells at each dose and administration period of the test compound.
- Test example 15 Combination drug efficacy evaluation test using tumor-bearing mice transplanted with PA-1 cells The antitumor effect was evaluated using the liposome preparation containing Example 1 and cisplatin.
- Cisplatin (Randa Injection 50 mg/100 mL, Nippon Kayaku Co., Ltd.) was used.
- a liposome formulation containing Example 1 was prepared as follows. Weighed 138.4 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 2437 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a high-pressure homogenizer Mocrofluidizer M-110 EH-30, manufactured by Microfluidics
- Z-average average particle size
- the aqueous phase outside the liposomes was mixed with 10mM L-histidine buffer/9.4% sucrose solution (pH 6.5). ) and filtered with a 0.2 ⁇ m membrane filter. This liquid was dispensed into glass vials in an amount of 50 mL each, which was capped and sealed.
- the compound concentration in the liposome solution of Example 1 was 1.98 mg/mL, and the encapsulation rate was 97%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows.
- Unencapsulated compound concentration Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Ovarian cancer PA-1 cells (ATCC) were injected into 4-7 week old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) at 5 ⁇ 10 6 cells/mouse. It was implanted intradermally around the ventral region. After confirming the engraftment of PA-1 cells 5 to 14 days after transplantation, administer intravenously once a week at a dose of 20 mg/kg of liposome preparation, 2.5 mg/kg of cisplatin, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination. The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated.
- the rate of complete tumor regression (CR) at the end of administration with liposome preparations, cisplatin, or combination administration was described. Empty liposome solution was used for the control administration group.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 24 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with PA-1 cells at each dose and administration period of the test compound.
- Example 1 In a combination drug efficacy evaluation test using tumor-bearing mice, it was revealed that Example 1, which was formulated into liposomes, exhibited excellent antitumor effects when used in combination with cisplatin. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 16 Combination drug efficacy evaluation test using tumor-bearing mice transplanted with ES-2 cells The antitumor effect was evaluated using a liposome preparation containing encapsulated Example 1 and gemcitabine.
- Gemcitabine 200 mg for Gemzar injection, Eli Lilly Japan was dissolved in physiological saline (Otsuka saline injection, Otsuka Pharmaceutical Factory).
- a liposome formulation was prepared in the same manner as in Test Example 6.
- the test compound was weighed out, an empty liposome solution with a total lipid concentration of 50 mM was added so that the compound concentration was 2 mg/mL, and the pH was adjusted to 6 to 7 by adding 1 mol/L hydrochloric acid.
- This solution was heated in a 65°C water bath for 10 to 30 minutes and then cooled on ice. After standing in a refrigerator at 5° C. for at least one night, it was filtered with a 0.22 ⁇ m membrane filter.
- the liposome encapsulation rate calculated by the method described in Test Example 6 was 99% or more.
- Ovarian cancer ES-2 cells (ATCC) were injected into 4- to 7-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) at 1 ⁇ 10 6 cells/mouse. It was implanted intradermally around the ventral region. After confirming the engraftment of ES-2 cells 5 to 14 days after transplantation, administer intravenously once a week at a dose of 4.5 mg/kg of liposome preparation, 30 mg/kg of gemcitabine, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination. The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated.
- the percentage of individuals with complete tumor regression (CR) at the end of treatment with liposome preparations, gemcitabine, or combination administration was described.
- an empty liposome solution prepared in the same manner as in Test Example 6 was used.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 25 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with ES-2 cells at each dose and administration period of the test compound.
- Example 1 In a combination drug efficacy evaluation test using tumor-bearing mice, it was revealed that Example 1, which was formulated into a liposome formulation, exhibited excellent antitumor effects when used in combination with gemcitabine. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 17 Measurement of the number of neutrophils using tumor-bearing mice transplanted with ES-2 cells The number of neutrophils was measured using a liposome preparation containing Example 1 and gemcitabine.
- Gemcitabine 200 mg for Gemzar injection, Eli Lilly Japan was dissolved in physiological saline (Otsuka saline injection, Otsuka Pharmaceutical Factory).
- a liposome formulation was prepared in the same manner as in Test Example 6.
- the test compound was weighed out, an empty liposome solution with a total lipid concentration of 50 mM was added so that the compound concentration was 2 mg/mL, and the pH was adjusted to 6 to 7 by adding 1 mol/L hydrochloric acid.
- This solution was heated in a 65°C water bath for 10 to 30 minutes and then cooled on ice. After standing in a refrigerator at 5° C. for at least one night, it was filtered with a 0.22 ⁇ m membrane filter.
- the liposome encapsulation rate calculated by the method described in Test Example 6 was 99% or more.
- Ovarian cancer ES-2 cells (ATCC) were injected into 4- to 7-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) at 1 ⁇ 10 6 cells/mouse. It was implanted intradermally around the ventral region. After confirming the engraftment of ES-2 cells 5 to 14 days after transplantation, administer intravenously once a week at a dose of 4.5 mg/kg of liposome preparation, 30 mg/kg of gemcitabine, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination. Blood was collected 96 hours after the final administration, and the number of neutrophils was measured. For comparison in this test, an empty liposome solution prepared by the same method as Test Example 6 was used.
- control group administered with empty liposome solution was compared with the administration group administered with liposome formulation Example 1, gemcitabine, and the combination, and the residual rate of neutrophils was calculated using the following formula.
- Neutrophil residual rate (%) (Number of neutrophils 96 hours after administration in the administration group) / (Number of neutrophils 96 hours after administration in the control group) x 100
- Table 26 shows the survival rate of neutrophils in tumor-bearing mice transplanted with ES-2 cells.
- Example 1 which was formulated into a liposome formulation, had a neutrophil survival rate of 87% at 4.5 mg/kg, and as shown in Test Example 17, it exhibited antitumor effects and exhibited no side effects of hematologic toxicity. Not shown. Furthermore, as shown in Test Example 17, the liposome-formulated Example 1 did not exacerbate the side effects of hematologic toxicity caused by gemcitabine when administered in combination with gemcitabine, in which tumor regression was observed, and increased neutrophils. It shows the survival rate of From the above, Example 1 formulated into a liposome formulation is an excellent compound having both high safety and efficacy, and has exceptional effects.
- Test example 18 Drug efficacy evaluation test regarding combination administration order using tumor-bearing mice transplanted with ES-2 cells The antitumor effect was evaluated using the liposome preparation containing Example 1 and gemcitabine.
- Gemcitabine 200 mg for Gemzar injection, Eli Lilly Japan was dissolved in physiological saline (Otsuka saline injection, Otsuka Pharmaceutical Factory).
- a liposome formulation containing Example 1 was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter.
- the compound concentration in the liposome solution of Example 1 was 2.08 mg/mL, and the encapsulation rate was 98%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Ovarian cancer ES-2 cells (ATCC) were injected into 4- to 7-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1nu/CrlCrlj, female, Charles River, Japan) at 1 ⁇ 10 6 cells/mouse. It was implanted intradermally around the ventral region. After confirming the engraftment of ES-2 cells 5 to 14 days after transplantation, a single intravenous administration and a single intraperitoneal administration of the liposome preparation and gemcitabine were administered at a dose of 4.5 mg/kg and 30 mg/kg, respectively. The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated.
- the percentage of individuals with complete tumor regression (CR) at the end of treatment with liposome preparations, gemcitabine, or combination administration was described. Empty liposome solution was used for the control administration group.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 27 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with ES-2 cells at each dose and administration period of the test compound.
- Example 1 which was formulated into a liposome formulation, exhibited excellent antitumor effects when used in combination with gemcitabine.
- Test Example 18 the antitumor effect of the combination of liposome formulation Example 1 and gemcitabine was most effective when the liposome formulation of Example 1 was administered the day after gemcitabine administration, followed by It was shown that simultaneous administration or administration of gemcitabine on the day after administration of the liposome preparation of Example 1 was highly effective. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 19 Combination drug efficacy evaluation test using tumor-bearing mice transplanted with MC38 cells The antitumor effect was evaluated using a liposome preparation containing Example 1 and an anti-PD-1 antibody.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation was prepared in the same manner as in Test Example 6.
- the test compound was weighed out, an empty liposome solution with a total lipid concentration of 50 mM was added so that the compound concentration was 2 mg/mL, and the pH was adjusted to 6 to 7 by adding 1 mol/L hydrochloric acid.
- This solution was heated in a 65°C water bath for 10 to 30 minutes and then cooled on ice. After standing in a refrigerator at 5° C. for at least one night, it was filtered with a 0.22 ⁇ m membrane filter.
- the liposome encapsulation rate calculated by the method described in Test Example 6 was 99% or more.
- Mouse colon cancer MC38 cells (Kerafast) were injected around the ventral region of 4-7 week old c57BL/6J mice (C57BL/6J, female, Charles River, Japan) at 5 x 10 5 cells/mouse. It was implanted intradermally. After confirming the engraftment of MC38 cells 5 to 14 days after transplantation, administer intravenously once a week at a dose of 10 mg/kg of liposome preparation, 200 ⁇ g/head of anti-PD-1 antibody, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination. The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated.
- rate of complete tumor regression (CR) at the end of administration of the liposome preparation, anti-PD-1 antibody, or combination administration was described.
- an empty liposome solution prepared in the same manner as in Test Example 6 was used.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 28 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with MC38 cells at each dose and administration period of the test compound.
- liposome formulation Example 1 was found to exhibit excellent antitumor effects when used in combination with liposome formulation Example 1 and anti-PD-1 antibody. It became clear. As shown in Test Example 19, tumor-bearing mice to which MC38 cells were transplanted are a model in which anti-PD-1 antibodies exhibit antitumor effects. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects in a model in which anti-PD-1 antibodies exhibit antitumor effects, and has exceptional effects.
- Test example 20 Combination drug efficacy evaluation test using tumor-bearing mice transplanted with EMT6 cells The antitumor effect was evaluated using a liposome preparation encapsulating Example 1 and an anti-PD-1 antibody.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter.
- the compound concentration in the liposome solution of Example 1 was 2.08 mg/mL, and the encapsulation rate was 98%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Mouse breast cancer EMT6 cells were implanted intradermally around the ventral region of 4-7 week old BALB/c mice (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 x 10 5 cells/mouse. did. After confirming the engraftment of EMT6 cells 5 to 14 days after transplantation, administer intravenously once a week at 10 mg/kg of liposome preparation, 200 ⁇ g/head of anti-PD-1 antibody, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination. The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated.
- the rate of complete tumor regression (CR) at the end of administration of the liposome preparation, anti-PD-1 antibody, or combination administration was described. Empty liposome solution was used for the control administration group.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 29 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with EMT6 cells at each dose and administration period of the test compound.
- liposome formulation Example 1 was found to exhibit excellent antitumor effects when used in combination with liposome formulation Example 1 and anti-PD-1 antibody. It became clear. As shown in Test Example 20, tumor-bearing mice to which EMT6 cells were transplanted are a model in which anti-PD-1 antibodies do not exhibit antitumor effects. From the results of this test, Example 1 showed excellent antitumor effects when used in combination with Example 1 formulated into liposomes and anti-PD-1 antibodies against a model in which anti-PD-1 antibodies did not show antitumor effects. It is a promising compound with exceptional effects.
- Test example 21 Drug efficacy evaluation test regarding combination administration order using tumor-bearing mice transplanted with EMT6 cells The antitumor effect was evaluated using the liposome preparation containing Example 1 and the anti-PD-1 antibody.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the concentration of the compound of Example 1 in the liposome solution was 2.01 mg/mL, the encapsulation rate was 97.5%, and the average particle size (Z-average) was 74 nm.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows.
- Unencapsulated compound concentration Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Mouse breast cancer EMT6 cells were intradermally implanted around the ventral region of a 5-week-old BALB/c mouse (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 ⁇ 10 5 cells/mouse. After confirming the engraftment of EMT6 cells 5 days after transplantation, the liposome preparation was administered intravenously and intraperitoneally once a week at a dose of 6 mg/kg and anti-PD-1 antibody at a dose of 200 ⁇ g/head. The tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated. The tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C was calculated using the following formula, and the antitumor effect was evaluated. Additionally, the rate of complete tumor regression (CR) at the end of administration with the liposome preparation and anti-PD-1 antibody was described. Empty liposome solution was used for the control administration group.
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 30 shows the T/C (%) and CR individual rate for tumor-bearing mice transplanted with EMT6 cells at each dose and administration period of the test compound.
- Example 1 formulated into liposomes exhibited excellent antitumor effects when used in combination with an anti-PD-1 antibody.
- Test Example 21 the antitumor effect of the combination of liposome-formulated Example 1 and anti-PD-1 antibody was strongest when administered simultaneously, followed by anti-PD-1 antibody after administration of the liposome preparation of Example 1. It was shown that the combination order of administering one antibody was strong. From the results of this test, Example 1 is a promising compound that exhibits excellent antitumor effects and has exceptional effects.
- Test example 22 Kinase selectivity test HotSpot Full Panel Kinase profiling (Reaction Biology) was used to evaluate the selectivity of prexasertib, Example 1, and Example 3 against 370 wild-type kinases.
- Buffer 20mM HEPES, pH 7.5, 10mM MgCl2 , 2mM MnCl2 (as needed), 1mM EGTA, 0.02% Brij35, 0.02mg/mL BSA, 0.1mM Na3VO4 , 2mM DTT ,1% DMSO ATP concentration: 10 ⁇ M Reaction time: 2 hours ATP conversion rate in 2 hours: 5-20% Compound concentration: 100nM
- Tables 31 to 33 show the name of the kinase and the residual activity (%) at 100 nM for prexasertib, Example 1 and Example 3, for the kinases whose residual activity was less than 25% at 100 nM among 370 wild-type kinases. ) is shown.
- Example 1 had an exceptional effect of selectively inhibiting CHK1 activity, and thus exhibited an excellent antitumor effect due to CHK1 inhibition while avoiding the toxicity caused by non-selective kinase inhibition. .
- Test example 23 CHK1/CHK2 selectivity test
- the test substance was dissolved in dimethylsulfoxide (DMSO) and further diluted with DMSO to prepare a solution with a concentration 100 times the test concentration.
- the solution was further diluted 25 times with assay buffer to obtain a test substance solution.
- a positive control substance solution was prepared in the same manner as above.
- a 4-fold concentrated test substance solution was prepared in assay buffer (20mM HEPES, 0.01% Triton X-100, 1mM DTT, pH 7.5).
- a 4x substrate/ATP/metal solution was prepared in kit buffer (20mM HEPES, 0.01% Triton X-100, 5mM DTT, pH 7.5).
- a double concentration kinase solution was prepared in assay buffer.
- the kinase reaction was evaluated using the product ratio (P/(P+S)) calculated from the substrate peptide peak height (S) and the phosphorylated peptide peak height (P).
- the average signal of control wells containing all reaction components was defined as 0% Inhibition, and the average signal of background wells (no enzyme added) was defined as 100% Inhibition, and the inhibition rate was calculated from the average signal of each test substance test well.
- the IC 50 value was determined by approximating a plot of test substance concentration and inhibition rate to a four-parameter logistic curve using the nonlinear least squares method.
- Table 34 shows the IC 50 values for CHK1 and CHK2 for prexasertib and Example 1.
- Example 1 As shown in the table above, the compound of Example 1 showed higher CHK1 selectivity compared to prexasertib. From this, Example 1 exhibited excellent antitumor effects due to CHK1 inhibition while avoiding toxicity due to CHK2 inhibition.
- Test example 24 Intratumoral immune cell evaluation test using tumor-bearing mice transplanted with EMT6 cells Using a liposome preparation encapsulating Example 1 and an anti-PD-1 antibody, the fraction of immune cells that had infiltrated into the tumor was evaluated. .
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 138.4 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 2437 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a high-pressure homogenizer Mocrofluidizer M-110 EH-30, manufactured by Microfluidics
- Z-average average particle size
- the aqueous phase outside the liposomes was mixed with 10mM L-histidine buffer/9.4% sucrose solution (pH 6.5). ) and filtered with a 0.2 ⁇ m membrane filter. This liquid was dispensed into glass vials in an amount of 50 mL each, which was capped and sealed.
- the compound concentration in the liposome solution of Example 1 was 1.98 mg/mL, and the encapsulation rate was 97%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- the tumor mass of EMT6 cells was cut into small pieces with scissors, and then subjected to gentle MACS Tissue Dissociators (Miltenyi Biotec) according to the protocol using a Tumor Dissociation Kit, Mouse (Miltenyi Biotec) to separate the tumor mass. was prepared into a cell suspension.
- the prepared cells were passed through a 70 ⁇ m cell strainer and then washed with RPMI1640 supplemented with 10% FBS. Thereafter, the cells were treated with red blood cell lysis solution (Lonza) for 1 minute to remove red blood cells, further washed with RPMI1640 supplemented with 10% FCS, and suspended in MACS Rinsing solution (Miltnyi Biotec, hereinafter referred to as MACS buffer) supplemented with 5% BSA. did. The cell suspension was counted using LUNA FL (Logos Biosystems), and 1 ⁇ 10 6 cells were stained using the following method and antibody.
- MACS Rinsing solution Miltnyi Biotec
- CD45+CD3+ T cells (CD3 positive T cells), CD45+CD3+CD8+ T cells (CD8 positive T cells), CD45+CD11b+f4/80+IAdlowCD206high cells (M2 macrophages), CD45+CD11b+f4/80+IAdhighCD206low cells (M1 macrophages)
- the percentage of living cells in LUNA FL (Logos Biosystems) The cell number was calculated by multiplying the number of viable cells counted by the tumor weight, and then dividing by the tumor weight to calculate the number of cells in each fraction per weight.
- Table 35 lists the empty liposomes, the liposome preparation of Example 1, anti-PD-1 antibody, and the number of CD3-positive T cells and CD8-positive T cells in the combination group, and Table 36 lists the number of 1 macrophages and the number of M2 macrophages.
- Administration of the liposome preparation of Example 1 increased CD3-positive T cells and CD8-positive T cells in the tumor by more than 3 times and 7 times, respectively, compared to the empty liposome administration group, indicating that the liposome preparation of Example 1 entered the tumor. was shown to enhance the influx of T cells.
- Administration of the liposome preparation of Example 1 resulted in a decrease in M2 macrophages and an increase in M1 macrophages compared to the group administered with empty liposomes, and the M1-M2 ratio was 7.7 times greater with the administration of the liposome preparation of Example 1, and anti-PD-1 antibodies. When used together, it increased by 14.8 times. From the above, it was shown that the liposome preparation of Example 1 changes the intratumoral microenvironment from an immunosuppressive environment to an inflammatory environment.
- Test example 25 Lymph node CD8-positive T cell fraction evaluation test using tumor-bearing mice transplanted with EMT6 cells Using a liposome preparation containing Example 1 and an anti-PD-1 antibody, the fractionation of CD8-positive T cells in lymph nodes was evaluated.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Mouse breast cancer EMT6 cells were implanted intradermally around the ventral region of 4-7 week old BALB/c mice (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 x 10 5 cells/mouse. did.
- the liposome preparation of Example 1 was administered intravenously once a week at a dose of 10 mg/kg, the anti-PD-1 antibody at 200 ⁇ g/head, or a combination thereof.
- intraperitoneal administration twice a week, or a combination thereof Ten days after the start of administration, regional lymph nodes were collected in HBSS buffer.
- the collected lymph nodes were ground on a slide glass and suspended in RPMI1640 supplemented with 10% FCS.
- the cell suspension was centrifuged, treated with hemocyte lysis solution (Lonza) for 1 minute to remove red blood cells, further washed with RPMI 1640 supplemented with 10% FCS, and treated with MACS Rinsing solution (Miltnyi Biotec, hereinafter referred to as 5% BSA supplemented). MACS buffer).
- the cell suspension was counted using LUNA FL (Logos Biosystems), and 5x10 5 cells were stained using the following method and antibody.
- CD45+CD3+CD8+CD62L+CD44+ T cells central memory CD8-positive T cells
- CD45+CD3+CD8+CD62L-CD44+ T cells no CD8-positive T cells
- CD45+CD3+CD8+CD62L+CD44-T cells effector memory CD8-positive T cells
- CD45+CD 3+CD8+CD62L-CD44-T cells effector CD8-positive T cells
- the liposome preparation of Example 1 By administering the liposome preparation of Example 1, the number of CD62L-negative CD44-positive cells and the number of CD62L-negative CD44-negative cells in the lymph nodes increased approximately three times compared to the empty liposome group. Furthermore, the combined use of the liposome preparation of Example 1 and anti-PD-1 antibody resulted in a 4- to 5-fold increase compared to the group administered with empty liposomes. From the above, it was shown that administration of the liposome preparation of Example 1 induced an immune reaction centered on CD8-positive T cells, and that the reaction was further strengthened when used in combination with an anti-PD-1 antibody. .
- Test example 26 Examination of the effect of improving immune checkpoint inhibitor resistance-related genes Using the liposome preparation containing Example 1 and anti-PD-1 antibody, changes in immune checkpoint inhibitor resistance-related genes were evaluated.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered with a 0.22 ⁇ m membrane filter.
- the compound concentration in the liposome solution of Example 1 was 2.08 mg/mL, and the encapsulation rate was 98%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- EMT6 cells were implanted intradermally around the ventral region of 4-7 week old BALB/c mice (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 x 10 5 cells/mouse. did. After confirming the engraftment of EMT6 cells 5 to 14 days after transplantation, administer intravenously once a week at 10 mg/kg of liposome preparation, 200 ⁇ g/head of anti-PD-1 antibody, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination.
- Administration of the liposome preparation of Example 1 increased the expression of PD-L1 by 3.92 times and decreased the expression of VEGFa by 0.66 times compared to the empty liposome administration group. Increased expression of PD-L1 is also used clinically as a biomarker to predict the therapeutic effect of anti-PD-1 antibodies. It is thought that the administration of the liposome preparation of Example 1 enhances the expression of PD-L1, creating an environment in which anti-PD-1 is more likely to exhibit drug efficacy. It is known that increased expression of VEGFa inhibits the influx of CD8-positive T cells into tumors. It is suggested that the decrease in the expression of VEGFa by administration of the liposome preparation of Example 1 helps to enhance the influx of CD8-positive T cells into the tumor.
- Test example 27 Examination of the effect of inducing long-term immune memory The induction of long-term immunological memory was evaluated using a liposome preparation containing Example 1 and an anti-PD-1 antibody.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. 11.08 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) and 200 mL of a 250 mM ammonium sulfate solution were mixed and dispersed with a homogenizer (ULTRA-TURRAX, manufactured by IKA) to obtain a crude liposome dispersion. Furthermore, the crude liposome dispersion was dispersed using a high-pressure homogenizer (Nano-Mizer NM2, manufactured by Yoshida Kikai Kogyo) at a pressure of 100 MPa to obtain liposomes with an average particle size (Z-average) of 81 nm.
- a homogenizer ULTRA-TURRAX, manufactured by IKA
- This liquid was heated in a 50°C water bath for 30 minutes, cooled on ice, and filtered through a 0.22 ⁇ m membrane filter.
- the compound concentration in the liposome solution of Example 1 was 2.08 mg/mL, and the encapsulation rate was 98%.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Encapsulation rate (%) (Compound concentration in liposome solution - Unencapsulated compound concentration) x 100/Compound concentration in liposome solution or Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.) 498.2 g was weighed out. , 8772 g of a 250 mM ammonium sulfate solution was added thereto, dispersed using a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing to obtain a crude liposome dispersion.
- CLEARMIX manufactured by M TECHNIQUE
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- EMT6 cells were implanted intradermally around the ventral region of 4-7 week old BALB/c mice (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 x 10 5 cells/mouse. did. After confirming the engraftment of EMT6 cells 5 to 14 days after transplantation, administer intravenously once a week at 10 mg/kg of liposome preparation, 200 ⁇ g/head of anti-PD-1 antibody, or a combination thereof, or for 1 week. The drug was administered intraperitoneally twice or in combination.
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- the liposome preparation and anti-PD-1 antibody combination group of Example 1 achieved complete remission with a higher probability than the liposome preparation monotherapy group of Example 1. Furthermore, in the individuals that achieved complete remission, compared to non-transplanted mice, tumor engraftment was not observed or tumor growth was suppressed when the cancer cells were secondarily transplanted. It was shown that the mice had acquired long-term immunological memory.
- Test example 28 Examination of TCR repertoire, CD8 score, and M1-M2 macrophage ratio of intratumoral CD8-positive cells using tumor-bearing mice transplanted with EMT6 cells Liposomal preparation containing Example 1 and anti-PD-1 Using antibodies, we examined repertoire changes of CD8-positive T cells within tumors and the M1-M2 macrophage ratio.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- the prepared cells were passed through a 70 ⁇ m cell strainer and then washed with RPMI1640 supplemented with 10% FBS. Thereafter, red blood cells were removed by treatment with red blood cell lysis solution (Lonza) for 1 minute, further washed with RPMI1640 supplemented with 10% FCS, and suspended in MACS Rinsing solution (Miltnyi Biotec, hereinafter referred to as MACS buffer) supplemented with 5% BSA. did.
- MACS Rinsing solution Miltnyi Biotec, hereinafter referred to as MACS buffer
- the cell suspension was counted using LUNA FL (Logos Biosystems), and CD45 MicroBeads and mouse (Miltenyi Biotec) were added to all cells according to the protocol, followed by autoMACS Pro Separator ( CD45 positive cells at Miltenyi (Biotec) was separated. The sorted cells were further stained with PerCP-labeled anti-mouse CD45 antibody for 20 minutes on ice. After washing once with MACS buffer, Hoechst 33342 (Thermo Fisher Scientific) diluted in PBS was added and allowed to react on ice for 5 minutes to stain dead cells. It was stained twice with MACS buffer. The stained cells were further sorted into CD45-positive living cells using a cell sorter. After counting the separated cells, a sequence library was created based on the protocol of Chromium Next GEN Single Cell 5' Kit v2 (10x GENOMICS), and sequence analysis was performed at Takara Bio.
- single cell gene expression and TCR clonotype were calculated using CellRanger software (10x GENOMICS), and cells were clustered based on the obtained gene expression data. For each cluster obtained, a cell type was assigned based on the expression of the marker gene. From the lymphocyte clusters identified here, CD8-positive T cells were assigned based on the expression of Cd8a and Cd8b1 and the absence of expression of Cd4 and Ncr1. Similarly, from macrophage clusters, M1 macrophages were assigned based on the expression of Stat1 and Cd86, and M2 macrophages were assigned based on the expression of Arg1 and Mrc1.
- the number of CD8-positive T cells relative to the total number of CD45-positive cells obtained was defined as the CD8-positive T cell ratio (FIG. 12).
- the ratio of M1 macrophages and M2 macrophages was determined, and the ratio was calculated as the M1-M2 macrophage ratio (FIG. 13).
- T cell clonality was analyzed using TCR clonotype information output from CellRanger. As an index of clonality, the ratio of clones of a certain size or more (specifically, clones in which two or more cells were detected) to all clones, and the Gini coefficient determined from the cell ratio of each clone were used.
- the index was calculated after randomly sampling an equal number of cells (35 cells) for each administration group. This sampling was performed 100 times, and the average of the index was calculated. The index was calculated for each administration group and compared between the administration groups ( Figure 11).
- T cell clonality was significantly increased in the liposome formulation administration group of Example 1 compared to the empty liposome administration group.
- the percentage of CD8-positive T cells and the M1-M2 macrophage ratio were more than 5 times higher in the liposome preparation of Example 1 and the liposome preparation and anti-PD-1 antibody combination group of Example 1 than in the empty liposome administration group, respectively.
- Test example 29 Combination drug efficacy evaluation test using tumor-bearing mice transplanted with Renca cells The antitumor effect was evaluated using a liposome preparation encapsulating Example 1 and an anti-PD-1 antibody.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Renca cells were implanted intradermally around the ventral region of 4- to 7-week-old BALB/c mice (BALB/cAnNCrlCrlj, female, Jackson Laboratory Japan) at 5 x 10 4 cells/mouse. .
- the liposome preparation was administered intravenously at 10 mg/kg, the anti-PD-1 antibody at 200 ⁇ g/head, or a combination thereof once a week, or twice a week. Administered intraperitoneally or in combination.
- the tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated.
- the tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 40 shows the T/C (%) for Renca-transplanted tumor-bearing mice at each dose and administration period of the test compound.
- Example 1 In a combination drug efficacy evaluation test using tumor-bearing mice, "Liposomal formulation Example 1" showed excellent antitumor effects as a “single agent” or "in combination with anti-PD-1 antibody” . As shown in Test Example 29, cancer-bearing mice to which Renca cells were transplanted are a model in which anti-PD-1 antibodies do not exhibit antitumor effects. From the results of this test, Example 1 showed that the liposome preparation, either as a single agent or in combination with an anti-PD-1 antibody, had excellent anti-tumor effects against a model in which anti-PD-1 antibodies did not show antitumor effects. It shows tumor effect and has an exceptional effect.
- Test example 30 Combination drug efficacy evaluation test using tumor-bearing mice transplanted with LLC cells The antitumor effect was evaluated using a liposome preparation containing Example 1 and an anti-PD-1 antibody.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Mouse lung cancer LLC cells (RIKEN BRC) were implanted intradermally around the ventral region of 4-7 week old B6 mice (C57BL/6J, female, Jackson Laboratory Japan) at 1 x 10 6 cells/mouse. did.
- the liposome preparation was administered intravenously at 10 mg/kg, the anti-PD-1 antibody at 200 ⁇ g/head, or a combination thereof once a week, or twice a week. Administered intraperitoneally or in combination.
- the tumor volume is measured over time from the start of administration, and the tumor volume reduction effect due to compound administration is evaluated.
- the tumor volume was calculated by the following formula using the short axis and long axis of the tumor measured with an electronic caliper (Mitutoyo).
- Tumor volume [mm 3 ] 0.5 x (breadth axis [mm]) 2 x long axis [mm]
- T/C (%) (Tumor volume at the end of administration of the compound administration group of the present disclosure - Tumor volume at the start of administration of the compound administration group of the present disclosure) / (Tumor volume at the end of administration of the control administration group - Control Tumor volume at the start of administration in the administration group) x 100
- Table 41 shows the T/C (%) for tumor-bearing mice transplanted with LLC cells at each dose and administration period of the test compound.
- Example 1 formulated with liposomes showed excellent antitumor effects when administered as a "single agent” or "in combination with anti-PD-1 antibody” It became clear that As shown in Test Example 30, tumor-bearing mice to which LLC cells have been transplanted are a model in which anti-PD-1 antibodies have difficulty showing antitumor effects. From the results of this test, Example 1 demonstrated that the liposome preparation, either as a single agent or in combination with an anti-PD-1 antibody, was superior to models in which anti-PD-1 antibodies have difficulty showing antitumor effects. It exhibits antitumor effects and has exceptional effects.
- Test example 31 Intratumoral immune cell evaluation test using tumor-bearing mice transplanted with Renca cells Using a liposome preparation encapsulating Example 1 and anti-PD-1 antibody, the fraction of immune cells infiltrated into the tumor was evaluated. .
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Renca cells were intradermally implanted around the ventral region of 4- to 7-week-old BALB/c mice (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 ⁇ 10 4 cells/mouse. .
- the liposome preparation was administered intravenously at 10 mg/kg, the anti-PD-1 antibody at 200 ⁇ g/head, or a combination thereof once a week, or twice a week. Administered intraperitoneally or in combination. Tumors were collected from 4 individuals in each group 15 days after the start of administration.
- the tumor mass of Renca cells was cut into small pieces with scissors, and then subjected to gentle MACS Tissue Dissociators (Miltenyi Biotec) according to the protocol using a Tumor Dissociation Kit, Mouse (Miltenyi Biotec) to dissect the tumor.
- the mass was prepared into a cell suspension.
- the prepared cells were passed through a 70 ⁇ m cell strainer and then washed with RPMI1640 supplemented with 10% FBS. Thereafter, red blood cells were removed by treatment with red blood cell lysis solution (Lonza) for 1 minute, further washed with RPMI1640 supplemented with 10% FCS, and suspended in MACS Rinsing solution (Miltnyi Biotec, hereinafter referred to as MACS buffer) supplemented with 5% BSA. did.
- MACS Rinsing solution Miltnyi Biotec, hereinafter referred to as MACS buffer
- Live/Dead Fixable Dye nearIR (Thermofisher Siecntific) diluted in PBS was added to the cell suspension and allowed to react on ice for 5 minutes to stain dead cells. After washing once with MACS buffer and blocking by adding Mouse BD Fc BlockTM (BD Biosciences), V450-labeled mouse CD45 (BD Biosciences) and BV510-labeled anti-mouse CD8a (Biole Gend) , PE-Cy7-labeled anti-mouse CD3 (Thermo Fisher Scientific), and APC-labeled anti-mouse CD4 (BD Biosciences). After staining twice with MACS buffer, the cells were fixed with 1% PFA/PBS and analyzed using a flow cytometer.
- Mouse BD Fc BlockTM BD Biosciences
- V450-labeled mouse CD45 BD Biosciences
- BV510-labeled anti-mouse CD8a Biole Gend
- CD45+ lymphocyte fraction CD8+ T cells CD8-positive T cells
- Table 42 shows the percentage of CD8-positive T cells in the empty liposome, the liposome preparation of Example 1, the anti-PD-1 antibody, and the combination group.
- the liposome preparation of Example 1 increased the number of CD8-positive T cells in the tumor by more than 3.5 times compared to the group administered with empty liposomes, indicating that the liposome preparation of Example 1 enhanced the influx of T cells into the tumor. It was shown that From the above, it was shown that the liposome preparation of Example 1 also changes the intratumoral microenvironment from an immunosuppressive environment to an inflammatory environment in the Renca mouse renal cancer model.
- Test example 32 Intratumoral immune cell evaluation test using tumor-bearing mice transplanted with LLC cells Using a liposome preparation encapsulating Example 1 and an anti-PD-1 antibody, the fraction of immune cells that had infiltrated into the tumor was evaluated. .
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Mouse lung cancer LLC cells (RIKEN BRC) were implanted intradermally around the ventral region of 4-7 week old B6 mice (C57BL/6J, female, Jackson Laboratory Japan) at 1 ⁇ 10 6 cells/mouse. did.
- the liposome preparation was administered intravenously at 10 mg/kg, the anti-PD-1 antibody at 200 ⁇ g/head, or a combination thereof once a week, or twice a week. Administered intraperitoneally or in combination. Tumors were collected from 4 individuals in each group 17 days after the start of administration.
- the tumor mass of LLC cells was cut into small pieces with scissors, and then subjected to gentle MACS Tissue Dissociators (Miltenyi Biotec) according to the protocol using a Tumor Dissociation Kit, Mouse (Miltenyi Biotec) to dissociate the tumor mass.
- MACS Tissue Dissociators Miltenyi Biotec
- a cell suspension was prepared.
- the prepared cells were passed through a 70 ⁇ m cell strainer and then washed with RPMI1640 supplemented with 10% FBS. Thereafter, red blood cells were removed by treatment with red blood cell lysis solution (Lonza) for 1 minute, further washed with RPMI1640 supplemented with 10% FCS, and suspended in MACS Rinsing solution (Miltnyi Biotec, hereinafter referred to as MACS buffer) supplemented with 5% BSA. did.
- MACS Rinsing solution Miltnyi Biotec, hereinafter referred to as MACS buffer
- Live/Dead Fixable Dye nearIR (Thermofisher Siecntific) diluted in PBS was added to the cell suspension and allowed to react on ice for 5 minutes to stain dead cells. After washing once with MACS buffer and blocking by adding Mouse BD Fc BlockTM (BD Biosciences), V450-labeled mouse CD45 (BD Biosciences) and BV510-labeled anti-mouse CD8a (Biole Gend) , PE-Cy7-labeled anti-mouse CD3 (Thermo Fisher Scientific), and PerCP-labeled anti-mouse CD4 (BD Biosciences). After staining twice with MACS buffer, the cells were fixed with 1% PFA/PBS and analyzed using a flow cytometer.
- Mouse BD Fc BlockTM BD Biosciences
- V450-labeled mouse CD45 BD Biosciences
- BV510-labeled anti-mouse CD8a Biole Gend
- CD45+ lymphocyte fraction CD8+ T cells CD8-positive T cells
- Table 43 shows the percentage of CD8-positive T cells in the empty liposome, the liposome preparation of Example 1, the anti-PD-1 antibody, and the combination group.
- Test example 33 Intratumoral immune environment evaluation test using tumor-bearing mice transplanted with Renca cells Using a liposome preparation encapsulating Example 1 and anti-PD-1 antibody, gene expression related to immune cells infiltrated into the tumor was evaluated. did.
- the anti-PD-1 antibody (114116, Biolegend) was diluted with PBS (Invitrogen).
- a liposome formulation containing Example 1 was prepared as follows. Weighed 498.2 g of Presome ACD-1 (manufactured by Nippon Fine Chemical Co., Ltd.), added 8772 g of 250 mM ammonium sulfate solution, dispersed with a homogenizer (CLEARMIX, manufactured by M TECHNIQUE), and defoamed by vacuum degassing. A crude liposome dispersion was obtained.
- the crude liposome dispersion was dispersed using a high-pressure homogenizer (Microfluidizer M-110 EH-30, manufactured by Microfluidics) at a pressure of 14,500 Psi to obtain liposomes with an average particle size (Z-average) of 73 nm.
- a Tangential Flow Filtration system equipped with five Pellicon cassettes (Pellicon 2 Mini 300kD 0.1m2, manufactured by Merck & Co., Ltd.)
- the liposome external aqueous phase was replaced with water for injection, and then 10mM L-histidine/9.4% sucrose was added.
- the compound concentration and encapsulation rate in the liposome solution were calculated as follows. Unencapsulated compound concentration: Mix 100 ⁇ L of liposome solution, 100 ⁇ L of 4% phosphoric acid aqueous solution, and 300 ⁇ L of physiological saline, centrifuge at 100,000 x g for 60 minutes to remove insoluble matter, and measure the compound concentration of the supernatant by HPLC. did.
- Compound concentration in liposome solution The liposome solution was diluted with a trifluoroacetic acid/water/methanol mixture (0.1/25/75) and centrifuged at 15,000 x g for 10 minutes at 4°C to remove insoluble matter. Compound concentration in the supernatant was determined by HPLC.
- the HPLC measurement conditions are as follows.
- Renca cells were intradermally implanted around the ventral region of 4- to 7-week-old BALB/c mice (BALB/cAnNCrlCrlj, female, Charles River, Japan) at 5 ⁇ 10 4 cells/mouse. .
- the liposome preparation was administered intravenously at 10 mg/kg, the anti-PD-1 antibody at 200 ⁇ g/head, or a combination thereof once a week, or twice a week. Administered intraperitoneally or in combination. Tumors were collected from 4 individuals in each group 15 days after the start of administration.
- the tumor mass of Renca cells was cut into small pieces with scissors, and then subjected to gentle MACS Tissue Dissociators (Miltenyi Biotec) according to the protocol using a Tumor Dissociation Kit, Mouse (Miltenyi Biotec) to dissect the tumor.
- the mass was prepared into a cell suspension.
- the prepared cells were passed through a 70 ⁇ m cell strainer and then washed with RPMI1640 supplemented with 10% FBS. Thereafter, red blood cells were removed by treatment with red blood cell lysis solution (Lonza) for 1 minute, further washed with RPMI1640 supplemented with 10% FCS, and suspended in MACS Rinsing solution (Miltnyi Biotec, hereinafter referred to as MACS buffer) supplemented with 5% BSA. did.
- MACS Rinsing solution Miltnyi Biotec, hereinafter referred to as MACS buffer
- Tables 44 to 46 show the variation in CD8-positive T cell-related markers (GranzymeB, Interferon ⁇ ), M1 macrophage-related genes (H2ab1, CD80), and M2 macrophage-related genes (Mrc1, Arg1) based on data from 5 or 6 individuals in each group. The average is calculated and shown as ratio data when the value of Vehicle is set to 1.
- intratumor CD8-positive T cells increased in the "liposome preparation group of Example 1" or the "combination group of the liposome preparation and anti-PD-1 antibody” compared to the empty liposome administration group.
- Related genes (GranzymeB, Interferon ⁇ ) increased by 2 times and more than 10 times, respectively, M1 macrophage related genes (H2ab1, CD80) increased by 1.5 times and more than 1.5 times, respectively, M2 macrophage related genes (Mrc1, Arginase1) was shown to be reduced by 0.6-fold and 0.7-fold, respectively.
- Example 1 also changes the intratumoral microenvironment in the Renca mouse renal cancer model from an immunosuppressive environment dominated by M2 macrophages to an inflammatory environment dominated by M1 macrophages. This change suggested that the single liposome preparation of Example 1 and the combination of the liposome preparation and anti-PD-1 antibody brought about significant drug efficacy in the Renca model.
- Test example 34 Cytoplasmic ssDNA evaluation test in cells Example 1 was used to evaluate replication stress within the tumor.
- mice breast cancer cells EMT6 and mouse kidney cancer cells Renca were treated with Example 1 and DMSO and cultured for 24 hours. Thereafter, the cells were collected, and cytoplasmic components were extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). After protein quantification was performed and the concentrations were equalized, ssDNA was quantified using Qbit ssDNA Assay Kit (Thermo Fisher Scientific).
- Example 1 As shown in FIG. 14, the treatment of Example 1 increased ssDNA in the cytoplasm by 1.3 times in EMT6 and 1.5 times in Renca. Since an increase in ssDNA in the cytoplasm is one of the markers of DNA replication stress, it was shown that Example 1 induces replication stress in these cells.
- Example 34 the treatment of Example 1 resulted in accumulation of ssDNA in the cytoplasm. Accumulation of ssDNA is caused by DNA damage caused by DNA replication stress and repair abnormalities. The accumulated cytoplasmic ssDNA activates the STING pathway, releases Type I interferon and cytokines, and activates immune cells in the tumor including dendritic cells as shown in Test Example 32.
- the above action is considered to be one of the mechanisms by which Example 1 exhibits remarkable efficacy when used in combination with anti-PD-1 antibody in anti-PD-1 antibody-resistant tumors.
- the compound of the present invention exhibited high CHK1 inhibitory activity (Test Example 1) and high cancer cell growth suppressive effect (Test Example 2). Furthermore, the compound of the present invention has the characteristic of having a low risk of cardiotoxicity (Test Example 3) and has the characteristic of being efficiently encapsulated in liposomes (Test Examples 6, 6A, and 6B).
- the present inventors newly discovered the problem that prexasertib has a concern about hepatotoxicity, and in particular, the compound represented by formula (3) (a pyridine derivative having a nitrogen atom at a specific position) overcomes this problem, It was found that it has high safety (Test Example 4). In addition, the compound represented by formula (3) in particular has excellent pharmacokinetics (Test Example 7).
- the compound of Example 1 which is a representative compound contained in formula (3), has a CHK1 inhibitory activity that is more than 5 times higher than that of prexasertib (Test Example 1), and has an exceptional effect showing a strong cell proliferation inhibitory effect. (Test Example 2).
- the compound of Example 1 has extremely low cardiotoxicity compared to prexasertib (Test Example 3). It was found that prexasertib does not show any concerns about hepatotoxicity, which is a new issue with prexasertib (Test Example 4), and has a unique effect in which the risk of hematotoxicity is significantly reduced compared to prexasertib (Test Example 5, and Test Example 10). Furthermore, the compound of Example 1 exhibits good pharmacokinetics (Test Example 7), is efficiently encapsulated in liposomes, and exhibits good liposome encapsulation operability (Test Examples 6, 6A, and 6B).
- the liposome-formulated compound of Example 1 has an exceptional effect showing excellent antitumor effects in vitro and in vivo, and at the same time has a heterogeneous effect with high safety (Test Example 8, Test Example 9, Test Example 11 to Test Example 14).
- the combination of existing anticancer drugs and the compound of Example 1 has the characteristics of having both extremely excellent antitumor effects and high safety (Test Examples 15 to 21).
- the compound of Example 1 has an exceptional effect of selectively inhibiting CHK1 compared to prexasertib, and thus exhibits excellent anti-CHK1 inhibition while avoiding toxicity due to non-selective kinase inhibition. Demonstrates tumor effect (Test Examples 22 to 23).
- the compound of Example 1 has an exceptional effect with high efficacy compared to prexasertib, and at the same time has a different effect that shows high safety, so it has unpredictable effects. Furthermore, the liposome preparation of Example 1 is an excellent drug that has excellent blood retention, antitumor effects, and high safety, and has unexpected effects.
- the present disclosure relates to a CHK1 inhibitor, and relates to an antitumor agent that has high therapeutic effects while reducing side effects.
- the present inventors found that the compound represented by formula (1) has a strong inhibitory effect on CHK1 and has an excellent antitumor effect. Among them, it was confirmed that a series of compounds having a pyridine ring having a nitrogen atom at a specific position represented by formula (3) exhibited special and unique effects, and the present invention was completed.
- the present inventors created compounds according to Examples 1 to 38, and a series of compounds exhibited extremely high CHK1 inhibitory activity (Test Example 1) and high cancer cytotoxicity (Test Example 1). Example 2). Since hERG inhibition is weak, it has a unique effect with high safety (Test Example 3). Furthermore, the present inventors found that prexasertib has the problem of hepatotoxicity, and the compound of the present invention found a unique effect that overcomes this problem (Test Example 4). Among them, "a compound represented by formula (3) having a pyridine ring in which a nitrogen atom is present at a specific substitution position" represented by Example 1 etc. had extremely special and unique effects.
- Example 1 Compounds such as Example 1 represented by formula (3), unlike prexasertib, do not inhibit human bone marrow cell colony formation, exhibit high safety in terms of blood toxicity (Test Example 5), and have extremely high liposome encapsulation efficiency. , showed good liposome encapsulation operability (Test Examples 6, 6A, 6B), and showed high blood retention due to liposome formulation (Test Example 7). Although the liposome preparation has a tumor regression effect that cannot be achieved with prexasertib in a cancer-bearing model (Test Example 8), it has extremely high safety (Test Examples 9 and 10).
- Example 1 itself has an excellent pharmacokinetic and pharmacodynamic profile (Test Example 11), and its liposome formulation shows an effect of prolonging survival time that cannot be achieved with prexasertib (Test Examples 12 and 13). It showed efficacy against a wide variety of cancers (Test Example 14). When the liposome formulation of Example 1 was used in combination with various anticancer drugs (cisplatin, gemcitabine, or PD-1 antibody), exceptional effects were shown (Test Example 15-21).
- various anticancer drugs cisplatin, gemcitabine, or PD-1 antibody
- the compound of Example 1 has an exceptional effect of selectively suppressing CHK1 activity compared to prexasertib, and therefore, the compound of Example 1 has an excellent effect of inhibiting CHK1 while avoiding the toxicity caused by non-selective kinase inhibition. Shows antitumor effects (Test Examples 22-23).
- the compound of Example 1 was shown to change the intratumoral microenvironment from an immunosuppressive environment to an inflammatory environment (Test Example 24).
- Administration of the liposome preparation of Example 1 induced an immune reaction centered on CD8-positive T cells, and it was shown that the reaction was further strengthened when used in combination with an anti-PD-1 antibody (Test Example 25).
- Example 1 reduced the expression of VEGFa (Test Example 26).
- the combination group of Example 1 and anti-PD-1 antibody had a higher probability of complete remission than the single drug administration group of Example 1, indicating that the mice with complete remission acquired long-term immunological memory (test example). 27). It was revealed that T cell clonality was significantly increased in the Test Example 1 administration group compared to the empty liposome administration group, and the CD8-positive T cell ratio and M1-M2 macrophage ratio were the same as those in Test Example 1 and Test Example 1. In the anti-PD-1 antibody combination group, the increase was more than 5 times that in the empty liposome administration group (Test Example 28).
- Example 1 which was formulated into a liposome, was used as a single agent, Alternatively, combined administration with anti-PD-1 antibody showed particularly remarkable antitumor effects (Test Examples 29 and 30). Furthermore, in tumor-bearing mice transplanted with Renca or LLC cells, Example 1, which was formulated into liposomes, showed that when used as a single agent or in combination with an anti-PD-1 antibody, the percentage of CD8-positive T cells in the tumor increased. The intratumoral microenvironment was changed from an immunosuppressive environment to an inflammatory environment (Test Examples 31 and 32).
- Example 1 which was formulated into a liposome, was used as a single agent or in combination with an anti-PD-1 antibody to inhibit CD8-positive T cell-related genes (GranzymeB, Interferon ⁇ ).
- M1 macrophage-related genes H2ab1, CD80
- M2 macrophage-related genes Mrc1, Arginase1
- CHK1 Checkpoint Kinase 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/867,830 US20250352541A1 (en) | 2022-05-27 | 2023-05-26 | Therapeutic for cancer refractory to immune checkpoint inhibitor |
| JP2024523363A JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2022-05-27 | 2023-05-26 | |
| CN202380043023.8A CN119403571A (zh) | 2022-05-27 | 2023-05-26 | 对免疫检查点抑制剂示出治疗抗性的癌症的治疗药 |
| EP23811904.4A EP4534100A4 (en) | 2022-05-27 | 2023-05-26 | THERAPEUTIC AGENT FOR CANCER REFRACTORY TO AN IMMUNE CHECKPOINT INHIBITOR |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087166 | 2022-05-27 | ||
| JP2022-087166 | 2022-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023229032A1 true WO2023229032A1 (ja) | 2023-11-30 |
Family
ID=88919516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/019755 Ceased WO2023229032A1 (ja) | 2022-05-27 | 2023-05-26 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250352541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4534100A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023229032A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023229032A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024118596A1 (en) * | 2022-11-29 | 2024-06-06 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| US12527790B2 (en) | 2021-05-27 | 2026-01-20 | Boundless Bio, Inc. | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077758A1 (en) * | 2008-12-17 | 2010-07-08 | Eli Lilly And Company | Compounds useful for inhibiting chk1 |
| WO2012064548A1 (en) * | 2010-11-08 | 2012-05-18 | Eli Lilly And Company | Compounds useful for inhibiting chk1 |
| JP2017508787A (ja) * | 2014-02-10 | 2017-03-30 | カスカディアン セラピューティクス, インコーポレイテッド | 医薬化合物 |
| WO2017132928A1 (en) * | 2016-02-04 | 2017-08-10 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| WO2020198510A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US20210332136A1 (en) * | 2020-03-13 | 2021-10-28 | Research Development Foundation | Methods for diagnosing and treating cancers |
| WO2022114189A1 (ja) * | 2020-11-30 | 2022-06-02 | 住友ファーマ株式会社 | 5-ヘテロアリール-1h-ピラゾール-3-アミン誘導体 |
-
2023
- 2023-05-26 JP JP2024523363A patent/JPWO2023229032A1/ja active Pending
- 2023-05-26 WO PCT/JP2023/019755 patent/WO2023229032A1/ja not_active Ceased
- 2023-05-26 US US18/867,830 patent/US20250352541A1/en active Pending
- 2023-05-26 EP EP23811904.4A patent/EP4534100A4/en active Pending
- 2023-05-26 CN CN202380043023.8A patent/CN119403571A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077758A1 (en) * | 2008-12-17 | 2010-07-08 | Eli Lilly And Company | Compounds useful for inhibiting chk1 |
| WO2012064548A1 (en) * | 2010-11-08 | 2012-05-18 | Eli Lilly And Company | Compounds useful for inhibiting chk1 |
| JP2017508787A (ja) * | 2014-02-10 | 2017-03-30 | カスカディアン セラピューティクス, インコーポレイテッド | 医薬化合物 |
| WO2017132928A1 (en) * | 2016-02-04 | 2017-08-10 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| WO2020198510A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US20210332136A1 (en) * | 2020-03-13 | 2021-10-28 | Research Development Foundation | Methods for diagnosing and treating cancers |
| WO2022114189A1 (ja) * | 2020-11-30 | 2022-06-02 | 住友ファーマ株式会社 | 5-ヘテロアリール-1h-ピラゾール-3-アミン誘導体 |
Non-Patent Citations (16)
| Title |
|---|
| "Curr Opin Drug Discov Devel.", vol. 13, January 2010, pages: 66 - 77 |
| BENADA JMACUREK L, BIOMOLECULES, vol. 5, 2015, pages 1912 - 1937 |
| DAI YGRANT S, CLIN CANCER RES, vol. 16, no. 2, 2010, pages 376 - 383 |
| DAVID H. ET AL., J CLIN ONCOL, vol. 34, 2016, pages 1764 - 1771 |
| DENT P, EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 28, no. 12, 2019, pages 1095 - 1100 |
| DRUG METABOLISM AND DISPOSITION, vol. 39, no. 7, 2011, pages 1247 - 1254 |
| EVANGELISTI G. ET AL., EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 29, no. 8, 2020, pages 779 - 792 |
| KING C, MOL CANCER THER, vol. 14, no. 9, 2015, pages 2004 - 2013 |
| LAMPERT ERIKA J., MIN-JUNG LEE; JANE B. TREPEL; AKIRA YUNO; ASHLEY CIMINO-MATHEWS; JOO-SANG LEE; EYTAN RUPPIN; JAYAKUMAR NAIR; IRE: "Abstract 5000: Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrent BRCA wild-type high-grade serous ovarian cancer (HGSOC) patients ", CANCER RESEARCH POSTER PRESENTATIONS, vol. 79, no. 13_Suppl., 1 July 2019 (2019-07-01), XP093111482, DOI: 10.1158/1538-7445.AM2019-5000 * |
| RAFFAELE A. ET AL., EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 19, no. 3, 2019, pages 169 - 171 |
| See also references of EP4534100A4 |
| SEN TRIPARNA, RODRIGUEZ B. LETICIA, CHEN LIMO, CORTE CARMINIA M. DELLA, MORIKAWA NAOTO, FUJIMOTO JUNYA, CRISTEA SANDRA, NGUYEN THU: "Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer", CANCER DISCOVERY, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 5, 1 May 2019 (2019-05-01), US , pages 646 - 661, XP093111475, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-18-1020 * |
| THEODORA W. GREENEPETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC. |
| THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 1, no. 1, 2005, pages 3 - 13 |
| XENOBIOTICA, vol. 39, no. 2, 2009, pages 99 - 112 |
| YOSHIMOTO YUYA, KONO KOJI, SUZUKI YOSHIYUKI: "ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW", FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, FUKUSHIMA SOCIETY OF MEDICAL SCIENCE, KUKUSHIMA CITY, JP, vol. 61, no. 1, 1 January 2015 (2015-01-01), JP , pages 13 - 22, XP093111484, ISSN: 0016-2590, DOI: 10.5387/fms.2015-6 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12527790B2 (en) | 2021-05-27 | 2026-01-20 | Boundless Bio, Inc. | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof |
| WO2024118596A1 (en) * | 2022-11-29 | 2024-06-06 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250352541A1 (en) | 2025-11-20 |
| CN119403571A (zh) | 2025-02-07 |
| EP4534100A4 (en) | 2026-05-20 |
| EP4534100A1 (en) | 2025-04-09 |
| JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410154B2 (en) | 5-heteroaryl-1H-pyrazol-3-amine derivative | |
| US11787801B2 (en) | Protein kinase inhibitors, preparation method and medical use thereof | |
| EP4334298B1 (en) | Urea derivatives which can be used to treat cancer | |
| US11564920B2 (en) | 5-heteroaryl-1H-pyrazol-3-amine derivative | |
| EP3849664B1 (en) | Phenoxy-pyridyl-pyrimidine compounds and methods of use | |
| JP2016511252A (ja) | 置換イミダゾピリダジン | |
| US20250352541A1 (en) | Therapeutic for cancer refractory to immune checkpoint inhibitor | |
| US20150274733A1 (en) | Dihydropyrrolidino-pyrimidines as kinase inhibitors | |
| WO2023120696A1 (ja) | 二環性骨格を有する1h-ピラゾール-3-アミン誘導体 | |
| JP7546104B2 (ja) | 5-ヘテロアリール-1h-ピラゾール-3-アミン誘導体からなる医薬 | |
| HK40119491A (en) | Therapeutic for cancer refractory to immune checkpoint inhibitor | |
| EA048701B1 (ru) | Производное 5-гетероарил-1h-пиразол-3-амина | |
| HK40094126A (en) | 5-heteroaryl-1h-pyrazol-3-amine derivative | |
| EA049737B1 (ru) | Производное 1h-пиразол-3-амина, имеющее бициклическую основную цепь | |
| TW202120511A (zh) | 雜環化合物 | |
| JP7857948B2 (ja) | 自己分解型cdk9阻害剤プロドラッグ及びそれを内封するリポソーム | |
| HK40115947A (en) | 1h-pyrazole-3-amine derivative having bicyclic backbone | |
| CN118434726A (zh) | 具有二环性骨架的1h-吡唑-3-胺衍生物 | |
| CN120379671A (zh) | 用于治疗癌症的化合物 | |
| HK1260629B (en) | 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23811904 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024523363 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202380043023.8 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023811904 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2023811904 Country of ref document: EP Effective date: 20250102 |
|
| WWP | Wipo information: published in national office |
Ref document number: 202380043023.8 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2023811904 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 18867830 Country of ref document: US |